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Abbreviation list 
 
BINAP: 2,2′-bis(diphenylphosphino)-1,1′-binaphthalene 
Bn: benzyl 
Boc: tert-butoxycarbonyl 
CPT: camptothecin 
DIAD: diisopropyl azodicarboxylate 
dba: dibenzylideneacetone 
DMF: dimethylformamide 
dppf: 1,1′-ferrocenediyl-bis(diphenylphosphine) 
LDA: lithium diisopropylamide 
m-CPBA: 3-chloroperbenzoic acid 
MW: microwave 
NMP: 1-methyl-2-pyrrolidinone 
PG: protecting group 
PTSA: p-toluenesulfonic acid 
TBA-HSO4: tetrabutylammonium hydrogensulfate 
THF: tetrahydrofuran 
Topo I: topoisomerase I 
Topo II: topoisomerase II 
TPT: topotecan 
Ts: tosyl 
GI50: growth inhibition (50%) 
1,10-Phen: 1,10-phenanthroline 
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Chapter 1 
 
Introduction 
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1.1 Relevance of nitrogen (poly)heterocycles in pharmaceutical field 
Nitrogen heterocycles are among the most significant structural components of pharmaceuticals. 
For instance, an analysis of the database of U.S. FDA approved drugs reveals that 59% of unique 
small-molecule drugs contain a nitrogen heterocycle. Six-membered rings are the most frequently 
used, followed by five-membered and fused rings.[1] Also nitrogen-containing heterocycles are 
central to the chemical reactions that occur in all organisms. The metabolic transformation of 
amino acids into five, six, and seven-member heterocycles reveals the chemical logic and 
enzymatic machinery for shunting primary metabolites into bioactive heterocyclic nitrogen 
scaffolds.[2] Among the five-membered ring fused with an aromatic ring benzoxazole and 
benzimidazole derivatives are occupying a remarkable ranking. The scaffold of benzoxazole is a 
constituent of several natural products and often incorporated in drug design. In particular 2-
substituted benzoxazoles is often found in ligands targeting a plethora of receptors and 
enzymes.[3,4] Furthermore, the pharmacological applications of benzimidazole derivatives include 
antitumor, antibacterial and antiviral activity, and analgesic, antiiflammatory, and antipyretic 
properties.[5] Also benzoxazines and quinoxalines, among the six-membered ring fused are 
scaffolds with a promising employments in pharmaceutical field. E.g. dihydrobenzoxazine 
derivatives have showed both thrombin inhibitory and glycoprotein IIb/IIIa (GPIIb/IIIa) receptor 
antagonistic activities[6], while quinoxaline derivatives has received particular attentions as 
promising anticancer agents.[7] At the end, nitrogen polycyclic scaffolds, such as pyrroloacridines, 
physostigmines, camptothecin and oxazinoindole derivatives are very relevant pharmaceutical 
classes in anticancer research. (Figure 1) 
 
 
 
Figure 1 
Nitrogen polyheterocycles 
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1.2 Transition metal-catalysis: advantages in nitrogen heterocycles synthesis 
In the field of synthesis of nitrogen heterocycles, transition-metal catalyzed reactions perform a 
prominent role, especially considering the new perspectives of sustainable chemistry. Among the 
transition metal-catalysts used in organic synthesis palladium is certainly the most exploited and 
the most versatile. In recent years, the interest for palladium-catalyzed C-N bond-forming 
reactions has been strongly increased, as documented by the number of reviews with high 
impact.[8,9,10,11,12,13] Both Pd(0) and Pd(II) oxidation state are exploited as catalysts in the organic 
synthesis, and they are exploited in many different reactions such as Buchwald-Hartwig reaction, 
hydroamination and amination to achieve the C-N bonds formation. Moreover the interest was 
broadened considering the metal-catalyzed domino processes, the carboamination, 
aminohalogenation, aminooxygenation and diamination reactions that lead to the formation of two 
or more bonds in the same synthetic step.  
Among the transition-metals, also platinum-catalyst was increasingly used in this field of C-N 
bond formations. Recent publications on the hydroamination reactions of alkenes[14]  and 
alkynes.[15] report the use of platinum catalysts. Both platinum and palladium always require the 
presence of a ligand, especially phosphines, that modulate the reactivity of the metal center. 
(Figure 2)  
 
 
Figure 2 
Phosphine ligands for palladium and platinum catalysis 
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This ligand permit fine tuning of the coordinated species allowing the properties of the complex at 
different steps of a catalytic cycle to be enhanced.[16] The choice of phosphine depends on the 
features of the substrates: e.g. in the palladium-catalyzed cross-coupling of amines and aryl 
halides, the electron donation of aryl substituent is the key to the stability of the amido complex 
with respect to reductive elimination. Using the class of ligands such as S-Phos, the reductive 
elimination step occurs readily for more nucleophilic amines such as N-alkyl anilines, N,N-dialkyl 
amines, and primary aliphatic amines.[17] Furthermore, ligands promote the solubility and prevent 
the ‘clusterization’ when the mechanism involves the formation of M(0) at the resting-state.  
Also copper catalysis will be considered in this thesis. The use copper-catalyzed Buchwald-type 
reactions has many advantages in the field C-N bond formation, such as the lower cost of the 
copper catalysts compared to the more expensive palladium complexes. Another advantage of 
copper catalysis is that in many cases, copper-catalysed reactions work well without ligand, and, 
when required, the ligands are usually structurally quite simple and inexpensive respect to 
palladium and platinum ligands. Instead of phosphines, cheaper N,O, N,N or O,O-ligands as 
amino acid, compounds with a rigid backbone such as quinolone derivatives and aliphatic 
diketones have been reported to be effective in copper-catalyzed reaction.[18] (Figure 3) The role 
of the ligand was not clear, it was probably involved in the stabilization of the copper(I) active 
species, the increase of solubility, or the avoidance of aggregation of the copper species.[19] At the 
end, it was proposed that the advantage of bidentate ligands would be to facilitate the reaction by 
blocking two adjacent coordination sites, so that the aryl donor and the nucleophile could be close 
enough to couple easily.[20] Furthermore, the copper complexes tolerate better the atmospheric 
oxygen compared to the palladium and platinum catalysts that often are air-sensitive and require 
inert atmosphere. [21,22]  
 
 
Figure 3 
Ligands for copper catalysis 
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1.3 Hydroamination reaction 
The hydroamination reaction is an atom-efficient pathway to add a nucleophilic nitrogen to a 
carbon-carbon unsaturated bonds. Intramolecular hydroamination of unactivated alkynes, alkenes 
or allenes bearing an amino group is one of the simplest methods to obtain nitrogen heterocycles. 
Generally, the hydroamination of alkenes is more difficult compared to the hydroamination of 
alkynes due to the lower reactivity and electron density of the double bonds.[23] Many efforts have 
been made toward the exploitation of this methodology in the field of natural products synthesis. 
Various metal complexes are used, in general metals with high Lewis acidity. Several studies to 
identify the most active transition-metal catalysts and to optimize the reaction conditions have 
been developed[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38].  Good results have been obtained with the 
palladium complexes, but different metal catalysts may be used, such as platinum. The choice is 
depending on the substrates. For example, palladium(II) complexes catalyze the intramolecular 
oxidative amination of unactivated olefins with arylamines[39] and amides[40,41,42] but are not 
compatible with alkylamines.[43] Conversely, examples of intramolecular hydroamination of γ- and 
δ-amino olefins with secondary alkylamines under platinum(II) catalysis are reported.[14] 
The reaction mechanisms can be quite different depending on the unsaturated substrates and the 
transition metals involved. Two potential mechanisms are commonly accepted. The first 
hypothesis considers the outer-sphere attack by a protic nucleophile NuH to a C-C unsaturated 
bond activated by the coordination with an electrophilic metal center. The newly formed M-C bond 
is then cleaved by protonolysis to regenerate the catalyst. (Scheme 1) 
 
 
Scheme 1 
Outer-sphere mechanism 
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An alternative mechanism regards the inner-sphere nucleophilic attack. In this case, the first step 
involves the oxidative addition of the metal to the NuH followed by alkene/alkyne insertion into the 
M-Nu bond. The resulting M-C bond is cleaved by a C-H reductive elimination or by protonolysis. 
(Scheme 2) 
 
 
 
Scheme 2 
Inner-sphere mechanism 
 
Mechanistic studies, both experimental and theoretical, have demonstrated that both pathways 
can be operative. While this latter is generally preferred for more electron-rich metals such as 
rhodium and iridium, several studies suggest that palladium and platinum-catalyzed addition of N-
H or O-H nucleophiles is more likely to run by the outer-sphere electrophilic activation 
mechanism.[44] A recent study of Widenhoefer’s group, regarding the mechanism of platinum-
catalyzed hydroamination of olefin, would seem to confirm this hypothesis. The first step can be 
the formation the nitrogen-bound platinum-amine complex I and this complex undergoes an 
intramolecular ligand exchange, forming the platinum alkene complex II, followed by the fast 
formation of the zwitterionic platinamethylpyrrolidinium complex III via rapid outer-sphere C−N 
bond formation. This complex reacts with free amine (that can be the starting secondary amine or 
the tertiary amine of the product) and the deprotonation restitutes the azaplatinacyclobutane 
complex IV. The complex IV represents the catalyst resting state and is consumed via turnover-
limiting intramolecular protonolysis. Associative ligand exchange of V with the starting amine 
would release the product and regenerate the nitrogen-bound platinum-amine complex I.[45] 
(Scheme 3) 
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Scheme 3 
Platinum catalyzed hydroamination: mechanism 
 
Starting from non-terminal alkynes, in some cases the formation of allene intermediate is 
proposed followed by the formation of the π-allyl-metal complex which undergoes the attack of 
the nucleophile to give allyl derivatives.[46,47,48] (Scheme 4) 
 
 
Scheme 4 
Allene intermediate in hydroamination of non-terminal alkynes 
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A particular mention regards the impact of the transition-metal catalysis on the regioselectivity. 
For example, 5-endo-dig-cyclization process or 6-exo-dig regioselectivity is observed starting 
from alkynylamines in the presence of different transition-metals catalysts. Regioselectivity can 
also be addressed changing reaction conditions or choosing different protecting group on the 
nitrogen involved as nuchleophile.[49] (Scheme 5) 
 
 
Scheme 5 
Regioselectivity in intramolecular hydroamination 
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1.4 Carboamination reaction 
The carboamination reactions consist of a domino process involving the formation of both C-C 
and C-N bonds. This reaction involves alkynes, alkenes or allenes-tethered amines and aryl 
halides as coupling partner. Carboamination reactions, and the analogous carboetherification (C-
C and C-O bonds formation) reported in literature are relatively rare.[50,51,52,53,54,55,56,57,58,59,60,61,62] 
This domino process occurs in presence of palladium(0) complex as catalyst and require the 
presence of a base. The mechanism of the process consists in the oxidative addition of the Pd(0) 
to the aryl halide resulting in the formation of Pd(II) complex I. The base intervenes in the 
formation of the amido complex II between the amine and the Pd(II) complex I. The subsequent 
syn-aminopalladation restitute the intermediate III, and the subsequent reductive elimination 
affords the product.[63] (Scheme 6)  
 
 
Scheme 6 
Carboamination reaction: mechanism 
 
Also the carboamination process can occour as endo-dig or exo-dig cyclization-step. The 
regioselectivity can be influenced by the reaction conditions, the N-protecting group or the 
different electron availability of the substrates.[64,65] (Scheme 7) 
 
 
Scheme 7 
Regioselectivity in carboamination reactions 
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In some cases, starting from chiral substrates, the reaction could be stereoselective, also without 
employing chiral ligand. This could be due to the particular conformation of the intermediate. The 
unfavourable transition state I contains a severe steric interaction between the H-substituent in 
C5 and the R-group, and also suffers from significant strain between the R-group in C2 and the 
N-aryl group justifying the improbable cyclization via this transition state. The products are 
obtained with good to excellent yield and 95–99% ee.[63] (Scheme 8) 
 
 
Scheme 8 
Proposed boat-like transition state model in stereoselective carboaminations 
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1.5 Buchwald-Hartwig reaction 
In 1995 Buchwald and Hartwig independently discovered an important amination/alkoxylation 
process based on the reaction between an aryl halide or pseudohalide (as triflate) and NH or OH 
functional groups able to react as a nucleophile.[66,67]   
This process is realized under palladium catalysis and requires the presence of phosphine 
ligands and a stoichiometric amount of base, the choice of which are of great influence on the 
products formation. Many kinds of phosphines has been synthesized in the last years with 
different steric and electronic properties resulting in a large possibility of applications of this 
reaction with different nucleophiles and various aryl halides.[68] The best catalyst is palladium 
acetate due to the low cost and easy handling in the presence of chelating phosphines BINAP or 
dppf as ligands (Figure 2). Toluene is the preferred solvent. The intramolecular version of the 
Buchwald-Hartwig reaction affords heterocyclic systems. 
The mechanism involves the oxidative addition of the palladium to the aryl halide giving the 
palladium complex I, followed by the coordination of the amine to the palladium. The base 
intervenes in the deprotonation of nucleophile, leading to the formation of the amido complex II. 
Reductive elimination produces the final aryl amine and regenerates the catalyst.[16] (Scheme 9) 
 
 
 
 
Scheme 9 
Buchwald-Hartwig reaction mechanism 
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1.6 Ullmann-type reaction 
The copper-mediated formation of C-N bonds (Ullmann condensation) is a well-known method, 
discovered more than a century ago, for the synthesis of N-aryl amines.[69] The initial reaction 
conditions were very harsh, using high-boiling polar solvents and stoichiometric amount of 
copper. In recent year new studies report the fundamental role of ligands in copper-catalyzed 
reactions and give a breakthrough in this coupling reaction (in term of copper loading, mild 
reaction conditions, substrate tolerance, yields obtained) leading to a renewed interest in 
Ullmann-type reactions. Compared to palladium, copper catalysis shows some interesting 
advantages, first of all, it is cheaper and has attracted recently high interest from the industry. The 
range of nucleophiles suitable for Ullmann arylations has become wider with time, and nowadays 
N-, O-, S-, P- and C-aryl bonds formation are easily accessible through these processes.[22]  
The reaction can be catalyzed by both copper(I) or copper(II) catalysts. Some investigations 
seemed to demonstrate that the active catalyst are copper(I) species, but the initial copper source 
remained not very important for the outcome of the reaction, due to oxidation/reduction processes 
leading to copper(I) in all the cases during the reaction.[70] Moreover radical scavenge 
experiments have shown that radicals are involved in some steps. In the case of copper(I) the 
reaction mechanism considers the oxidative addition with formation of copper(III) intermediate as 
first step and the subsequent reductive elimination that regenerates the catalyst. In the case of 
copper(II) catalyst the first step is a transmetallation. The reductive elimination produce copper(0) 
that can be easily reoxidized in atmospheric conditions.[71] (Scheme 10)  
 
 
 
 
Scheme 10 
Copper catalyzed coupling reaction: proposed mechanism 
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1.7 Aim of the thesis 
Having a survey of literature regarding the transition-metals catalyzed reactions applied to the C-
N bonds formation, we intend to study the intramolecular reactions of unsaturated systems 
(alkynes, alkenes and allenes) tethered to a nucleophile with particular attention to the 
regioselectivity. Among different transition metals, palladium and platinum have been identified for 
their characteristics of reactivity, compatibility with different functional groups, easily to handle. 
The aim of the thesis is to apply in particular the hydro- and carbamination reactions on 
aminophenol and diaminobenzene derivatives devoted to the preparation of nitrogen benzofused 
heterocycles, comparing the results with different catalysts.  
In a separate chapter we show specific applications of two particular processes the Buchwald-
Hartwig and Ullmann-type reactions. The cross-coupling reaction of amines and heteroaryl 
halides through amination process allows the synthesis of particular class of heteropolycyclic 
systems endowed with pharmacological properties as anticancer. In particular the C-N bond 
formation was the key step between tryptamines and 2-chloroquinolines to obtain the designed 
skeleton.  
On a different application, the Ullmann-type reaction was used to afford oxazinoindole scaffold 
exploiting the intramolecular C-O bond formation starting from N-hydroxyethyl-isatin derivatives. 
The choice of the copper-catalyzed reaction stems from the low cost of the copper catalysts and 
their tolerance toward many reactive functional groups, and the reactions do not require 
rigorously anaerobic and anhydrous conditions. These features strongly support the development 
of this procedure for C−O (and also C−N) bond forming reactions. 
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Chapter 2 
 
Hydroamination and carboamination reactions on unsaturated 
aminophenols and diaminobenzene derivatives 
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2.1 Hydroamination reactions: palladium catalysis 
The first reaction devoted to the synthesis of heterocycles considered in this thesis is the 
hydroamination of terminal alkynes. O-propargyl ether of 2-aminophenol was the convenient 
substrate to obtain dihydrobenzo[1,4]oxazine, a scaffold with many interesting applications in 
pharmaceutical field.[72] The substrates were synthesized starting from commercially available 4-
substituted 2-amino-phenols, protected at the nitrogen atom with tert-butoxycarbonyl. The 
subsequent reaction with propargyl bromide has provided the suitable substrates for the 
hydroamination reaction in two simple steps and good yield. (Scheme 11) 
   
Scheme 11 
Substrates synthesis 
 
At first we have tested the hydroamination reactions, following the reactions conditions previously 
developed in our research group, using tetrakis(triphenylphosphine)palladium(0) as catalyst, in 
toluene under microwave irradiation.[73] We have noted that there were no significant differences 
carrying out the reaction in toluene at reflux and we have chosen to extend the reaction scope 
exploiting the traditional heating. As expected, the reaction was occurred with a 6-exo-dig 
cyclization process and 3-methylene-dihydrobenzo[1,4]oxazines (4a-d) were achieved in good 
yields. During the chromatography we have observed a partial isomerization of these products 
and 3-methyl-benzo[1,4]oxazines (5a-d) were found beside 4, probably due also to electron-
withdrawing effect of the tert-butoxycarbonyl group on nitrogen. (Scheme 12, Table 1) 
 
 
Scheme 12 
Palladium catalyzed hydroamination on O-propargyl derivatives 
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Table 1 
Palladium catalyzed hydroamination on O-propargyl derivatives 
 Substrate Product Yield (%)a 
1 
  
95 (58) 
2 
  
82 (76) 
3 
  
87 (45) 
4 
  
88 (70) 
a Conversion calculated by NMR of the crude mixture. In parenthesis 
 yield after chromatography. 
 
The hydroamination reaction was extended to the N-propargyl derivative of o-diaminobenzene. 
This substrate was obtained in a similar synthetic pathway. (Scheme 13).  
 
Scheme 13 
Substrate synthesis 
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The 2-methylenedihydroquinoxaline 9 was obtained in good yield, reporting the same problem of 
isomerization of the exocyclic double bond. Also in this case, the 2-methylquinoxaline 10 was 
isolated after chromatography. (Scheme 14) 
 
Scheme 14 
Palladium catalyzed hydroamination on N-propargyl derivative 
 
Having in mind the hypothesis in which the formation of allene is proposed as possible 
intermediate of hydroamination reaction on triple bond[46,47,48] (Chapter 1, Scheme 4), we have 
explored this procedure on the allenyl derivatives. The allene derivatives was easily achieved 
starting from the propargyl derivatives 3a-e and 8 using potassium tert-butoxide as base in THF 
as solvent. The reaction occurs in 1 minutes starting from O-propargyl ethers and in 10 minutes at 
0 °C with a lower yield working on N-propargyl derivative. (Scheme 15) Furthermore, these 
allenes are stable and can be purified through silica gel column chromatography.  
 
Scheme 15 
Allene fomation 
 
The reported reaction conditions on the allenyl derivative 11a afforded the 2-vinyl-2,3-
dihydrobenzoxazole 13a in moderate yield, arising from a 5-exo-allylic cyclization.[74]  This result 
excludes the formation of the allene as intermediate in hydroamination reaction on terminal 
alkynes.  
The reaction conditions were optimized to obtain 5-exo-allylic cyclization, and the best conditions 
were found using an excess of triphenylphosphine respect to the catalyst. (Table 2) Although the 
exact role of the triphenylphosphine is not clear at present, we believe that the added phosphine 
might act as a Brønsted base helping to promote the initial hydropalladation step.[75] Regard to the 
21 
 
reaction mechanism we can hypothesize that π-allyl–Pd(II) complex intermediate is involved in 
the crucial step.[30,31]  
Table 2 
Palladium catalyzed hydroamination on allenes: optimization of reaction conditions 
 
 
 Catalyst  Additive Solvent Temp [°C] Time (min) Yield (%) 
1 Pd(PPh3)4 (8 mol %) - toluene 100 240 22 
2 Pd(PPh3)4 (8 mol %) - toluene 120 (MW) 40 50 
3 Pd(PPh3)4 (8 mol %) - MeCN 120 (MW) 40 34 
4 Pd(PPh3)4 (8 mol %) - THF 120 (MW) 40 42 
5 Pd(PPh3)4 (8 mol %) - DMF 120 (MW) 40 38 
6 PdCl2(MeCN)2 (5 mol %) - MeCN 120 (MW) 40 48 
7 Pd(PPh3)4 (8 mol %) PPh3 (10 mol %) toluene 120 (MW) 60 76 
8 Pd(PPh3)4 (8 mol %) PPh3 (10 mol %) toluene 110 240 94 
 
Then, starting from propargyl substrates, through an isomerization of the unsaturated bond, it is 
possible to achieve different regioselectivity obtaining different cyclization products. (Scheme 16)  
 
 
Scheme 16 
Divergent regioselectivity between propargyl and allene derivatives 
 
The optimized procedure was extended to a different substituted substrates with analogous 
results in moderate to good yields. (Scheme 17, table 3) 
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Scheme 17 
Palladium catalyzed hydroamination on allenes: scope of reaction 
Table 3 
Palladium catalyzed hydroamination on allenes: scope of reaction 
 Substrate Product Yield (%) 
1 
  
94 
2 
 
 
51 
3 
  
71 
4 
 
 
74 
5 
  
75 
6 
  
60 
23 
 
 
Going on in this study we have planned to test this methodology using allene tethered to an 
electron-poor heterocycles, such as pyrimidine and pyridine derivatives. The possibility to achieve 
dihydro-purine and dihydro-deazapurine respectively has encouraged our effort. Besides, 
commercially available 4,6-dichloro-5-nitropyrimidine (15) and 4-chloro-3-nitropyridine (23) have 
been identified as suitable substrates. As previously described for diaminobenzene, tosyl group 
was used as protecting group for the nitrogen bearing the unsaturated residue.  
 
The first step of the synthetic pathway starting from 15 was the substitution of one the two 
chlorine atoms with an inert methoxy group. The remaining chlorine was exploited for a 
nucleophilic aromatic substitution with N-tosyl-propargylamide giving the unsaturated derivative 
17. The reduction of the nitro group afforded the compound 18, and tert-butoxycarbonyl group 
was initially chosen for the protection of the nitrogen acting as nucleophile. Unfortunately the 
hydroamination reaction failed in different conditions, also with tosyl protecting group, then we 
have explored the N-acetyl derivative (19). (Scheme 18) 
 
 
Scheme 18 
Synthesis of pyrimidine derivative 
 
In this case, the allene preparation with potassium tert-butoxide gave simultaneous deprotonation 
of the acetyl group with consequent intramolecular attack on the allenyl residue affording the 8-
vinyl-dihydro-pyrimidodiazepinone (20) in moderate yield. (Scheme 19)  
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Scheme 19 
Preparation of allene tethered diaminopyrimidine 
 
To avoid the presence of acid hydrogens able to react with the allene we have chosen as 
protecting group the trifluoroacetyl group. On compound 21 the isomerization of the triple bond 
proceeded slowly: one hour was required to obtain the allene instead of 1 minute as reported for 
the analogue propargyl derivatives tethered to the benzene ring. (Scheme 20) 
 
Scheme 20 
Synthesis of allene-tethered diaminopyrimidine 
  
The same synthetic pathway was repeated starting from the pyridine substrate 23. (Scheme 21) 
 
 
Scheme 21 
Synthesis of allene-tethered diaminopyridine  
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The hydroamination reactions afforded the desired purine and deazapurine 28 and 29, but the 
different electronic availability of these substrates has enforced different reaction conditions. 
Indeed, high temperature was detrimental, inducing the decomposition of substrates. Best yield 
was achieved at room temperature. Furthermore, less time was needful for the complete 
consumption of the starting material. Tetrakis(triphenylphosphine)palladium(0) remained the best 
catalyst, but in this case the excess of triphenylphosphine has not induced a significative yield 
improvement. Working on the N-allenyl-pyrimidine 22 it is noteworthy the loss of the trifluoroacetyl 
protecting group. (Scheme 22, table 4) 
 
 
Scheme 22 
Palladium catalyzed hydroamination on allene-tethered pyrimidine and pyridine 
Table 4 
 Substrate Product Yield (%) 
 
  
73 
 
  
64 
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2.2 Hydroamination reactions: platinum catalysis 
In order to verify the regioselectivity in the hydroamination process the allene derivative 11a was 
also tested under platinum catalysis. Using platinum(II) chloride without ligand in dioxane as 
solvent, no different regioselectivity was observed and the dihydrobenzoxazole 13a was obtained 
in lower yield respect to the palladium catalysis, beside the 15% of dealkylated starting material. 
(Scheme 23) 
 
 
Scheme 23 
Platinum catalyzed hydroamination on allene 
 
The alkenes are cheaper and easier handling than alkynes and allenes. Moreover, intramolecular 
hydroamination of unactivated alkenes is one of the simplest methods to obtain nitrogen 
heterocycles. Continuing to explore platinum catalysis in hydroamination reactions and 
considering the hydroamination reactions reported in literature on the unactivated olefins,[14,15] we 
decided to study the reactivity of substituted O-allyl ethers and N-allyl amide, arising respectively 
from 2-aminophenols and o-diaminobenzene. The substrates were prepared as shown in scheme 
25 following different synthetic pathways depending on the substituents. We synthesized different 
derivatives having the nucleophilic nitrogen substituted with benzyl group (33a-d and 35a-c), alkyl 
residue (36a-b) and tert-butoxycarbonyl group (37), with the aim to investigate the influence of the 
substituent on the nucleophilic nitrogen. (Scheme 24)  
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Scheme 24 
Substrates synthesis 
 
The cyclization reactions were carried out with platinum(II) chloride as catalyst, Xantphos as 
ligand in toluene at reflux. The reaction resulted as a 6-exo-trig-cyclization, leading to the 
formation of 3-methyl-3,4-dihydrobenzo[1,4]oxazine (38a-i). (Scheme 25) The best result was 
achieved when the nucleophilic nitrogen was substituted whit a benzyl group, while the presence 
of an alkyl residue, as the butyl, gave lower yield and required more reaction time for the 
complete consumption of starting material. On the allyl derivative of o-diaminobenzene the yield 
was lower. No result was obtained on the substrate protected with an electron withdrawing group.  
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Scheme 25 
Hydroamination reaction on allyl derivatives 
Table 5 
 Substrate Product Yield (%) 
1 
 
 
90 
2 
 
 
60 
3 
 
 
88 
4 
 
 
70 
29 
 
5 
 
 
87 
6 
 
 
97 
7 
  
30 a 
8 
  
10 a 
9 
  
35 a 
10 
 
- 0 b 
a Reaction time was 10 h; b reaction time was 24 h. 
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2.3 Unexpected hydroarylation reactions: platinum catalysis 
To complete our screening on aminophenols derivatives, we have explored the platinum catalysis 
on O-propargyl derivative 3, with the aim to achieve a different regioselectivity in hydroamination 
reactions, encouraged by some examples in literature on alkynylamides[76,77,78,79,80,81], reporting a 
7-endo-dig cyclization. The substrate 3a showed a different reactivity, where no hydroamination 
process was observed but a hydroarylation reaction involving the aromatic ring was reported. The 
benzopyran 39a was formed as major product beside the isomerized compound 40a. The 
isomerization of the double bond was probably due to the reaction mechanism. Different reaction 
conditions have been tested and the best result was found using platinum(II) chloride, without 
ligand in toluene at 80 °C. The use of ligand was detrimental, increasing the formation of 
dealkylated product. As well as, the use of platinum(IV) chloride reported lower yield, though this 
catalyst allowed the occurrence of reaction at lower temperature. (Table 6) 
Table 6 
Hydroarylation reaction conditions 
 
 
 
Catalyst Ligand Solvent 
Temp. 
(°C) 
Time 
(h) 
Yield 
(%)a 
1 PtCl2(MeCN)2 - toluene 110 6 40 (10) 
2 PtCl2(MeCN)2 PPh3 1,4-dioxane 100 3 30 (-) 
3 PtCl2 - toluene 80 3 50 (10) 
4 PtCl2 Xantphos MeCN 80 5 30 (-) 
5 PtCl2 - 1,4-dioxane 100 2 30 (20) 
6 PtCl2 JohnPhos 1,4-dioxane 70 2 25 (10) 
7 PtCl2 - MeCN 80 3 40 (10) 
8 PtCl2 - MeOH 65 3 20 (-) 
9 PtCl4 - toluene 80 8 - 
10 PtCl4 - 1,2-dichloroethane 20 2 35 (5) 
a In parenthesis yield of compound 40a 
 
The mechanism usually proposed is based on a Friedel–Crafts alkenylation reaction, in fact 
electron-donating substituents facilitate the hydroarylation process.[82] Thus, coordination of 
platinum(II) chloride to 3a affords I, which undergoes an electrophilic aromatic substitution to give 
the Wheland-type intermediate II, following an anti-Markovnikov process. This intermediate gives 
39a probably by a formal 1,3-H shift. The competitive 5-exo-dig cyclization with the formation of a 
five-membered ring III appears unlikely. Computational studies regarding the high energy of the 
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distorted structure of intermediate shows a kinetic and thermodynamic preference for 6-endo-dig 
versus 5-exo-dig cyclization.[83] (Scheme 26) 
 
 
Scheme 26 
Proposed Platinum catalyzed hydroarylation mechanism 
 
The method was extended to different substituted O-propargyl derivatives. The best yields were 
achieved on substrates bearing electron-donor residues on the aromatic ring. The nature of these 
substituents influenced the yields as well as the formation of the isomerized product. The 
presence of an electron-withdrawing group, as the nitro was detrimental and no product was 
achieved. To clarify if this result was due to the electron disposability of substrate or is due to the 
ability of nitro group to chelate the catalyst we have synthesized a compound with a strong 
electron-withdrawing substituent, unequivocally unable to coordinate the platinum, as the 
trifluoromethyl group (3f). Also in this case, no result was obtained, confirming the importance of 
electron disposability of the aromatic ring for the success of this reaction. Bad result was obtained 
using the N-propargyl derivative of diaminobenzene, only trace of product was found in the crude 
mixture. (Scheme 27, Table 7) 
 
Scheme 27 
Hydroarylation reaction 
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Table 7 
Hydroarylation reaction 
 Substrate Product Yield (%)a 
1 
 
 
50 (10) 
2 
 
- - 
3 
 
 
20 (5) 
4 
 
 
60 (5) 
5 
 
 
65 (-) 
6 
 
- - 
33 
 
7 
 
 
traces (-) 
a In parenthesis yield of isomerized product. 
 
Considering that the trials on propargyl derivatives were carried out on N-Boc protected 
derivatives and the good results on allyl derivatives were achieved on N-benzyl derivatives, we 
have thought to synthesize the 2-N-benzyl-O-propargyl-phenol 41, starting from 3a, using sodium 
hydride as base and benzyl bromide in DMF. The tert-butoxycarbonyl protecting group was 
removed using trifluoroacetic acid in methylene chloride. (Scheme 28)  
 
 
Scheme 28 
Synthesis of substrate 
 
Working on 41 no result was obtained as hydroamination product and poor result in 
hydroarylation reaction. (Scheme 29) 
 
 
 
Scheme 29 
  Hydroamination versus hydroarylation reactions 
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2.4 Carboamination reactions on allenes: palladium catalysis 
Considering the good result achieved in the hydroamination reaction carried out on allenyl 
derivatives we thought to explore the carboamination reactions with the aim of having a styryl 
substituent at C-2 of the heterocyclic ring that would permit further functionalization. The allenyl 
derivatives 3a-e were treated with aryl- or heteroaryl iodides, following the conditions previously 
used by our research group, in the presence of tetrakis(triphenylphosphine)palladium(0), 
potassium carbonate as base in acetonitrile at reflux.[73] The carboamination process proceed with 
complete regioselectivity resulting in the formation of five-membered ring products. The 
hypothesized mechanism occurs via the formation of a π-allyl palladium complex intermediate, 
accessible by the carbopalladation of the allene moiety followed by nucleophilic addition of the 
nitrogen atom. (Scheme 30) 
 
 
Scheme 30 
Carboamination proposed mechanism 
 
The process, which involves sequential C–C and C–N bond formation, occurred with a variety of 
electron-poor as well as electron-rich aryl iodides. The scope of the reaction was also 
successfully extended to different heteroaryl iodides, ranging from electron-rich, such as 2-
iodothiophene and N-phenylsulfonyl-3-iodoindole, to electron-poor, such as 2-iodopyridine, to 
give the corresponding heteroaryl-substituted dihydrobenzazoles in moderate-to-good yields. 
Bromobenzene was also tested; the corresponding coupling product 43a was obtained albeit in a 
lower yield (Table 8, entry 12). Moreover, it should be noted that the reaction of 11a with allyl 
bromide provided 2-(1,4-pentadienyl)-dihydrobenzoxazole (43p) in 65 % yield. (Scheme 31, Table 
8, entry 17) 
 
 
Scheme 31 
Carboamination of allenes: scope of reaction 
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Table 8 
 Substrate RX Product Yield (%) 
1 
 
 
 
76 
2 
 
 
 
62 
3 
 
 
 
54 
4 
 
 
 
48 
5 
 
 
 
57 
6 
 
 
 
78 
36 
 
7 
 
 
 
71 
8 
 
 
 
65 
9 
 
 
 
64 
10 
  
 
67 
11 
 
 
 
86 
12 
 
 
 
50 
37 
 
13 
 
 
 
86 
14 
 
 
 
70 
15 
 
 
 
65 
16 
 
 
 
46 
17 
 
 
 
65 
 
As in the case of hydroamination, we tried to extend this method to allenyl derivatives of electron-
poor heterocycles as pyrimidine and pyridine. The cyclization required the trifluoroacetyl as 
protecting group on the nucleophilic nitrogen. Compared to the aryl substrate (o-
diaminobenzene), the most relevant remark was the different regioselectivity in the C-N bond 
formation obtaining the pyrimido[4,5]diazepine (44a) through the 7-endo-cyclization process. The 
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reaction conditions required lower temperature respect to the electron-rich substrates, no 
carboamination products were obtained with different aryl- or heteroaryl iodides.  
Starting from the substituted pyridine 27, the same regioselectivity was reported in the cyclization 
step, affording 3-(4-nitrophenyl)-pyrido[3,4-b]diazepine (44b) in comparable yield. (Scheme 32) 
 
 
Scheme 32 
Carboamination of allene tethered pyridine and pyrimidine 
Table 9 
 Substrate RX Product Yield (%) 
1 
 
 
 
35 
2 
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To identify the factors that could have influenced the different regioselectivity, we have tried, at 
first, the same reaction conditions on the allenyl derivative of diamino-benzene (46), protected 
with strong electron-withdrawing trifluoroacetyl group on the nucleophilic nitrogen. (Scheme 33) 
Also in this case, we reported the 7-endo-cyclization leading the formation of 1,4-benzodiazepine 
(47) in good yield. On the same substrate we have tested different aryl-iodide but surprisingly no 
7-endo-cyclization has occurred and only the corresponding heteroaryl-substituted 
dihydrobenzazoles (43) was found in the crude mixture. (Scheme 34) 
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Scheme 33 
Substrate synthesis 
 
 
Scheme 34 
Carboamination of allene tethered o-diaminobenzene  
 
At last, we have changed the protecting group on the nitrogen bearing the allenyl moiety, leaving 
unchanged the protecting group on the nucleophilic nitrogen. The compound (52) was 
synthesized from tert-butyl N-(2-nitrophenyl)-carbamate (48), following a synthetic pathway seen 
above for the preparation of the N-tosyl derivatives. (Scheme 35)  
 
Scheme 35 
Substrate synthesis 
In this case the presence of the quite labile trifluoroacetyl group afforded a five-membered 
dihydrobenzimidazole following a 5-exo-cyclization process with loss of the trifluoroacetyl group 
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and concomitant N-aryl functionalization (53), obtained in a mixture with the non-isolated NH 
derivative (54). (Scheme 36) 
 
Scheme 36 
Carboamination of allene tethered o-diaminobenzene: influence of protecting group  
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2.5 Carboamination reaction on alkenes: palladium catalysis 
The carboamination reactions was also tried on O-allyl derivative of aminophenol, exploiting aryl 
bromide as coupling reactant. The first trial was carried out on N-tert-butoxycarbonyl protected 
derivative 37 but no result was obtained. A domino process was achieved using N-benzyl 
derivative 33a. The best reaction conditions were found exploiting 
tris(dibenzylideneacetone)dipalladium(0) as pre-catalyst, xantphos as ligand and sodium tert-
butoxide as base in toluene. (Table 10) 
Table 10 
Carboamination reactions on O-allyl ether: reaction conditions 
 
 Catalyst Ligand Solvent Time (h) Yield (%) 
1 Pd(OAc)2 (5 mol %) DPE-Phos (5 mol %) toluene 24 46 
2 Pd2(dba)3 (2 mol %) xantphos (8 mol %) toluene 4 70 
3 Pd2(dba)3 (2 mol %) xantphos (8 mol %) THF 48 20 
4 Pd2(dba)3 (2 mol %) P(o-tol)3 (8 mol %) toluene 48 - 
5 Pd2(dba)3 (2 mol %) xantphos (8 mol % toluene 2 50 
 
As expected, using a more activate bromide, such as 1-bromo-4-chlorobenzene, higher yield was 
achieved. (Scheme 37) In this process a new stereocenter was formed and the next challenge will 
be to obtain stereoselective ciclization reaction. 
 
Scheme 37 
Carboamination reactions on O-allyl ether 
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Chapter 3 
 
Synthesis of polyheterocyclic systems of biological interest through 
transition-metal catalysis 
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3.1 Design, synthesis and biological evaluation of a new scaffold of topoisomerase I 
inhibitors[84] 
Inhibition of topoisomerases activities, essential enzymes for vital cellular processes, is lethal and 
leads to cell death, thus establishing topoisomerases as a promising target for cancer 
treatment.[85] Recently, a series of 2,3-heteroaryl substituted maleimides and heterofused imides 
as well the corresponding bis-derivatives were prepared by our research group and their 
antiproliferative effects on human cells (NCI-H460 lung carcinoma) and rat aortic smooth muscle 
cells (SMC's), as well as their ability to stabilize the DNA-intercalator-topoisomerase II ternary 
complex were evaluated. The compounds of these series showed IC50 values comparable to 
those observed for the leading molecule Elinafide. They affected G1/S phase transition of the cell 
cycle, showed in vitro DNA intercalating activity and in vivo antitumor activity.[86,87] Continuing the 
researches having topoisomerases as biological target, our interest is now addressed to 
topoisomerase I (Topo I).  The interest in topoisomerase I as a therapeutic target promoted 
various efforts to identify other chemotypes effective as topoisomerase inhibitors and 
chemical/modelling efforts to rationally design specific analogs among known inhibitors. Their 
screening with purified Topo I and isolated DNA substrates led to the discovery of various Topo I 
inhibitors belonging to the different chemistry families. 
 
 
3.2 DNA topoisomerases: mechanism and role in cancer treatment 
The topoisomerases are ubiquitous enzymes essential for the vital cellular processes as involved 
in different steps of DNA replication, transcription and recombination. In particular topoisomerase 
I and topoisomerase II play a key role binding to the DNA double helix inducing temporary single 
(Topo I) or double strand break (Topo II) allowing relaxation of the DNA for replication. 
The catalytic mechanism of topoisomerases in all cases consists in a nucleophilic attack of a DNA 
phosphodiester bond by a catalytic tyrosyl residue of the enzyme. The resulting covalent 
attachment of the tyrosine to the DNA phosphate is either at the 3′-end of the broken DNA in the 
case of topoisomerase I enzymes or at the 5′-end of the broken DNA for the topoisomerase II. 
Topoisomerase I are the only that operates through covalent link with the 3′-end of the broken 
DNA while generating a 5′-hydroxyl end at the other end of the break. Topo I relaxation 
mechanism consists in “controlled rotation”: the enzyme relaxes DNA by letting the 5′-hydroxyl 
end swivel around the intact strand. This processive reaction does not require ATP or divalent 
metal binding (Mg2+), which is different from the case of Topo II enzymes.[88] (Figure 4) 
44 
 
 
 
Figure 4 
Topo I establishes a covalent bond to the DNA, creating a nick that allows for rotation of the DNA about the 
remaining, intact DNA strand; at last the DNA has been religated.[89] 
 
Topoisomerases are required for both normal and cancer cells, but are overexpressed in cancer 
cells due to the high level of DNA metabolism and intrinsic defects in DNA repair and 
checkpoints, which are the landmarks of cancer cells. The inhibition of these enzymes lead to the 
cell apoptosis. Thus DNA topoisomerases I and II are established molecular targets of anticancer 
drugs. 
 
3.3 Camptothecin and synthetic Topo I inhibitors 
Camptothecin was first isolated from the bark of the Chinese tree, Camptotheca acuminata. 
(Figure 5) It was discovered and was tested clinically in the mid 1970’s and showed anticancer 
activity, but was discontinued because of its side effects. 
 
 
Figure 5 
Camptotheca acuminate and camptothecin 
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Besides the major limitation of camptothecins is the instability at physiological pH. They are 
inactivated within minutes by lactone E ring opening. (Figure 6a). Two approaches have been 
taken to overcome this problem: addition of a methylene group in the E ring whit the synthesis of 
homocamptothecins, as Diflomotecan and conversion of the E ring to a five-membered ring. The 
first approach limits E ring opening but, once this happens, they become irreversibly. In the 
second approach, conversion of the E ring to a five-membered ring completely stabilizes the drug. 
The complete stabilization of the E-ring has been successfully achieved with the removal of the 
lactone. The α-keto derivatives, as S39625.51, are highly potent synthetic compounds against 
Topo I.[85] (Figure 6b) 
 
Figure 6 
a) E-ring lactone opening; b) synthetic approach to overcome the E-ring opening 
 
The other drawback in the use of camptothecins is their low solubility in water. After the discovery 
that Topo I is the cellular target of camptothecin, the water-soluble derivatives of camptothecin, 
Topotecan and Irinotecan, were successfully developed. Unlike the first, Irinotecan is a prodrug: 
the bis-piperidine residue is removed in liver by carboxylesterase.[89] (Figure 7) 
 
Figure 7 
Topotecan and Irinotecan 
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3.4 Noncamptothecin Topo I Inhibitors 
Since camptothecins have several limitations in therapeutic employ (instability and low solubility, 
as said above, but also resistance and severe side-effects), noncamptothecin Topo I inhibitors 
have been developed in the last years. Three important chemical families are 
indenoisoquinolines[90] and indolocarbazoles[91] and phenantridines.[92] (Figure 8) 
 
 
Figure 8 
Noncamptothecin Topo I Inhibitors families 
 
The indolocarbazoles were the first introduced but appear to hit other cellular targets besides 
Topo I. The indenoisoquinolines are chemically stable and their antiproliferative activity is similar 
to or greater than that of camptothecins (NCI60 cell lines). They selectively target Topo I, but they 
trap the enzyme at differential sites from camptothecins. They are not substrates for the ABC 
membrane transporters which suggests an ability to overcome resistance to camptothecins. The 
phenanthridine derivatives share many of the same advantages as the indenoisoquinolines, 
which is not surprising considering the chemical similarities between the two families. 
 
3.5 Mechanism of action of Topo I inhibitors 
From a mechanistic point of view, agents that inhibit topoisomerase I can be grouped into two 
classes: poisons and suppressors. Both inhibit the catalytic activity of the enzyme, nevertheless 
poisons stabilize a covalent intermediate complex, called cleavable complex, thus producing 
single-stranded DNA breakages. Otherwise, suppressors interfere with other steps of the catalytic 
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cycle without stabilize the cleavable complex, for example through a direct interaction with the 
enzyme or the formation of a molecular complex with DNA. The cytotoxicity of Topo I inhibitors is 
due to the trapping of Topo I rather than a real inhibition of catalytic activity, thus camptothecins 
are defined as Topo I poison. As said above the Topo I acts through cutting of a single DNA 
strand thus allowing a controlled rotation of the DNA-Topo I complex around the unbroken strand. 
 
 
 
Figure 9 
Ternary complex formation 
 
The early interaction between Topo I and DNA leads to the formation of a complex binary 
complex. The camptothecins show affinity for the binary complex rather than either Topo I or DNA 
alone. The interaction of the drug with the binary complex generate the ternary complex. (Figure 
9) The stabilization of the cleavage ternary complex is the result of specific inhibition of the 
religation, the most critical step in the catalytic cycle. The ternary complex is potentially reversible 
and non lethal, but the collision of this complex with the replication fork leads the cell apoptosis. 
The ternary complex is stabilized by an array of hydrogen bonding and hydrophobic interactions 
between the drug and both the enzyme and the DNA.[85,88,Errore. Il segnalibro non è definito.] 
 
3.6 Scaffold, design and retrosyntethic pathway 
Our efforts were addressed to realize a new heteropolycyclic scaffold, having Topo I as biological 
target. The general structure has been designed considering some structural analogies among 
the 5-lipooxygenase inhibitors, physostigmine derivatives and camptothecins.[84] (Scheme 41) 
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Scheme 41  
Scaffold design 
 
 
3.7 Scaffold synthesis 
Two possible retrosynthetic pathways were initially identified to obtain the scaffold: path A, 
starting from triptamine and path B starting from 3-substituted indoline, in both cases followed as 
a key steps by a sequence of N-arylation/aromatic acylation. The minor steps prompted us to 
follow path A. (Scheme 38) 
Starting from substituted tryptamines (56), the first step provided the formation of the tricyclic 
tetrahydropyrrolo[2,3-b]indoles (58) through the intramolecular reaction of the carbamates (57) 
under the catalysis of Pd-complex/Lewis acid (Pd(PPh3)4/Et3B) in THF as solvent at r.t.[93] The 
alkylative amination step was performed in the presence of allyl alcohol as electrophile resulting 
the concomitant insertion of the allyl substituent in position 3a. Both Pd-complex and Et3B Lewis 
acid were necessary to obtain allylation. The intramolecular amination was stereoselective giving 
only the cis isomer in the junction of the B and C rings, as stated by 1H NMR NOESY experiments 
(Scheme 39). 
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Scheme 38 
Retrosynthetic pathway 
 
50 
 
The tricyclic systems (58) were in all the cases obtained as enantiomers mixture. Attempts to 
separate the isomers as diastereoisomers by using chiral carbamate derivatives of the triptamine 
(S)-(-)-2-methylbutyl carbamate, (1S)-(+)-menthyl carbamate, (1R)-(-)-myrtenol carbamate) gave 
unsatisfactory results or failed in the cyclization step. 
 
 
 
Scheme 39 
Synthesis of tetrahydropyrrolo[2,3-b]indoles 
 
The subsequent step consist in the substitution of the indolic nitrogen with an opportune aryl 
halide, the 2-chloroquinoline-3-carbaldehydes (59). No result was obtained attempting the SNAr 
reaction using LDA. Thus a Pd-catalyzed Buchwald-Hartwig N-arylation has been attempted, 
using the conditions reported in literature. At first we used palladium acetate as catalyst, BINAP 
as ligands and Cs2CO3 base in toluene at 110 °C. The reaction condition was after optimized as 
reported in Table 1.  The best conditions employed tris(dibenzylideneacetone)dipalladium(0) as 
pre-catalyst, triisobutylphosphatrane (A) as ligand and sodium tert-butoxide as base in toluene at 
110°C. The reaction required the protection of the formyl substituent as acetal (60) (Scheme 40, 
table 11) The subsequent step was the intramolecular Friedel-Crafts reaction of the intermediate 
61 using the BF3-Et2O as Lewis acid and carrying out the reaction on the protected formyl group 
directly. The polyheterocyclic alkylated derivative was obtained as a mixture of two products 62 
and 63, one of which was the oxidized form in position 7. (Scheme 41) This is due to the 
particular mechanism of the reaction, which occurs through an oxido-reductive path.[94] (Scheme 
42) The treatment of the mixture with oxidants manganese(IV) oxide and m-CPBA resulted in the 
complete transformation of compound 62 in 63. 
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Scheme 40 
Buchwald-Hartwig reaction  
 
Table 11 
Buchwald-Hartwig reaction optimization 
 Catalyst Ligand Base T °C Time (h) Yield (%) 
1 Pd(OAc)2 (2 mol %) BINAP (2 mol %) Cs2CO3 110 24 10 
2 Pd(OAc)2 (2 mol %) dppf (2 mol %) tBuOK  110 24 5 
3 Pd(OAc)2 (2 mol %) Ligand A (4 mo l%) Cs2CO3 110 24 25 
4 Pd2(dba)3 (5 mol %) BINAP (10 mol %) tBuONa  110 24 60 
5 Pd2(dba)3 (5 mol %) BINAP (10 mol %) Cs2CO3 100 24 70 
6 Pd2(dba)3 (1 mol %) Ligand A (4 mol %) tBuONa 100 24 75 
7 Pd2(dba)3 (0.5 mo l%) Ligand A (2 mol %) K2CO3 100 24 75 
8 Pd2(dba)3 (2 mol %) Ligand A (8 mol %) tBuONa  110 3 85 
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Scheme 41 
Friedel-Crafts intramolecular reaction  
 
 
Scheme 42 
Proposed mechanism for Friedel-Crafts intramolecular reaction 
53 
 
3.8 Functionalization of the scaffold 
The insertion of different substituents on the polycyclic scaffold has been realized with the aim to 
evaluate changes in the biological activity, in fact the presence of polar groups may have strong 
interaction with the enzyme. The functionalization in position 1 may be obtained from 63 by 
reduction of the carbomethoxy group using sodium bis(2-methoxyethoxy)aluminium hydride (Red-
Al) in toluene to give compound 64. (Scheme 43) or by basic hydrolysis obtaining derivatives 65a-
d. (Scheme 44)  
 
Scheme 43 
Reduction of carbomethoxy group in position 1 
 
 
Scheme 44 
Hydrolysis of carbomethoxy group in position 1 
 
The methoxy substituents may be present in positions 5 and 10, the reaction with BBr3 in 
dichloromethane of the intermediates 65b and 65d resulted in the formation of the phenolic 
derivatives 66a-b. (Scheme 45) 
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Scheme 45 
Hydrolysis of methoxy substituents 
 
 
 
Scheme 46 
Modification of allyl residue in 3a position 
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The 2-hydroxyethyl substituent selected as polar branch, was formed in position 3a from the allyl 
substituent through the sequence oxidation and reduction. The first attempt using ozone failed, 
probably due to instability of the tetrahydropyrroloindole portion under ozonolysis conditions. 
Thus, osmium tetroxide and sodium periodate was employed to obtain the aldehyde derivative 
67, followed by the reduction with sodium borohydride achieving the hydroxyethyl residue 68. 
(Scheme 46)  
The hydrolysis of the compound 68 carried out in basic conditions afforded in satisfactory yield 
the free amine derivative 69.  (Scheme 47) 
 
 
Scheme 47 
Hydrolysis of carbomethoxy group in position 1 
 
The projected decoration of the scaffold involved the insertion of a dimethylaminomethyl group, 
present also on the TPT, synthetic derivative of CPT. The product was obtained through a 
Mannich reaction but to have the product it is required the presence of both hydroxy group in 
position 10 and the protection on the amine in position 1. The Mannich reaction was carried out 
on compound 70, protected with tert-butoxycarbonyl group in position 1, obtained from 66a with 
di-tert-butyl dicarbonate. The Mannich product was achieved using aq. formaldehyde and 
dimethylamine, in ethanol at room temperature. The N-protecting group was at last removed 
using chlorotrimethylsilane, giving the compound 72. (Scheme 48) 
The same synthetic pathway was repeated starting from the compound 69. In this case the first 
step was the hydrolysis of the methoxy group in position 10. The last step has to be also in this 
case the deprotection of the amine in position 1, but the compound 75 is unstable under the 
reaction conditions. Different deprotection procedures were tried, but in all case with 
unsatisfactory results. (Scheme 49) 
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Scheme 48 
Insertion of dimethylaminomethyl group in position 9 
 
 
 
Scheme 49 
Insertion of dimethylaminomethyl group in position 9 
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This synthetic pathway allowed the synthesis various derivatives, diversified each other by the 
presence of different substituents in position 1, 3a, 5, 9 and 10 of the hexacyclic scaffold. (Figure 
10, table 11) 
 
 
Figure 10 
Different substituents on the hexacyclic scaffold 
 
Table 11 
 R1 R2 R3 R4 R5 
64 Me Allyl OMe H OMe 
65a H Allyl H H H 
65b H Allyl H H OMe 
65c H Allyl OMe H H 
65d H Allyl OMe H OMe 
66a H Allyl H H OH 
66b H Allyl OH H OH 
69 H (CH2)2OH H H OMe 
70 Boc Allyl H H OH 
74 Boc (CH2)2OH H H OH 
71 Boc Allyl H CH2NMe2 OH 
75 Boc (CH2)2OH H CH2NMe2 OH 
72 H Allyl H CH2NMe2 OH 
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3.9 Biological evaluation: antiproliferative activity 
The ability of new derivatives to inhibit cell growth was investigated by an in vitro assay on three 
human tumor cell lines, H460 (large cell lung carcinoma), MSTO-211H (human biphasic 
mesothelioma) and HeLa (cervix adenocarcinoma). The results, expressed as GI50 indicate for all 
tested derivatives a detectable antiproliferative activity, with values in the micromolar range. 
Among the new synthesized compounds, the most active is 69, characterized by the 2-
hydroxyethyl substituent in position 3a and a methoxy group in 10, which shows GI50 values in the 
low micromolar range in all considered cell lines. For 65b and 66b, GI50 values lower that 10 µM 
are obtained in two cell lines (H460 and MSTO-211H). For all other compounds the cytotoxicity is 
lower and indeed GI50 values ranging from 13.0 to 35.2 µM can be observed. All results, 
expressed as GI50 values, are shown in Table 2. The camptothecin was used as reference 
compound. 
 
Table 12 
Cell growth inhibition in the presence of tested compounds (CPT as reference compound) 
 
 GI50a (µM) 
 H-460 MSTO-211H HeLa 
64 › 50 34.2 ± 7.9 18.3 ± 1.2 
65a 14.4 ± 0.9 13.0 ± 2.1 16.5 ± 1.0 
65b 8.9 ± 1.4 7.8 ± 1.0 14.8 ± 1.5 
65c 32.2 ± 4.7 14.4 ± 3.3 30.7 ± 4.8 
65d 18.6 ± 0.3 13.5 ± 2.6 16.6 ± 3.8 
66a › 50 18.7 ± 0.6 19.0 ± 0.5 
66b 4.8 ± 1.0 7.0 ± 0.9 15.3 ± 0.8 
69 0.85 ± 0.09 1.9 ± 0.3 1.4 ± 0.3 
70 32.7 ± 0.8 24.1 ± 1.6 30.5 ± 1.8 
74 26.8 ± 2.0 13.7 ± 0.9 13.0 ± 2.2 
71 17.8 ± 1.7 22.8 ± 2.4 35.2 ± 1.6 
75 16.4 ± 1.4 20.0 ± 1.6 13.0 ± 1.0 
75 26.2 ± 1.2 29.1 ± 1.9 29.3 ± 5.6 
CPT 0.0020 ± 0.0002 0.0021 ± 0.0001 0.0054 ± 0.0002 
 
a Mean values ±SD of at least three independent experiments are reported 
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On the basis of these data, some preliminary structure-activity relationships could be drawn. In 
particular, the presence of the 2-hydroxyethyl chain in 69 seems to be determinant for the 
biological activity. Indeed, the presence of the allyl substituent (65b) induces a significant 
decrease in cytotoxicity, especially in H460 and HeLa cells where an increase of about of one 
order of magnitude can be observed. Nevertheless, the effectiveness of the 2-hydroxyethyl is 
considerably dampened by the presence of Boc in position 1 and hydroxyl in position 10 and/or a 
dimethylaminomethyl side chain in position 9 as suggested by the comparison between 69 and 74 
or 71. It is noteworthy that the presence of a substituent in position 1 (methyl or Boc) appears 
detrimental for the occurrence of the cytotoxic capacity in all compounds (64, 70, 74, 71 and 75) 
and indeed they show high GI50 values. 
 
3.10 Biological evaluation: interaction with DNA 
The interesting antiproliferative effect exerted by the most biologically active compound 69 and in 
particular, the presence of a wide planar heteropolycyclic scaffold, suggested an investigation on 
the ability to form a molecular complex with DNA through an intercalative mode of binding. For 
this purpose flow linear dichroism (LD) experiments were performed with DNA solutions in the 
absence and in the presence of 69 and the corresponding allyl derivative 65b. The obtained LD 
spectra are shown in Figure 11, the UV-vis absorbance spectra of the test compounds (A) are 
also reported as reference. 
 
Figure 11 
Absorbance spectra (A) for compounds 69 and 65b at 1.2 X 10-5 M. Linear flow dichroism spectra (LD) for 
compounds 69 and 65b at different [compound]/[DNA] ratios: dotted line ¼ 0; continuous line ¼ 0.08.  
[DNA] ¼ 1.9 X 10-3 M 
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Both LD spectra show an evident negative signal at 260 nm, typical of the macromolecule and 
due to the strong absorption of DNA base pairs at this wavelength. Moreover, interestingly, in the 
presence of the considered derivative (continuous lines) a further dichroic signal appears at 
higher wavelengths (380e520 nm). Because no contribution from the macromolecule exists in this 
latter spectral region, the occurrence of the signal has to be attributed to the added chromophore, 
which, otherwise, absorbs at these wavelengths (see absorption spectra, A). Since small 
molecules, such as 69 and 65b, cannot become oriented in the flow field, the occurrence of the 
LD signal has to be attributed to the formation of a molecular complex with DNA that permit them 
the orientation. Moreover, the negative sign of the LD signal, as the strong band at 260 nm, 
indicate a parallel orientation of the planar hexacyclic system of new derivatives with respect to 
the plane of the purine and pyrimidine base pairs. This means that 69 and 65b form a complex 
with DNA via an intercalative mode of binding. 
3.11 Biological evaluation: effect on topoisomerase 
 
 
Figure 12 
Effect of compounds 69 and 65b on relaxation of supercoiled pBR322 DNA mediated by topo I  
 
At this point the ability of the most active derivative 69 and 65b to affect the catalytic activity of 
Topo I were investigated. Figure 12 shows the effect of the test compounds on the relaxation of 
supercoiled DNA mediated by Topo I. The enzyme removes supercoils from pBR322 plasmid 
supercoiled DNA 
69      CPT  
100       50  (M) 
 relaxed and nicked DNA 
  relaxed DNA 
 relaxed and nicked 
DNA 
supercoiled DNA 
65b   CPT  
100   50 (M) 
  relaxed DNA 
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DNA (lane DNA) giving rise to a population of relaxed DNA topoisomers that migrates differently 
depending on their linking number (lane Topo I). The results shown in figure 12 indicate that both 
69 and 65b affects the relaxation activity of the enzyme and indeed they induce both a decrease 
in the number of topoisomers and an increase in the intensity of the band corresponding to the 
relaxed plus nicked DNA. This behavior, similar to that observed for CPT, a well-known 
topoisomerase I poison, demonstrate the capacity of test compounds to interfere with the catalytic 
activity, but does not allow to establish if it is due to a poisoning effect.  
 
 
Figure 13 
Effect of compounds 24 and 20b on the stabilization of covalent-DNA Topo I complex 
 
Therefore, to discriminate between a specific poisoning action and other possible nonspecific 
effects, due for example to DNA intercalation, the experiments were performed with agarose gel 
containing ethidium bromide and the results are showed in figure 13, in comparison with 
champtothecin. Indeed, in these latter experimental conditions the DNA species moving toward 
the anode become progressively saturated by the intercalative effect of ethidium and this 
influences significantly their rate of migration. Otherwise, the electrophoretic mobility of the band 
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corresponding to the nicked DNA, resulting from the stabilization of the cleavable complex, is 
unaffected by the presence of ethidium bromide and thus can be easily detected. 
The results obtained by incubating DNA and enzyme in the presence of increasing concentrations 
(from 10 to 100 µM) of 69 indicate for this compound the ability to induce the formation of the 
cleavable complex as from 25 µM. For the analogue 65b a lower poisoning effect emerges from 
the experiments reported in Figure 13. Indeed, for this latter derivative, a concentration of 500 µM 
has to be used to detect a significant increase in the band corresponding to the nicked DNA. For 
the well-known poison champtothecin, as expected, a notable amount of nicked DNA is formed 
already at 0.5 µM concentration. It is interestingly to note that these results are in agreement with 
cytotoxicity data reported in Table 12. Indeed, 69 demonstrates an antiproliferative effect clearly 
higher with respect to 65b, with GI50 values from 4 to 11 times lower, depending on the cell line 
taken into consideration. As regard CPT, its cytotoxicity is notably higher with respect to both new 
derivatives and indeed 
GI50 even in the nanomolar range are obtained (Table 12). Thus, it can be concluded that a 
correlation can be drawn between the poisoning effect and the antiproliferative ability. 
 
3.12 Analysis of the binding mode 
The binding mode of the most interesting compounds 69 and 65b was analyzed by docking 
calculations and compared to that of the reference crystallographic compound topotecan (Figure 
14). The docked conformation of reference compound topotecan is in excellent accord with the 
crystallographic structure (Figure 15), providing support to the following discussion. Moreover, the 
binding energies computed for topotecan, 69 and 65b are -129.4, -128.4 and -128.2 kcal/mol, 
respectively, thus the docking software correctly ranks the three compounds.  
The binding mode predicted for 69 and 65b (Figure 12, panels A, C and D) shows that the 
tetracyclic planar moiety is in both cases well packed in-between the two DNA bases pairs made 
by deoxycytidine 599 and deoxyguanosine 576 (corresponding to the 50 terminus of the cleaved 
DNA strand) and by deoxyadenosine 600 and thymidine 575, which is covalently bound to Tyr523 
through its 30 phosphate group.  
The benzonaphthyridinone group of 69 and 65b (rings A-C) are partially overlaid with the 
pyrroloquinoline group of topotecan (rings A-C), with the scaffold of the former compounds being 
slightly shifted toward the a-helix formed by residues Thr518 Tyr523. This shift allows compounds 
69 and 65b to form a moderately strong H-bond involving the nitrogen atom of ring B and the 
guanidine group of Arg164 (N…H distance = 2.47 and 2.42 Å; N…HeN angle = 170.8 and 169.0 
deg. for compounds 69 and 65b, respectively). The difference in antiproliferative activity (Table 
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12) and in Topo I poisoning (Figures 12 and 13) observed for compounds 69 and 65b are 
reasonably due to the substituent at C-3a. Indeed, the allyl chain of 65b is not apparently involved 
in any interaction with either topoisomerase or DNA. Conversely, a rather strong H-bond is 
observed between the hydroxyethyl substituent and the acidic group of Asp333 (H…O=C distance 
= 1.65 Å; O-H…O=C angle = 175.5 deg.). 
 
Figure 14 
Panel A: Predicted binding mode for compounds 69 (carbon atoms coloured in magenta) and 65b 
(carbon atoms coloured in orange). The crystallographic structure of topotecan (PDB code: 1K4T; 
carbon atoms coloured in green) is also reported as a reference. Panels B, C and D: diagram 
reporting all ligand interactions for topotecan and compounds 65b and 69, respectively. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web 
version of this article.) 
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Figure 15 
Comparison between the binding pose of topotecan obtained by docking (carbon atoms colored in 
magenta) and the crystallographic structure (1K4T.pdb, carbon atoms colored in green). 
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3.13 Synthesis of new oxazino[2,3,4-hi]indole derivatives  
Different scaffold endowed with inhibitory capacity against topoisomerases I and II and in 
particular showing no parallel cytotoxic activities was represented by pyrido[3,2,1-kl]phenoxazine 
derivatives as compound A-62176.[95] Recently, more evidence has been obtained that suggests 
that phyto-, endo- and synthetic cannabinoids could be useful in the treatment of cancer due to 
their ability to regulate cellular signaling pathways critical for cell growth and survival.[96] Among 
the cannabinoid derivatives, the chemical structure of WIN 55,212-2 involving the 1,4-oxazine ring 
fused with the indole skeleton exhibits anti-cancer effects in a variety of different cancerous cell 
lines including human prostate cancer,[97] human glioblastoma multiforme,[98] rat glioma[99] and 
B16 melanoma cells.[100] Moreover a series of 5,7-dibromo isatin derivatives exhibited in vitro 
anticancer activity on the human cancer cell lines including colon HT29. They were demonstrated 
efficient dual inhibitors of tubulin polymerization and the Akt (Protein kinase B) pathway.[101,102] 
(Figure 16) 
 
 
 
Figure 16 
Cytotoxic heterocycles 
 
These considerations prompted us to design a heteropolycyclic system endowed with cytotoxic 
activity, based on scaffold hopping combining some of the structural features of 
pyridophenoxazine, oxazinoindole and dibromoisatin.[103] (Figure 17) 
 
 
Figure 17 
Designed scaffold 
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We have identified as key intermediate of the synthetic pathway the N-2-hydroxyethyl-5,7-
dibromo isatin able to give a double functionalization through the transition-metal catalyzed 
reactions. (Figure 18) 
 
 
 
Figure 18 
Designed substrate for double functionalization 
 
 
The first trial for the synthesis of the scaffold, starting from 5,7-dibromoisatin and using 2-
bromoethanol and sodium hydride as base in DMF as solvent failed. Indeed, the N-hydroxyalkyl 
intermediate was unstable and rearranged in basic condition leading the formation of 
spiroisatin.[104] Thus, we have exploited this reactivity to achieve N-hydroxyalkyl spiroisatin in one 
step, using two equivalent of 2-bromoethanol and sodium hydride. (Scheme 50) 
 
 
 
Scheme 50 
Synthesis of designed key intermediate 
 
The subsequent desired cyclization didn’t give product in different reaction conditions then we 
prepared dibromo isatins protected in position 3 with different acetals, exploiting similar synthetic 
pathways. (Scheme 51).  
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Scheme 51 
Synthesis of substrates 
 
The intermediate 79 was then cyclized through an intramolecular alkoxylation reaction in order to 
obtain the oxazinoindole scaffold. The C-O bond formation was achieved under copper catalysis, 
exploiting the Ullmann-type reaction. The use of oxygen nucleophile, compared to nitrogen, has 
remained a less explored area due to the diminished nucleophilicity of this atom and different 
reaction conditions were tested to achieve the cyclized product. The best reaction conditions used 
copper acetate as catalyst, in toluene as solvent in the presence of sodium hydride as base. 
(Entry 12) No reaction was obtained with different bases. (Table 13) 
 
Table 13 
Intramolecular Ullmann-type reaction condition 
 
 
 
 Catalyst (mol %) Ligand Base Yield 
1 Pd(OAc)2 (2.5 mol %) JohnPhos (3 mol %) Cs2CO3 (1.5 equiv.) -. 
2 Pd2(dba)3 (2 mol %) BINAP (5 mol %) NaH (2.5 equiv.) - 
4 Pd2(dba)3 (2 mol %) t-BuDavePhos (7 mol %) t-butONa (1.5 equiv.) dimer 
5 Pd(OAc)2 (2.5 mol %) t-BuDavePhos (7 mol %) Cs2CO3 (1.5 equiv.) - 
6 Pd(OAc)2 (2.5 mol %) dppf (4 mol %) t-butONa (1.2 equiv.) dimer 
8 CuI (10 mol %) 1,10-Phen (20 mol %) Cs2CO3 (2 equiv.) 20 % 
9 CuI (5 mol %) 8-OH-quinoline (10 mol %) NaH (1.25 equiv.) 10 % 
10 Cu(OAc)2 (10 mol%) - NaH (2 equiv.) 80 % 
68 
 
Using spiro[1,3]dioxane derivative 81 the cyclization reaction was performed using copper(I) 
iodide as catalyst and 8-hydroxyquinoline as ligand. NaH as base and toluene as solvent have 
remained irreplaceable. (Scheme 52) 
 
 
Scheme 52 
Intramolecular Ullmann-type reaction 
 
To afford the functionalized scaffold the bromine atom in position 5 was susceptible of a second 
nucleophilic substitution, exploiting tandem Cu/Pd catalyzed processes as alkoxyamination, 
alkoxyarylation, a double alkoxylation. The alkoxylation/arylation process (involving Suzuki-
Miyaura reaction) starting from 79 and using the p-tolyl boronic acid afforded 5-tolyl oxazinoindole 
(84). The yield of the one-pot reaction was comparable with the overall yield of two reactions 
carried out with the isolation of the intermediate product. (Scheme 53)  
 
Scheme 53 
One-pot alkoxylation/arylation reaction 
 
The alkoxylation/amination (involving Buchwald-Hartwig reactions) using substituted anilines 
resulted in a 5-arylamino oxazinoindoles (85a). (Scheme 54) The same amination reactions, in 
lower yields, were obtained under copper catalysis (involving Ullmann-type reaction) (85a-d) 
(Scheme 55, table 14) 
 
Scheme 54 
Palladium catalyzed amination reaction 
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Scheme 55 
Copper catalyzed amination reactions 
 
Table 14 
Copper catalyzed amination reactions 
 
 Substrate RNH2 Cat. Solvent 
Product Yield 
(%)  
1 
 
 
CuI DMSO 
 
40 
2 
 
 
Cu MeCN 
 
20 
3 
 
 
CuI DMSO 
 
50  
4 
 
 
CuI DMSO 
 
40  
 
Alkoxylation using p-cresol, copper(I) chloride as catalyst in NMP as solvent, was obtained in 
lower yield, due to the less nucleophilicity of the oxygen. (Scheme 56) 
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Scheme 56 
Double alkoxylation reaction 
 
Then we explored the possibility to perform the alkoxyamination or the double alkoxylation in one 
step, starting from 81 under copper catalysis without the need of the isolation of intermediate 83, 
as a cascade process. The development of cascade reactions is an important goal in organic 
synthesis from the viewpoint of operational simplicity and assembly efficiency. (Scheme 57) 
 
 
Scheme 57 
One step alkoxyamination reactions 
 
The 5-bromoindolooxazines 82, 83 and the substituted derivatives 85 will be tested in order to 
evaluate the cytotoxicity. Preliminary results in collaboration with Catania University showed 
some activity of the N-alkylated-5,7-dibromoisatin derivatives but no anticancer activity for the 
oxazinoindole derivatives. A positive aspect was regarding the toxicity in primary cells, we 
observed that none of the compounds was toxic at the concentrations effective on cancer cells. 
 
  
71 
 
 
 
Chapter 4 
 
Conclusion  
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In conclusion, different scaffolds were achieved exploiting palladium and platinum catalysis. 
Starting from the same or similar substrates substituted with alkynes, alkenes and allenes and 
using different protecting group we have obtained dihydrobenzoxazines, dihydroquinoxalines, 
dihydrobenzoxazole, dihydrobenzoimidazoles, benzopyrans and dihydroquinolines. Furthermore, 
dihydro-purine and dihydro-deazapurine, pyrimido- and pyridodiazepine was achieved starting 
pyridine and pyrimidine tethered with the same unsaturated residues. At the end, exploiting 
carboamination reactions we have achieved different scaffolds substituted with aryl moiety. 
(Figure 19) 
 
Figure 19 
Hydroamination, hydroarylation and carboamination product 
 
Furthermore, the preparation of a new scaffold starting from triptamines exploiting as a key step 
the sequential protocol palladium catalyzed N-arylation/intramolecular Friedel-Crafts alkylation. 
The antiproliferative activity of the derivatives due to the Topo I inhibition has been evaluated. 
Although the potency of the new derivatives is two orders of magnitude lower than that of CPT, all 
compounds resulted active on at least two of the three evaluated cell lines. A computational 
binding mode analysis has been performed on most active compound to provide insights possibly 
useful for designing decorations that might improve the activity of the scaffold. 
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At the end, the copper catalysis was exploited to achieve of new oxazino[2,3,4-hi]indole 
derivatives. The synthesis, starting from commercially available 5,7-dibromoisatin exploit a double 
sequential functionalization as alkoxyamination, alkoxyarylation, or double alkoxylation. The 5-
bromoindolooxazines intermediate and the substituted derivatives will be tested in order to 
evaluate the cytotoxicity. 
All the methodologies exploited in this thesis afforded heterocycles and heteropolycyclic systems 
obtained in good yields, performed with normal procedures not requiring particular conditions or 
apparatus. The different yields of the products are due to the different reactivity of the substrates 
used, the efficiency of the processes are in all the cases confirmed. 
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Chapter 5 
 
Experimental section  
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All NMR spectra regarding the third chapter are available in the Supporting Information (A. Mazza, E. M. 
Beccalli, A. Contini, A. N. Garcia-Argaez, L. Dalla Via, M. L. Gelmi, A new scaffold of topoisomerase I 
inhibitors: design, synthesis and biological evaluation, Eur. J. Med. Chem., 2016 (124) 326-339): 
http://dx.doi.org/10.1016/j.ejmech.2016.08.045 
 
 
1. Chemisrty 
 
 
General details: melting points were determined by the capillary method with a Büchi B-540 
apparatus. IR spectra were recorded with a Jasco FT/IR 5300 spectrometer. 1H and 13C NMR 
spectra were recorded with a Bruker AVANCE 400 spectrometer at 400 and 100 MHz, a Varian 
Gemini 200 MHz spectrometer at 200 and 50 MHz and a Varian Oxford 300 MHz spectrometer at 
300 and 75 MHz. Chemical shifts are given as δ values in ppm relative to residual solvent peaks 
(CHCl3) as the internal reference. 13C NMR spectra were 1H-decoupled and the multiplicities 
determined by the APT pulse sequence. Mass spectra were recorded with a LCQ Advantage 
Thermo Finningan spectrometer. Elemental analyses were executed with a Perkin–Elmer CHN 
Analyser Series II 2400. TLC separations were performed on pre-coated Merck silica-gel 60-
F254. Preparative separations were performed by flash chromatography on Merck silica gel 
(0.035–0.070 mm).  
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tert-Butyl (2-(4-methyl-N-(prop-2-yn-1-yl)phenylsulfonamido)-phenyl)carbamate (8) 
 
 
Boc2O (1.2 equiv.) was added to a solution of N-tosyl-N-propargyl-2-aminoaniline 7 (1 equiv) in THF (60 
mL) at room temperature. The reaction mixture was heated at reflux for 24 h. Every 8 h, further Boc2O (1.2 
equiv.) was added. The solvent was removed under reduced pressure, water was added to the residue and 
the solution was extracted with AcOEt (3 ×). The organic phases were dried with Na2SO4, filtered and the 
solvent removed under reduced pressure. The crude product was purified by flash chromatography on 
silica gel to afford the product. 
Yield: 67%. 
White solid; m.p.: 125 - 127 °C. 
1H NMR (200 MHz, CDCl3): δ = 8.14 (dd, J = 8.4, 1.3 Hz, 1 H), 7.59 (d, J = 8.4 Hz, 2 H), 7.40 (br. s, 1 H, 
exchange with D2O), 7.25– 7.34 (m, 3 H), 6.82 (td, J = 8.0, 1.5 Hz, 1 H), 
6.66 (dd, J = 8.0, 1.5 Hz, 1 H), 4.40 (br. s, 1 H), 4.34 (br. s, 1 H), 2.17 (t, J 
= 2.5 Hz, 1 H), 1.52 (s, 9 H), 2.44 (s, 3 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 153.0 (s), 144.6 (s), 138.5 (s), 134.8 (s), 130.1 (d), 129.6 (d), 128.8 (d), 
128.7 (d), 127.6 (s), 122.6 (d), 120.7 (d), 80.9 (s), 77.6 (s), 74.3 (d), 41.9 
(t), 28.6 (q), 21.8 (q), ppm. 
IR: ν˜ = 3395, 3266, 2999, 2968, 2930, 2120, 1722, 1525, 1445, 1338 cm–1. 
MS (ESI): m/z = 423.0 [M+Na]+. (C21H24N2O4S). 
 
 
 
General procedure for the preparation of O-propargyl ethers 
 
Under N2, K2CO3 was added (1.2 equiv.) to a stirred solution of the corresponding commercially available 
tert-butyl (2-hydroxyphenyl)carbamate (1 equiv.) in THF/DMF (3 mL/1 mL/mmol) at room temperature. The 
mixture was cooled to 0 °C and a solution of propargyl bromide (80% in toluene, 1.2 equiv.) was added 
dropwise. The resulting mixture was stirred at room temperature overnight. The solvent was removed under 
reduced pressure and the mixture was extracted with AcOEt (3 ×) and then washed with brine. The organic 
phases were dried with Na2SO4, filtered and the solvent removed under reduced pressure. The crude 
product was purified by crystallization or flash chromatography on silica gel. 
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tert-Butyl (2-(prop-2-yn-1-yloxy)phenyl)carbamate (3a) 
 
Yield: 97%. 
Data are consistent with literature.[105] 
 
tert-Butyl (5-nitro-2-(prop-2-yn-1-yloxy)phenyl)carbamate (3b) 
 
Yield: 80%. 
Yellow solid; m.p.: 111 - 113 °C.  
1H NMR (200 MHz, CDCl3): δ = 9.03 (d, J = 2.9 Hz, 1 H), 7.90 (dd, J = 9.2, 2.9 Hz, 1 H), 7.10 (br. s, 1 H, 
exchange with D2O), 7.04 (d, J = 9.2 Hz, 1 H), 4.86 (d, J = 2.6 Hz, 2 H), 
2.61 (t, J = 2.6 Hz, 1 H), 1.54 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 152.3 (s), 149.9 (s), 142.7 (s), 129.3 (s), 118.4 (d), 113.8 (d), 110.9 (d), 81.8 
(s), 77.6 (d), 76.9 (s), 57.0 (t), 28.5 (q) ppm. 
IR: ν˜ = 3361, 3258, 2993, 2939, 2120, 1706, 1594, 1535, 1345, 1278 cm–1. 
MS (ESI): m/z = 315.0 [M+Na]+. (C14H16N2O5) 
 
tert-Butyl (5-chloro-2-(prop-2-yn-1-yloxy)phenyl)carbamate (3c) 
 
 
Yield: 94%. 
White solid; m.p.: 62 - 65 °C.  
1H NMR (200 MHz, CDCl3): δ = 8.17 (s, 1 H), 7.05 (br. s, 1 H, exchange with D2O), 6.89–7.00 (m, 2 H), 
4.73 (d, J = 2.6 Hz, 2 H), 2.55 (t, J = 2.6 Hz, 1 H), 1.53 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 152.5 (s), 144.2 (s), 129.9 (s), 127.6 (s), 121.8 (d), 118.6 (d), 112.9 (d), 81.1 
(s), 78.6 (s), 76.3 (d), 57.0 (t), 28.5 (q) ppm. 
IR: ν˜ = 3436, 3299, 2980, 2933, 2125, 1729, 1598, 1520, 1273 cm–1. 
MS (ESI): m/z = 304.0 [M+Na]+. (C14H16ClNO3). 
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tert-Butyl (5-methyl-2-(prop-2-yn-1-yloxy)phenyl)carbamate (3d) 
 
Yield: 97%. 
White solid; m.p.: 58 - 60 °C. 
1H NMR (200 MHz, CDCl3): δ = 7.95 (s, 1 H), 7.04 (br. s, 1 H, exchange with D2O), 6.86 (d, J = 8.1 Hz, 1 
H), 6.75 (ddd, J = 8.1, 2.0, 0.6 Hz, 1 H), 4.71 (d, J = 2.6 Hz, 2 H), 2.53 (t, J 
= 2.6 Hz, 1 H), 2.30 (s, 3 H), 1.53 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 153.0 (s), 144.7 (s), 132.0 (s), 128.6 (s), 122.7 (d), 119.4 (d), 112.1 (d), 80.5 
(s), 78.6 (s), 76.0 (d), 56.9 (t), 28.5 (q), 21.3 (q) ppm. 
IR: ν˜ = 3408, 3276, 2980, 2930, 2129, 1731, 1532 cm–1. 
MS (ESI): m/z = 284.1 [M+Na]+. (C15H19NO3). 
 
tert-Butyl (5-methoxy-2-(prop-2-yn-1-yloxy)phenyl)carbamate (3e) 
 
Yield: 99%.  
White solid; m.p.: 72 - 74 °C. 
1H NMR (400 MHz, CDCl3): δ = 7.79 (br. s, 1 H), 7.08 (br. s, 1 H, exchange with D2O), 6.89 (d, J = 8.9 Hz, 1 
H), 6.48 (dd, J = 8.9, 3.0 Hz, 1 H), 4.67 (d, J = 2.4 Hz, 2 H), 3.78 (s, 3 H), 
2.52 (t, J = 2.4 Hz, 1 H), 1.52 (s, 9 H) ppm. 
13C NMR (100 MHz, CDCl3): δ = 154.9 (s), 152.5 (s), 139.7 (s), 129.8 (s), 113.4 (d), 107.3 (d), 104.4 (d), 
80.4 (s), 78.5 (s), 75.8 (d), 57.4 (t), 55.7 (q), 28.3 (q) ppm. 
IR: ν˜ = 3433, 3255, 2997, 2945, 2127, 1698, 1619, 1606, 1534 cm–1. 
MS (ESI): m/z = 300.3 [M+Na]+. (C15H19NO4). 
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4-Methyl-N-(2-nitrophenyl)-N-(prop-2-yn-1-yl)benzenesulfonamide (6A) 
 
A suspension of N-tosyl-2-nitroaniline (1 equiv.), prop-2-yn-1-ol (1.1 equiv.) and PPh3 (1.5 equiv.) in 
anhydrous THF (6 mL/mmol) was stirred under N2. The mixture was cooled to 0 °C and a solution of 
diisopropyl azodicarboxylate (1.5 equiv.) in THF (1 mL/mmol) was added dropwise over a period of 30 min. 
The reaction mixture was warmed to room temperature and stirred for 6 h. The solvent was removed under 
reduced pressure and the crude product was dissolved in CH2Cl2. Then it was washed sequentially with 2 
M NaOH, 1 M HCl, saturated NaHCO3 solution and brine. The organic phases were dried with Na2SO4, 
filtered and the solvent removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel to afford the product. 
Yield: 95%.  
Yellow solid; m.p.: 87 - 88 °C. 
1H NMR (200 MHz, CDCl3): δ = 7.85–7.89 (m, 1 H), 7.51–7.62 (m, 4 H), 7.34–7.38 (m, 1 H), 7.24–7.28 (m, 
2 H), 4.60 (br. s, 2 H), 2.43 (s, 3 H), 2.26 (t, J = 2.5 Hz, 1 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 149.9 (s), 144.5 (s), 136.2 (s), 133.3 (d), 133.1 (d), 131.8 (s), 130.2 (d), 
129.8 (d), 128.1 (d), 125.4 (d), 78.3 (s), 74.6 (d), 41.3 (t), 21.8 (q) ppm. 
IR: ν˜ = 3436, 3277, 2921, 2123, 1728, 1599, 1532 cm–1. 
MS (ESI): m/z = 353.0 [M+Na]+. (C16H14N2O4S). 
 
N-(2-Aminophenyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide (7) 
 
 
Fe powder (6 equiv.) was added to a suspension of 6A (1 equiv.) in a mixture of AcOH (20% in H2O, 2.5 
ml/mmol), EtOH (5 ml/mmol). The resulting suspension was heated at reflux for 3 h. The reaction mixture 
was filtered through a pad of Celite using AcOEt to remove the iron excess. The filtrate was washed with 
NaHCO3 sat. (3 ×), dried with Na2SO4, filtered and the solvent removed under reduced pressure. The crude 
product was purified by flash chromatography on silica gel to afford the product. 
Yield: 87%. 
Pale yellow solid; m.p.: 109 - 111 °C. 
1H NMR (400 MHz, CDCl3): δ = 7.68 (d, J = 8.2 Hz, 2 H), 7.29 (d, J = 8.2 Hz, 2 H), 7.14 (t, J = 7.6 Hz, 1 H), 
6.85 (d, J = 7.6 Hz, 1 H), 6.64 (d, J = 7.6 Hz, 1 H), 6.58 (t, J = 7.6 Hz, 1 H), 
4.57 (d, J = 16.1 Hz, 1 H), 4.33–4.46 (br. s, 2 H, exchange with D2O), 4.26 
(d, J = 16.1 Hz, 1 H), 4.26 (d, J = 16.1 Hz, 1 H), 2.18 (s, 1 H) ppm. 
13C NMR (100 MHz, CDCl3): δ = 145.7 (s), 143.9 (s), 135.5 (s), 129.9 (d), 129.4 (d), 129.3 (d), 128.4 (d), 
124.9 (s), 118.4 (d), 117.1 (d), 78.1 (s), 73.6 (d), 40.8 (t), 21.6 (q) ppm. 
IR: ν˜ = 3446, 3362, 3303, 2921, 1911, 1617, 1498, 1335 cm–1. 
MS (ESI): m/z = 322.9 [M+Na]+. (C16H16N2O2S). 
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General procedure for the Pd-catalyzed hydroamination reactions on alkynyl derivatives 
 
Pd(PPh3)4 (8 mol %) were added to a solution of the suitable propargyl derivative (1 equiv.) in toluene (10 
mL/mmol) under nitrogen atmosphere. The reaction mixture was stirred at reflux at 90 °C for 4 h. The 
reaction mixture was filtered under reduced pressure through a Celite pad washing with AcOEt. The solvent 
was removed under reduced pressure and the crude was purified by silica gel chromatography. 
tert-Butyl 3-methylene-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate (4a) 
 
Yield: 58%.  
Colourless oil.  
1H NMR (200 MHz, CDCl3) δ = 7.01-6.76 (m, 4 H), 5.34 (s, 1 H), 5.13 (s, 1 H), 4.56 (s, 2H), 1.53 (s, 9 H). 
13C NMR (50 MHz, CDCl3) δ = 152.0 (s), 147.2 (s), 133.7 (s), 131.6 (s), 24.7 (d), 123.6 (d), 120.9 (d), 117.1 
(d), 107.9 (t), 82.5 (s), 69.8 (t), 28.4 (q) ppm. 
IR: ν˜ = 3433, 3058, 2979, 2932, 2870, 1717, 1602, 1494 cm–1. 
MS (ESI): m/z = 270.1 [M+Na]+, 249.0 [M]+. (C14H17NO3). 
 
 
tert-Butyl 3-methylene-6-nitro-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate (4b) 
 
Yield: 76%. 
Colourless oil.  
1H-NMR (200 MHz, CDCl3) δ = 8.76 (d, J = 2.7 Hz, 1 H), 7.89 (dd, J = 9.0, 2.7 Hz, 1 H), 6.93 (d, J = 9.0 Hz 
1 H), 5.43 (s, 1 H), 5.35 (s, 1 H), 4.66 (s, 2 H), 1.57 (s, 9 H) ppm. 
13C-NMR (50 MHz, CDCl3) δ = 152.4 (s), 151.6 (s), 143.0 (s), 134.0 (s), 129.6 (s), 120.3 (d), 119.6 (d), 
117.3 (d), 111.5 (t), 81.8 (s), 69.7 (t), 28.5 (q) ppm. 
IR: ν˜ = 3436, 3128, 2986, 2923, 2851, 2626, 1926, 1721, 1588, 1513 cm–1. 
MS (ESI): m/z = 315.0 [M+Na]+. (C14H16N2O5). 
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tert-Butyl 6-chloro-3-methylene-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate (4c) 
 
Yield: 45%. 
Colourless oil. 
1H-NMR (200 MHz, CDCl3) δ = 7.79 (d, J = 2.4 Hz, 1 H), 6.94 (dd, J = 8.7, 2.4 Hz, 1 H), 6.79 (d, J = 8.7 Hz 
1 H), 5.35 (d, J = 0.5 Hz, 1 H), 5.19 (d, J = 0.5 Hz, 1 H), 4.54 (d, J = 0.5 Hz, 
2 H), 1.54 (s, 9 H) ppm. 
13C-NMR (50 MHz, CDCl3) δ = 151.5 (s), 145.5 (s), 135.7 (s), 127.7 (s), 125.7 (s), 124.5 (d), 123.2 (d), 
118.0 (d) 109.0 (t), 83.0 (s), 69.5 (t), 28.3 (q) ppm. 
IR: ν˜ = 3422, 3086, 2979, 2930, 2333, 1858, 1719, 1601 cm–1. 
MS (ESI): m/z = 281.0 [M+H]+. (C14H16ClNO3). 
 
 
 
tert-Butyl 6-methyl-3-methylene-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate (4d) 
 
Yield: 70%. 
Colourless oil. 
1H-NMR (200 MHz, CDCl3) δ = 7.53 (s, 1 H), 6.95-6.67 (m, 2 H), 5.34 (s, 1 H), 5.15 (s, 1 H), 4.54 (d, J = 0.6 
Hz, 2 H), 2.30 (s, 3 H), 1.54 (s, 9 H) ppm. 
13C-NMR (50 MHz, CDCl3) δ = 152.0 (s), 145.0 (s), 136.9 (s), 133.8 (s), 126.8 (s), 125.3 (d), 123.8 (d), 
116.7 (d), 107.6 (t), 82.4 (s), 69.8 (t), 28.4 (q), 21.13 (q) ppm. 
IR: ν˜ = 3432, 3056, 2977, 2928, 1715 cm–1. 
MS (ESI): m/z = 284.0 [M+H]+. (C15H19NO3). 
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tert-Butyl 2-methylene-4-tosyl-3,4-dihydroquinoxaline-1(2H)-carboxylate (4e) 
 
Yield: 83%. 
Colourless oil. 
1H-NMR (200 MHz, CDCl3) δ = 7.71-7.38 (m, 4 H), 7.26-7.13 (m, 4 H), 5.14 (, d, J = 0.8 Hz, 1 H), 4.53 (d, J 
= 0.8 Hz, 1 H), 4.36 (s, 2 H), 2.30 (s, 3 H), 1.34 (s, 9 H) ppm. 
13C-NMR (50 MHz, CDCl3) δ = 151.8 (s), 143.7 (s), 138.5 (s), 134.7 (s), 133.8 (s), 131.7 (s), 129.6 (d), 
127.7 (d), 127.4 (d), 126.6 (d), 124.8 (d), 124.7 (d), 98.8 (t), 82.6 (s), 53.1 (t), 28.1 (q), 21.8 (q) ppm. 
IR: ν˜ = 3422, 2979, 2330, 1920, 1720 cm–1. 
MS (ESI): m/z = 423.0 [M+Na]+. (C21H24N2O4S). 
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General procedure for the preparation of allenes  
 
 
The corresponding N-Boc-O-propargyl ether 3a-e, 8 (1 equiv.) was dissolved in THF (12 mL/mmol) at room 
temperature. tBuOK (2.5 equiv.) was added to the solution in one portion and the mixture was stirred for 3 
min. Water was then added and the mixture extracted with AcOEt (3 ×). The solvent was removed in vacuo 
and the crude was purified by flash chromatography on silica gel to afford the product. 
 
tert-Butyl N-(2-(propa-1,2-dien-1-yloxy)phenyl)carbamate (11a) 
 
Yield: 84%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 8.11 (d, J = 7.5 Hz, 1 H), 6.91–7.09 (m, 4 H, 3 H after exchange with D2O), 
6.81 (t, J = 5.9 Hz, 1 H), 5.48 (d, J = 5.9 Hz, 2 H), 1.52 (s, 9 H), ppm. 
13C NMR (50 MHz, CDCl3): δ = 202.7 (s), 152.8 (s), 145.4 (s), 129.6 (s), 123.7 (d), 122.4 (d), 119.1 (d), 
118.4 (d), 115.7 (d), 90.4 (t), 80.7 (s), 28.6 (q) ppm. 
IR: ν˜ = 3440, 2980, 2931, 1965, 1732, 1602, 1522 cm–1. 
MS (ESI): m/z = 270.1 [M+Na]+. (C14H17NO3). 
 
tert-Butyl N-(5-nitro-2-(propa-1,2-dien-1-yloxy)phenyl)carbamate (11b) 
 
Yield: 52%. 
Yellow solid; m.p.: 117 - 118 °C. 
1H NMR (200 MHz, CDCl3): δ = 9.06 (d, J = 2.6 Hz, 1 H), 7.88 (dd, J = 9.0, 2.6 Hz, 1 H), 7.10–7.15 (m, 2 H, 
1 H after exchange with D2O), 6.84 (t, J = 5.9 Hz, 1 H), 5.56 (d, J = 5.9 Hz, 
2 H), 1.54 (s, 9 H), ppm. 
13C NMR (50 MHz, CDCl3): δ = 202.6 (s), 152.3 (s), 149.7 (s), 143.5 (s), 129.7 (s), 118.2 (d), 116.7 (d), 
114.2 (d), 113.8 (d), 91.2 (t), 81.9 (s), 28.5 (q) ppm. 
IR: ν˜ = 3435, 2974, 2928, 2002, 1733, 1541, 1343 cm–1. 
MS (ESI): m/z = 315.0 [M+Na]+. (C14H16N2O5). 
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tert-Butyl N-(5-chloro-2-(propa-1,2-dien-1-yloxy)phenyl)carbamate (11c) 
 
Yield: 66% 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 8.19 (d, J = 2.0 Hz, 1 H), 7.01 (br. s, 1 H, exchange with D2O), 6.87–6.95 
(m, 2 H), 6.78 (t, J = 5.9 Hz, 1 H), 5.48 (d, J = 5.9 Hz, 2 H), 1.53 (s, 9 H), 
ppm. 
13C NMR (50 MHz, CDCl3): δ = 202.4 (s), 152.5 (s), 143.7 (s), 130.5 (s), 129.0 (s), 122.0 (d), 118.9 (d), 
118.3 (d), 116.6 (d), 91.0 (t), 81.3 (s), 28.5 (q) ppm. 
IR: ν˜ = 3438, 2980, 2933, 1967, 1732, 1600, 1520 cm–1. 
MS (ESI): m/z = 304.0 [M+Na]+. (C14H16ClNO3). 
 
 
 
tert-Butyl N-(5-methyl-2-(propa-1,2-dien-1-yloxy)phenyl)carbamate (11d) 
 
Yield: 70%  
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 7.95 (d, J = 1.3 Hz, 1 H), 6.98 (br. s, 1 H, exchange with D2O), 6.93 (d, J = 
8.1 Hz, 1 H), 6.79 (t, J = 5.9 Hz, 1 H), 6.75 (dd, J = 8.1, 1.3 Hz, 1 H), 5.45 
(d, J = 5.9 Hz, 2 H), 2.30 (s, 3 H), 1.53 (s, 9 H), ppm. 
13C NMR (50 MHz, CDCl3): δ = 202.6 (s), 152.9 (s), 143.2 (s), 133.6 (s), 129.2 (s), 122.8 (d), 119.5 (d), 
118.9 (d), 115.8 (d), 90.6 (t), 80.7 (s), 28.6 (q), 21.4 (q) ppm. 
IR: ν˜ = 3441, 2978, 2928, 1965, 1730, 1602, 1530, 1467 cm–1. 
MS (ESI): m/z = 284.0 [M+Na]+. (C15H19NO3). 
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tert-Butyl N-(5-methoxy-2-(propa-1,2-dien-1-yloxy)phenyl)carbamate (11e) 
 
Yield: 90% 
White solid; m.p.: 41 - 43 °C. 
1H NMR (400 MHz, CDCl3): δ = 7.78 (br. s, 1 H), 7.00 (br. s, 1 H, exchangewith D2O), 6.94–6.99 (m, 1 H), 
6.78 (t, J = 5.9 Hz, 1 H), 6.48 (dd, J = 8.8, 3.0 Hz, 1 H), 5.43 (d, J = 5.9 Hz, 
2 H), 3.78 (s, 3 H), 1.52 (s, 9 H) ppm. 
13C NMR (100 MHz, CDCl3): δ = 202.0 (s), 155.9 (s), 152.5 (s), 138.8 (s), 130.4 (s), 119.6 (d), 117.4 (d), 
107.6 (d), 104.1 (d), 90.7 (t), 80.6 (s), 55.7 (q), 28.3 (q), ppm. 
IR: ν˜ = 3437, 2982, 2934, 1959, 1715, 1607, 1540 cm–1. 
MS (ESI): m/z = 300.0 [M+Na]+. (C15H19NO4). 
 
 
tert-Butyl N-(2-(4-methyl-N-(propa-1,2-dien-1-yl)phenylsulfonamido)phenyl)carbamate (12) 
 
Yield: 40% 
White solid; m.p.: 125 - 126 °C. 
1H NMR (200 MHz, CDCl3): δ = 8.17 (dd, J = 8.4, 1.3 Hz, 1 H), 7.60 (d, J = 8.4 Hz, 2 H), 7.22–7.32 (m, 3 H, 
2 H after exchange with D2O), 7.18 (br. s, 1 H), 7.10 (t, J = 6.2 Hz, 1 H), 
6.75 (td, J = 7.9, 1.5 Hz, 1 H), 6.34 (dd, J = 7.9, 1.5 Hz, 1 H), 5.02 (d, J = 
6.2 Hz, 2 H), 2.46 (s, 3 H), 1.52 (s, 9 H), ppm. 
13C NMR (50 MHz, CDCl3): δ = 201.2 (s), 152.8 (s), 144.7 (s), 137.9 (s), 134.6 (s), 130.1 (d), 129.9 (d), 
129.5 (d), 128.3 (d), 125.4 (s), 121.9 (d), 120.3 (d), 102.2 (d), 88.2 (t), 80.9 
(s), 28.5 (q), 21.9 (q), ppm. 
IR: ν˜ = 3422, 2981, 1728, 1595, 1516, 1445, 1355 cm–1. 
MS (ESI): m/z = 423.1 [M+Na]+. (C21H24N2O4S). 
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General procedure for hydroamination reactions on allenes 
 
Pd(PPh3)4 (8 mol %) and PPh3 (10 mol %) were added to a solution of the corresponding allene (1 equiv.) 
in toluene (15 mL/mmol) and the mixture was stirred at 80 °C for 8 h. The reaction mixture was 
concentrated in vacuo, brine was added and the mixture extracted with AcOEt (3 ×). The combined organic 
phases were dried with Na2SO4, filtered and the solvent removed in vacuo. The product was purified by 
flash chromatography on silica gel. 
 
tert-Butyl 2-vinylbenzo[d]oxazole-3(2H)-carboxylate (13a) 
 
Yield: 94%. 
Colourless oil. 
1H NMR (400 MHz, CDCl3): δ = 7.42 (br. s, 1 H), 6.87–6.94 (m, 2 H), 6.80 (d, J = 7.7 Hz, 1 H), 6.40 (br. s, 1 
H), 5.94–6.02 (m, 1 H), 5.55 (d, J = 16.8 Hz, 1 H), 5.38 (d, J = 10.2 Hz, 1 
H), 1.58 (s, 9 H) ppm. 
13C NMR (100 MHz, CDCl3): δ = 150.1 (s), 146.8 (s), 132.8 (d), 130.1 (s), 123.3 (d), 121.3 (d), 119.3 (t), 
114.0 (d), 108.7 (d), 93.4 (d), 82.2 (s), 28.3 (q) ppm. 
IR: ν˜ = 3409, 3060, 2978, 2932, 1875, 1712 cm–1. 
MS (ESI): m/z = 270.1 [M+Na]+. (C14H17NO3). 
 
tert-Butyl 5-nitro-2-vinylbenzo[d]oxazole-3(2H)-carboxylate (13b) 
 
Yield: 51%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 8.30 (br. s, 1 H), 7.92 (dd, J = 8.7, 2.4 Hz, 1 H), 6.80 (d, J = 8.7 Hz, 1 H), 
6.52 (d, J = 6.0 Hz, 1 H), 5.96 (ddd, J = 16.5, 10.2, 6.0 Hz, 1 H), 5.57 (d, J 
= 16.5 Hz, 1 H), 5.44 (d, J = 10.2 Hz, 1 H), 1.57 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 155.5 (s), 149.8 (s), 142.9 (s), 132.1 (d), 130.8 (s), 121.1 (d), 120.8 (t), 
109.8 (d), 108.1 (d), 95.9 (d), 83.8 (s), 28.4 (q) ppm. 
IR: ν˜ = 3413, 3131, 2980, 2931, 2853, 2425, 2303, 1875, 1721 cm–1. 
MS (ESI): m/z = 315.1 [M+Na]+. (C14H16N2O5) 
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tert-Butyl 5-chloro-2-vinylbenzo[d]oxazole-3(2H)-carboxylate (13c) 
 
 
Yield: 72%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 7.50 (br. s, 1 H), 6.85 (dd, J = 8.4, 2.2 Hz, 1 H), ), 6.66 (d, J = 8.4 Hz, 1 H), 
6.38 (d, J = 6.4 Hz, 1 H), 5.94 (ddd, J = 17.0, 10.8, 6.4 Hz, 1 H), 5.52 (d, J 
= 17.0 Hz, 1 H), 5.38 (d, J = 10.8 Hz, 1 H), 1.55 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 150.1 (s), 149.2 (s), 132.7 (d), 130.7 (s), 126.4 (s), 122.9 (d), 119.9 (t), 
114.7 (d), 109.3 (d), 94.6 (d), 83.0 (s), 28.5 (q) ppm. 
IR: ν˜ = 3491, 2979, 2932, 1716, 1599 cm–1. 
MS (ESI): m/z = 304.0 [M+Na]+. (C14H16ClNO3). 
 
 
 
 
 
 
tert-Butyl 5-methyl-2-vinylbenzo[d]oxazole-3(2H)-carboxylate (13d) 
 
Yield: 74%. 
Colourless oil. 
1H NMR (400 MHz, CDCl3): δ = 7.22 (br. s, 1 H), 6.70 (d, J = 7.9 Hz, 1 H), 6.65 (d, J = 7.9 Hz, 1 H), 6.35 
(br. s, 1 H), 5.90–5.98 (m, 1 H), 5.51 (d, J = 16.9 Hz, 1 H), 5.35 (d, J = 10.2 
Hz, 1 H), 2.29 (s, 3 H), 1.55 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 150.5 (s), 148.3 (s), 133.1 (d), 131.1 (s), 129.4 (s), 123.5 (d), 119.4 (t), 
115.1 (d), 108.4 (d), 93.8 (d), 82.3 (s), 28.5 (q), 21.3 (q) ppm. 
IR: ν˜ = 2977, 2930, 1713, 1645 cm–1. 
MS (ESI): m/z = 261.9 [M+Na]+. (C15H19NO3). 
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tert-Butyl 5-methoxy-2-vinylbenzo[d]oxazole-3(2H)-carboxylate (13e) 
 
Yield: 75%. 
Colourless oil. 
1H NMR (400 MHz, CDCl3): δ = 7.07 (br. s, 1 H), 6.66 (d, J = 8.6 Hz, 1 H), 6.40 (dd, J = 8.6, 2.7 Hz, 1 H), 
6.34 (br. s, 1 H), 5.90–5.99 (m, 1 H), 5.51 (d, J = 16.8 Hz, 1 H), 5.35 (d, J = 
10.3 Hz, 1 H), 3.76 (s, 3 H), 1.55 (s, 9 H) ppm. 
13C NMR (100 MHz, CDCl3): δ = 154.7 (s), 150.1 (s), 144.3 (s), 132.8 (d), 129.9 (s), 119.2 (t), 108.3 (d), 
107.6 (d), 101.3 (d), 93.9 (d), 82.3 (s), 55.9 (q), 28.3 (q) ppm. 
IR: ν˜ = 3409, 3090, 2977, 2933, 2834, 1711, 1622 cm–1. 
MS (ESI): m/z = 300.1 [M+Na]+. (C15H19NO4). 
 
 
 
 
 
tert-Butyl 3-tosyl-2-vinyl-2,3-dihydro-1H-benzo[d]imidazole-1-carboxylate (14) 
 
Yield: 60%. 
Pale yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 7.61 (d, J = 7.2 Hz, 1 H), 7.51–7.55 (m, 1 H), 7.42 (d, J = 8.1 Hz, 2 H), 
7.03–7.30 (m, 4 H), 6.24 (br. s, 1 H), 5.83–5.91 (m, 1 H), 5.48 (d, J = 16.2 
Hz, 1 H), 5.28 (d, J = 10.2 Hz, 1 H), 2.34 (s, 3 H), 1.44 (s, 9 H) ppm. 
13C NMR (100 MHz, CDCl3): δ = 152.9 (s), 143.9 (s), 138.7 (s), 134.2 (s), 133.1 (s), 132.7 (d), 129.5 (d), 
128.2 (d), 127.2 (d), 126.6 (d), 123.3 (d), 118.7 (d), 117.9 (t), 115.1 (d), 
80.5 (s), 28.1 (q), 21.5 (q) ppm. 
IR: ν˜ = 3427, 2978, 2931, 1919, 1713 cm–1. 
MS (ESI): m/ z = 423.1 [M+Na]+. (C21H24N2O4S). 
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Synthesis of 4-chloro-6-methoxy-5-nitropyrimidine (16) 
 
 
 
To a solution of 4,6-dichloro-5-nitropyrimidine 15 (1 equiv.) in MeOH (5 mL/mmol) was added triethylamine 
(1 equiv.). The reaction mixture was stirred at rt for 24 h. The reaction mixture was concentrated in vacuo, 
brine was added and the mixture extracted with AcOEt (3 ×). The combined organic phases were dried with 
Na2SO4, filtered and the solvent removed in vacuo. The product was purified by flash chromatography on 
silica gel. 
Yield: 99%. 
Pale yellow oil. 
1H NMR (200 MHz, CDCl3): δ = 8.64 (s, 1 H), 4.15 (s, 3 H) ppm. 
MS (ESI): m/ z = 190.5 [M+H]+. (C5H4ClN3O3). 
 
 
 
 
 
Synthesis of 
N-(6-methoxy-5-nitropyrimidin-4-yl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide (17) 
 
To a solution of compound 16 (1.2 equiv.) in DMF, was added, under nitrogen atmosphere, K2CO3 (5 
equiv.), TBA-HSO4 (10 mol %) and 16 (1 equiv.). The reaction mixture was stirred at 40 °C for 24 h. The 
reaction mixture was concentrated in vacuo, brine was added and the mixture extracted with AcOEt (3 ×). 
The combined organic phases were dried with Na2SO4, filtered and the solvent removed in vacuo. The 
product was purified by flash chromatography on silica gel. 
Yield: 62% 
Pale yellow solid; m. p.: 118 - 122 °C. 
1H NMR (200 MHz, CDCl3): δ = 8.66 (s, 1 H), 7.67 (d, J = 8.2 Hz, 2 H), 7.32 (d, J = 8.2 Hz, 2 H), 4.36 (d, J 
= 2.6 Hz, 2 H), 4.16 (s, 3 H), 2.45 (s, 3 H), 2.15 (t, J = 2.6 Hz, 1 H) ppm. 
MS (ESI): m/ z = 363.5 [M+H]+. (C15H14N4O5S). 
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Synthesis of 
N-(5-amino-6-methoxypyrimidin-4-yl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide (18) 
 
Fe powder (6 equiv.) was added to a suspension of 17 (1 equiv.) in a mixture of AcOH (20 % in H2O, 2.5 
ml/mmol), EtOH (5 ml/mmol). The resulting suspension was heated at reflux for 3 h. The reaction mixture 
was filtered through a pad of Celite using AcOEt to remove the iron excess. The filtrate was washed with 
NaHCO3 sat. (3 ×), dried with Na2SO4, filtered and the solvent removed under reduced pressure. The crude 
product was purified by flash chromatography on silica gel to afford the product. 
Yield: 84%. 
Pale yellow solid; m. p.: 159 - 161 °C. 
1H NMR (200 MHz, CDCl3): δ = 7.94 (s, 1 H), 7.56 (d, J = 8.4 Hz, 2 H), 7.27 (d, J = 8.4 Hz, 2 H), 4.40 (bs, 
exchange with D2O, 2 H), 4.29 (d, J = 2.6 Hz, 2 H), 4.04 (s, 3 H), 2.41 (s, 3 
H), 2.10 (t, J = 2.6 Hz, 1 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 160.2 (s), 145.1 (d), 144.7 (s), 140.8 (s), 134.2 (s), 129.8 (2C, d), 129.4 (s), 
128.6 (2C, d), 77.5 (s), 73.1 (d), 54.6 (q), 39.5 (t), 21.8 (q) ppm. 
IR: ν˜ = 3458, 3358, 3271, 2947, 2126, 1608 cm-1. 
MS (ESI): m/z = 333.1 [M+H]+. (C15H16N4O3S). 
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Synthesis of 
N-(4-methoxy-6-(4-methyl-N-(prop-2-yn-1-yl)phenylsulfonamido)pyrimidin-5-yl)acetamide (19) 
 
 
 
Compound 18 (1 equiv.) was dissolved in THF (10 mL/mmol) and the solution cooled to 0 °C, then 
(CH3CO)2O (2 equiv.) was added dropwise. The resulting mixture was stirred for 3 h. After completion of 
the reaction the mixture was concentrated under reduced pressure and extracted with AcOEt (3 ×). The 
organic phases were washed with a saturated solution of NaHCO3 sat. (2 x) and water, dried with Na2SO4, 
filtered and the solvent removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel. 
Yield: 65%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 8.56 (s, 1 H,), 7.56 (d, J = 8.4 Hz, 2 H), 7.28 (br. s, exchange with D2O, 1 
H), 7.27 (d, J = 8.4 Hz, 2 H), 4.51 (q, J = 7.0 Hz, 2 H), 4.50 (d, J = 2.6 Hz, 2 
H), 2.25 (t, J = 2.6 Hz, 1 H), 2.41 (s, 3 H),  2.10 (s, 3 H), 1.38 (t, J = 7.0 Hz, 
3 H) ppm.  
MS (ESI): m/z = 397.0 [M+Na]+. (C17H18N4O4S). 
Synthesis of 
4-methoxy-9-tosyl-8-vinyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one (20) 
 
 
The compound 19 (1 equiv.) was dissolved in THF (12 mL/mmol) at room temperature. tBuOK (2.5 equiv.) 
was added to the solution in one portion and the mixture was stirred for 1 h. Then, water was added and 
the mixture extracted with AcOEt (3 ×). The solvent was removed in vacuo and the crude was purified by 
flash chromatography on silica gel to afford the product. 
Yield: 40%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 8.17 (s, 1 H), 7.56 (d, J = 8.4 Hz, 2 H), 7.27 (d, J = 8.4 Hz, 2 H), 5.90 (m, 1 
H), 5.41 (m, 2 H, 1 H after exchange with D2O), 5.25 (1H, d, J = 9.9 Hz), 
4.47 (1H, m ), 4.51 (2H, q, J = 7.0 Hz), 2.76 (2H, m), 2.41 (s, 3 H), 1.43 
(9H, s), 1.38 (3H, t, J = 7.0 Hz) ppm. 
MS (ESI): m/z = 397.1 [M+Na]+. (C17H18N4O4S). 
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Synthesis of 
2,2,2-trifluoro-N-(4-methoxy-6-(4-methyl-N-(prop-2-yn-1-yl) 
phenylsulfonamido)pyrimidin-5-yl)acetamide (21) 
 
 
Compound 18 (1 equiv.) was dissolved in THF (10 mL/mmol) and the solution cooled to 0 °C, then 
(CF3CO)2O (2 equiv.) was added dropwise. The resulting mixture was stirred for 3 h at 40 °C. After 
completion of the reaction the mixture was concentrated under reduced pressure and extracted with AcOEt. 
The organic phases were washed with NaHCO3 sat. (2 x) and water, dried with Na2SO4, filtered and the 
solvent removed under reduced pressure. The crude product was purified by flash chromatography on 
silica gel. 
Yield: 86%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 8.51 (s, 1 H), 8.38 (br. s, 1 H, exchange with D2O), 7.66 (d, J = 8.2 Hz, 2 
H), 7.32 (d, J = 8.2 Hz, 2 H), 6.60 (t, J = 6.2 Hz, 1 H), 5.16 (d, J = 6.2 Hz, 2 
H), 4.09 (s, 3 H), 2.45 (s, 3 H) ppm. 
MS (ESI): m/z = 429.3 [M+H]+. (C17H15F3N4O4S). 
 
Synthesis of 
2,2,2-trifluoro-N-(4-methoxy-6-(4-methyl-N-(propa-1,2-dien-1-yl)phenylsulfonamido) pyrimidin-5-
yl)acetamide (22) 
 
 
The compound 21 (1 equiv.) was dissolved in THF (12 mL/mmol) at room temperature. tBuOK (2.5 equiv.) 
was added to the solution in one portion and the mixture was stirred for 1 h. Then added water and the 
mixture extracted with AcOEt (3 ×). The solvent was removed in vacuo and the crude was purified by flash 
chromatography on silica gel to afford the product. 
Yield: 64%. 
Pale yellow oil. 
1H NMR (200 MHz, CDCl3): δ =  8.51 (s, 1 H), 8.38 (br. s, exchange with D2O, 1 H), 7.66 (d, J = 8.2 Hz, 2 
H), 7.32 (d, J = 8.2 Hz, 2 H), 6.60 (t, J = 6.2 Hz, 1 H), 5.16 (d, J = 6.2 Hz, 2 
H), 4.09 (s, 3 H), 2.45 (s, 3 H) ppm. 
MS (ESI): m/z = 429.3 [M+H]+. (C17H15F3N4O4S). 
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Synthesis of 4-methyl-N-(3-nitropyridin-4-yl)-N-(prop-2-yn-1-yl)benzenesulfonamide (24) 
 
To a solution of 4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide (1.2 equiv.) in DMF, was added, under 
nitrogen atmosphere, K2CO3 (5 equiv.), TBA-HSO4 (10 mol %) and 23 (1 equiv.). The reaction mixture was 
stirred at 40 °C for 24 h. The reaction mixture was concentrated in vacuo, brine was added and the mixture 
extracted with AcOEt (3 ×). The combined organic phases were dried with Na2SO4, filtered and the solvent 
removed in vacuo. The product was purified by flash chromatography on silica gel. 
Yield: 47%. 
Yellow solid; m.p.: 110 - 112 °C. 
1H NMR (200 MHz, CDCl3): δ = 9.13 (s, 1 H), 8.78 (d, J = 5.1 Hz, 1 H), 7.59 (d, J = 8.2 Hz, 2 H), 7.38 (d, J 
= 5.1 Hz, 1 H), 7.29 (d, J = 8.2 Hz, 2 H), 4.55 (d, J = 2.6 Hz, 2 H), 2.44 (s, 3 
H), 2.27 (t, J = 2.6 Hz, 1 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 154.4 (d), 146.9 (d), 154.2 (s), 140.1 (s), 135.4 (s), 130.1 (d), 128.1 (d), 
126.4 (d), 117.6 (s), 77.1 (s), 75.5 (d), 40.7 (t), 21.8 (q) ppm. 
IR: ν˜ = 3436, 3277, 2122 cm-1. 
MS (ESI): m/z = 332.4 [M+H]+. (C15H13N3O4S). 
 
Synthesis of N-(3-aminopyridin-4-yl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide (25) 
 
Fe powder (6 equiv.) was added to a suspension of 24 (1 equiv.) in a mixture of AcOH (20 % in H2O, 2.5 
ml/mmol), EtOH (5 ml/mmol). The resulting suspension was heated at reflux for 8 h. The reaction mixture 
was filtered through a pad of Celite using AcOEt to remove the iron excess. The filtrate was washed with 
NaHCO3 sat. (3 ×), dried with Na2SO4, filtered and the solvent removed under reduced pressure. The crude 
product was purified by flash chromatography on silica gel to afford the product. 
Yield: 81% 
White solid; m.p.: 118 - 119 °C. 
1H NMR (200 MHz, CDCl3): δ = 8.24 (d, 1 H), 7.84 (br. d, J = 5.1 Hz, 1 H), 7.64 (d, J = 8.2 Hz, 2 H), 7.30 (d, 
J = 8.2 Hz, 2 H), 6.54 (d, J = 5.1 Hz, 1 H), 4.36 (d, J = 2.6 Hz, 2 H), 4.28 
(br. s, 2 H, exchange with D2O), 2.45 (s, 3 H), 2.17 (t, J = 2.6 Hz, 1 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 144.8 (s), 142.8 (s), 140.2 (d), 139.7 (d), 135.1 (s), 131.1 (s), 129.8 (d), 
128.5 (d), 123.1 (d), 77.6 (s), 74.3 (d), 40.6 (t), 21.8 (q) ppm. 
IR: ν˜ = 3295, 2925, 2121, 1615 cm-1. 
MS (ESI): m/z = 302.2 [M+H]+. (C15H15N3O2S). 
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Synthesis of 
2,2,2-trifluoro-N-(4-(4-methyl-N-(prop-2-yn-1-yl)phenylsulfonamido)pyridin-3-yl)acetamide (26) 
 
 
Compound 25 (1 equiv.) was dissolved in THF (10 mL/mmol) and the solution cooled to 0 °C, then 
(CF3CO)2O (2 equiv.) was added dropwise. The resulting mixture was stirred for 3 h at 40 °C. After 
completion of the reaction the mixture was concentrated under reduced pressure and extracted with AcOEt 
(3 ×). The organic phases were washed with a saturated solution of NaHCO3 (2 x) and water, dried with 
Na2SO4, filtered and the solvent removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel. 
Yield: 91%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 9.01 (br. S, 1 H), 8.91 (br. s, 1 H, exchange with D2O), 8.55 (d, J = 5.3 Hz, 
1 H), 7.48 (d, J = 5.3 Hz, 1 H), 4.32 (d, J = 2.2 Hz, 2 H), 2.39 (t, J = 2.2 Hz, 
1 H), 1.53 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 155.6 (q, J = 38.1 Hz), 153.6 (s), 149.0 (d), 147.7 (d), 142.9 (s), 127.5 (s), 
119.7 (d), 116.0 (q, J = 288.4 Hz), 84.6 (s), 78.7 (s), 73.5 (d), 40.8 (t), 28.2 
(q) ppm. 
IR: ν˜ = 3291, 2983, 2123, 1713 cm-1. 
MS (ESI): m/z = 398.0 [M+H]+. (C17H14F3N3O3S). 
Synthesis of 2,2,2-trifluoro-N-(4-(4-methyl-N-(propa-1,2-dien-1-yl) 
phenylsulfonamido)pyridin-3-yl)acetamide (27) 
 
The compound 26 (1 equiv.) was dissolved in THF (12 mL/mmol) at room temperature. tBuOK (2.5 equiv.) 
was added to the solution in one portion and the mixture was stirred for 1 h. Then, water was added and 
the mixture extracted with AcOEt (3 ×). The solvent was removed in vacuo and the crude was purified by 
flash chromatography on silica gel to afford the product. 
Yield: 40%. 
Colourless oil. 
1H-MNR (200 MHz, CDCl3): δ = 9.18 (s, 1 H), 8.52 (d, J = 5.1 Hz, 1 H), 8.35 (br. s, 1 H, exchange with 
D2O), 7.24 (d, J = 5.1 Hz, 1 H), 7.09 (t, J = 6.2 Hz, 1 H), 5.14 (d, J = 6.2 Hz, 
2 H), 1.50 (s, 9 H) ppm. 
MS (ESI): m/z = 398.0 [M+H]+. (C17H14F3N3O3S). 
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 General procedure for hydroamination reactions on allenes 
 
Pd(PPh3)4 (8 mol %) were added to a solution of the corresponding allene (1 equiv.) in toluene (15 
mL/mmol) and the mixture was stirred at rt for 1-2 h. The reaction mixture was concentrated in vacuo, brine 
was added and the mixture extracted with AcOEt (3 ×). The combined organic phases were dried with 
Na2SO4, filtered and the solvent removed in vacuo. The product was purified by flash chromatography on 
silica gel. 
6-Methoxy-9-tosyl-8-vinyl-8,9-dihydro-7H-purine (28) 
 
Yield: 73%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 8.49 (s, 1 H), 7.84 (d, J = 8.4 Hz, 2 H), 7.28 (d, J = 8.4 Hz, 2 H), 6.63 (d, J 
= 4.4 Hz, 1 H), 5.81 (m, 1 H), 5.55 (d, J = 16.9 Hz, 1 H), 5.38 (d, J = 10.6 
Hz, 1 H), 4.05 (s, 3 H), 2.43 (br. s, 1 H, exchange with D2O), 2.40 (s, 3 H) 
ppm. 
MS (ESI): m/z = 333.3 [M+H]+. (C15H16N4O3S). 
 
 
2,2,2-Trifluoro-1-(1-tosyl-2-vinyl-1H-imidazo[4,5-c]pyridin-3(2H)-yl)ethanone (29) 
 
Yield: 64%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 9.10 (s, 1 H), 8.51 (d, J = 5.1 Hz, 1 H), 7.50 (d, J = 8.1 Hz, 2 H), 7.42 (d, J 
= 5.1 Hz, 1 H), 7.22 (d, J = 8.1 Hz, 2 H), 6.49 (d, J = 4.4 Hz, 1 H), 5.86 
(ddd, J = 16.9, 10.3, 4.4 Hz, 1 H), 5.52 (d, J = 16.9 Hz, 1 H), 5.42 (d, J = 
10.3 Hz, 1 H), 2.38 (s, 3 H) ppm. 
MS (ESI): m/z = 398.4 [M+H]+. (C17H14F3N3O3S). 
97 
 
 
General procedure for the preparation of O-allyl ethers and N-allyl amide  
 
Under N2, K2CO3 was added (1.2 equiv.) to a stirred solution of compound 30a-c or 6 (1 equiv.) in 
THF/DMF (3 mL/1 mL/mmol) at room temperature. The mixture was cooled to 0 °C and a solution of allyl 
bromide (1.2 equiv.) was added dropwise. The resulting mixture was stirred at room temperature overnight. 
The solvent was removed under reduced pressure and the mixture was extracted with AcOEt and then 
washed with brine (3 ×). The organic phases were dried with Na2SO4, filtered and the solvent removed 
under reduced pressure. The crude product was purified by crystallization or flash chromatography on silica 
gel. 
  1-(Allyloxy)-2-nitrobenzene (31a) 
 
Yield: 95%. Data are consistent with literature.[106] 
  1-(Allyloxy)-4-methoxy-2-nitrobenzene (31b) 
 
Yield: 95%. Data are consistent with literature.[107] 
1-(Allyloxy)-2-nitro-4-(trifluoromethyl)benzene 
 
1H NMR (200 MHz; CDCl3): δ = 8,12 (d, J = 1.8 Hz, 1 H), 7,76 (m, 1 H), 7,18 (d, J = 8.8 Hz, 1 H), 6,03 (m, 1 
H), 5,43 (m, 2 H), 4,76 (m, 2 H) ppm. 
MS (ESI): m/z = 248.0 [M+H]+. (C10H8F3NO3). 
N-Allyl-4-methyl-N-(2-nitrophenyl)benzenesulfonamide 
 
1H NMR (200 MHz; CDCl3): δ =  7.85 (s, 1 H), 7.50 (m, 5 H), 7.29 (s, 1 H), 7.11 (m, 1 H), 5.90 (m, 1 H), 
5.05 (m, 2 H), 4.24 (d, J = 7.1 Hz, 2 H), 2.44 (s, 3 H) ppm. 
MS (ESI): m/z = 333.0 [M+H]+. (C16H16N2O4S). 
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General procedure for reduction of nitro group 
 
Fe powder (6 equiv.) was added to a suspension of 31 (1 equiv.) in a mixture of AcOH (20% in H2O, 2.5 
ml/mmol), EtOH (5 ml/mmol). The resulting suspension was heated at reflux for 8 h. The reaction mixture 
was filtered through a pad of Celite using AcOEt to remove the iron excess. The filtrate was washed with 
NaHCO3 (3 ×), dried with Na2SO4, filtered and the solvent removed under reduced pressure. The crude 
product was purified by flash chromatography on silica gel to afford the product. 
 
 
  2-(Allyloxy)aniline (31a) 
 
Yield: 95%. Data are consistent with literature.[108] 
 
 
2-(Allyloxy)-5-methoxyaniline (31b) 
 
Yield: 95%. Data are consistent with literature.[107] 
 
 
2-(Allyloxy)-5-(trifluoromethyl)aniline (31c) 
 
Yield: 95%. Data are consistent with literature.[109] 
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N-Allyl-N-(2-aminophenyl)-4-methylbenzenesulfonamide (32d) 
 
Yield: 82%. 
Pale yellow oil. 
1H NMR (200 MHz; CDCl3): δ = 7.59 (d, J = 8.1 Hz, 2 H), 7.28 (d, J = 9.5 Hz, 2 H), 7.06 (t, J = 7.1 Hz, 1 H), 
6.75 (d, J = 8.1 Hz, 1 H), 6.51 (t, J = 8.1 Hz, 1 H), 6.31 (d, J = 6.6 Hz, 1 H), 
5.77 (m, 1 H), 5.05 (m, 2 H), 4.44 (m, 1 H), 4.17 (br. s, 1 H), 4.10 (m, 2 H), 
3.79 (m, 1 H), 2.45 (s, 3 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 146.9 (s), 143.9 (s), 135.7 (s), 132.7 (d), 129.7 (d), 129.5 (d), 128.8 (d), 
128.3 (d), 124.9 (s), 119.4 (t), 118.0 (d), 116.9 (d), 56.4 (t), 21.8 (q) ppm. 
IR: ν˜ = 3479, 3383, 3204, 3067, 3032, 2982, 2923, 2863, cm-1. 
MS (ESI): m/z = 303.1 [M+H]+. (C16H18N2O2S). 
General procedure for preparation of benzyl derivatives 
 
To a solution of 32 (1 equiv.) in EtOH (5 ml/mmol) was added benzaldehyde at 0 °C. The reaction mixture 
was stirred at 40 °C for 24 h. Then NaBH4 (1.1 equiv.) was added and the reaction was warmed at 70 °C 
for 4 h. The solvent was removed under reduced pressure and the mixture was extracted with AcOEt and 
then washed with brine (3 ×). The organic phases were dried with Na2SO4, filtered and the solvent removed 
under reduced pressure. The crude product was purified by crystallization or flash chromatography on silica 
gel. 
2-(Allyloxy)-N-benzylaniline (33a) 
 
Yield: 60%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.32 (m, 5 H), 6.83 (m, 2 H), 6.64 (m, 2 H), 6.08 (m, 1 H), 5.34 (m, 2 H), 
4.85 (br. s, 1 H, exchange with D2O), 4.58 (m, 2 H) 4.37 (s, 2 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 146.1 (s), 139.9 (s), 138.7 (s), 133.9 (d), 128.8 (d), 127.6 (d), 127.3 (d), 
121.9 (d), 117.7 (t), 116.8 (d), 111.5 (d), 110.7 (d), 69.6 (t), 48.3 (t) ppm. 
IR: ν˜ = 3428, 3063, 3029, 2917, 2850 cm-1. 
MS (ESI): m/z = 240.1 [M+H]+. (C16H17NO). 
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2-(Allyloxy)-N-benzyl-5-methoxyaniline (33b) 
 
Yield: 82%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.39 (m, 4 H), 7.33 (m, 1 H), 6.76 (d, J = 8.6 Hz, 1 H), 6.29 (d, J = 2.8 Hz, 1 
H), 6.20 (dd, J = 8.6 Hz; J = 2,8, 1 H), 6.12 (m, 1 H), 5.44 (m, 1 H), 5.32 (m, 
1 H), 4.71 (br. s, 1 H, exchange with D2O), 4.57 (m, 2 H), 4.40 (s, 2 H), 3.76 
(s, 3 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 155.1 (s), 140.4 (s), 139.7 (s), 139.4 (s), 133.9 (d), 128.7 (d), 128.2 (d), 
127.2 (d), 117.4 (t), 112.1 (d), 99.1 (d), 98.5 (d), 70.2 (t), 55.4 (q), 48.0 (t) 
ppm. 
IR: ν˜ = 3428, 3063, 3029, 2917, 2850 cm-1. 
MS (ESI): m/z = 270.1 [M+H]+. (C17H19NO2). 
 
 
 
2-(Allyloxy)-N-benzyl-5-(trifluoromethyl)aniline (33c) 
 
Yield: 91%.  
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.32 (m, 5 H), 6.92 (m, 1 H), 6.79 (m, 2 H), 6.05 (m, 1 H), 5.35 (m, 2 H), 
4.85 (br. s, 1 H, exchange with D2O), 4.62 (m, 2 H), 4.37 (s, 2 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 148.5 (s), 138.4 (s), 137.8 (s), 133.0 (d), 128.9 (d), 127.96 (, d), 127.7 (d), 
124.8 (q, J = 271.3 Hz), 123.9 (q, J = 37.0 Hz), 118.4 (t), 114.8 (d), 110.5 
(d), 69.7 (t), 48.4 (t) ppm. 
IR: ν˜ = 3428, 3063, 3029, 2917, 2850 cm-1. 
MS (ESI): m/z = 308.1 [M+H]+. (C17H16F3NO). 
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N-Allyl-N-(2-(benzylamino)phenyl)-4-methylbenzenesulfonamide (33d) 
 
Yield: 97%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.61 (d, J = 8.4 Hz, 2 H), 7.31 (m, 7 H), 7.02 (m, 1 H), 6.61 (d, J = 1.1 Hz, 1 
H), 6.44 (m, 2 H), 5.76 (m, 1 H), 5.16 (br. s, 1 H, exchange with D2O), 5.04 
(m, 2 H), 4.44 (m, 1 H), 4.37 (d, J = 5.5 Hz, 2 H), 3.79 (m, 1 H), 2.44 (s, 3 
H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 147.4 (s), 143.9 (s), 139.3 (s), 135.5 (s), 132.6 (d), 129.7 (d), 128.8 (d), 
128.6 (d), 128.4 (d), 127.4 (d), 127.3 (d), 124.6 (s), 119.6 (t), 116.4 (d), 
112.2 (d), 54.9 (t), 47.9 (t), 218 (q) ppm. 
MS (ESI): m/z = 393.3 [M+H]+. (C23H24N2O2S). 
General procedure for allylation reactions 
 
To a solution of 34 (1 equiv.) in THF (5 ml/mmol) at 0 °C, was added Cs2CO3 (1.2 equiv.) and allyl bromide 
(1.1 equiv.). The reaction mixture was stirred at rt for 48 h. The solvent was removed under reduced 
pressure and the mixture was extracted with AcOEt and then washed with brine (3 ×). The organic phases 
were dried with Na2SO4, filtered and the solvent removed under reduced pressure. The crude product was 
purified by crystallization or flash chromatography on silica gel. 
 
2-(Allyloxy)-N-benzyl-5-nitroaniline (35a) 
 
Yield: 40%. 
Pale yellow oil. 
1H NMR (200 MHz; CDCl3): δ = 7.61 (dd, J = 2.6 Hz; J = 8.8 Hz, 2 H), 7.34 (m, 5 H), 6.77 (d, J = 8.8 Hz, 1 
H), 6.05 (m, 1 H), 5.38 (m, 2 H), 4.67 (m, 3 H, 2 H after exchange with 
D2O), 4.42 (s, 2 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 150.7 (s), 142.8 (s), 138.6 (s), 138.4 (s), 132.3 (d), 129.3 (d), 128.8 (d), 
127.8 (d), 127.7 (d), 119.0 (t), 113.5 (d), 109,5 (d), 69.9 (t), 47.9 (t) ppm. 
IR: ν˜ = 3428, 3063, 3029, 2917, 2850 cm-1. 
MS (ESI): m/z = 285.1 [M+H]+. (C16H16N2O3). 
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2-(Allyloxy)-N-benzyl-5-methylaniline (35b) 
 
Yield: 20%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.32 (m, 5 H), 6.68 (t, J = 4.0 Hz, 1 H), 6.45 (m, 2 H), 6.06 (m, 1 H), 5.32 
(m, 2 H), 4,63 (br. s, 1 H, exchange with D2O), 4.54 (m, 2 H), 4.35 (s, 2 H), 
2.22 (s, 3 H) ppm. 
MS (ESI): m/z = 254.3 [M+H]+. (C17H19NO). 
 
2-(Allyloxy)-N-benzyl-5-chloroaniline (35c) 
 
 
Yield: 48%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.33 (m, 5 H), 6.64 (m, 3 H), 6.06 (m, 1 H), 5.35 (m, 2 H), 4.75 (br. s, 1 H, 
exchange with D2O), 4.56 (m, 2 H), 4.34 (s, 2 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 144.5 (s). 139.7 (s). 139.1 (s). 133.4 (d). 128.9 (d), 127.6 (d), 127.5 (d), 
127.0 (s), 118.1 (t), 115.9 (d), 112.0 (d), 110.4 (d), 69.8 (t), 48.0 (t) ppm. 
IR: ν˜ = 3428, 3063, 3029, 2917, 2850 cm-1. 
MS (ESI): m/z = 274.5 [M+H]+. (C16H16ClNO). 
  
103 
 
 
General procedure for N-alkylation of allyl derivatives 
 
To a solution of 32 (1 equiv.) in THF (5 ml/mmol) at 0 °C, was added n-BuLi (1.2 equiv.) and n-butyl 
bromide (1.1 equiv.). The reaction mixture was stirred at rt for 48 h. The solvent was removed under 
reduced pressure and the mixture was extracted with AcOEt and then washed with brine (3 ×). The organic 
phases were dried with Na2SO4, filtered and the solvent removed under reduced pressure. The crude 
product was purified by crystallization or flash chromatography on silica gel. 
2-(Allyloxy)-N-butylaniline (36a) 
 
Yield: 40%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 6.83 (m, 3 H), 6.61 (m, 1 H), 6.07 (m, 1 H), 5.34 (m, 2 H), 4.55 (m, 2 H), 
4.21 (br. s, 1 H, exchange with D2O), 3.13 (t, J = 6,9 Hz, 2 H), 1.53 (m, 4 
H), 0.96 (t, J = 7.3 Hz, 3 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 145.9 (s), 139.1 (s), 133.9 (d), 121.9 (d), 117.5 (t), 116.2 (d), 111.3 (d), 
110.2 (d), 69.5 (t), 43.6 (t), 31.9 (t), 20.6 (t), 14.7 (q) ppm. 
IR: ν˜ = 3428, 3063, 3029, 2917, 2850 cm-1. 
MS (ESI): m/z = 206.1 [M+H]+. (C13H19NO) 
2-(Allyloxy)-N-butyl-5-methoxyaniline (36b) 
 
 
Yield: 53%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 6.67 (d, J = 8.4 Hz, 1 H), 6.21 (d, J = 2.9, 1 H), 6.05 (m, 2 H), 5.32 (m, 2 H), 
4.49 (m, 2 H), 4.24 (br. s, 1 H, exchange with D2O), 3.76 (s, 3 H), 3.10 (t, J 
= 7.0 Hz, 2 H), 1.62 (m, 2 H), 1.43 (m, 2 H), 0.95 (t, J = 7.0 Hz, 3 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 155.4 (s), 140.6 (s), 140.3 (s), 134.2 (d), 117.4 (t), 112.3 (d), 98.6 (d), 98.2 
(d), 70.4 (t), 55.7 (q), 43.5 (t), 31.8 (t), 20.6 (t), 14.1 (q) ppm. 
IR: ν˜ = 3428, 3063, 3029, 2917, 2850 cm-1. 
MS (ESI): m/z = 236.1 [M+H]+. (C14H21NO2). 
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Synthesis of tert-butyl (2-(allyloxy)phenyl)carbamate (37) 
 
To a solution of 32a (1 equiv.) in THF (5mL/mmol), Boc2O (1.2 equiv.) was added at room temperature and 
the reaction mixture was stirred at room temperature for 24-48h. The solvent was then removed under 
reduce pressure, brine was added and the solution was extracted with AcOEt (3 x). The collected organic 
phases dried over Na2SO4, and the solvent removed under reduced pressure. The crude product was 
purified by silica gel flash column chromatography. 
1H NMR (300 MHz; CDCl3): δ = 8.08 (br. s, 1 H), 7.09 (br. s, 1 H, exchange with D2O), 6.93 (m, 2 H), 6.83 
(m, 1 H), 6.06 (ddd, J = 17.3, 10.7, 4.2 Hz, 1 H), 5.40 (dd, J = 17.3, 1.4 Hz, 
1 H), 5.32 (dd, J = 10.7, 1.4 Hz, 1 H) 4.59 (dd, J = 4.1, 1.4 Hz, 2 H), 1.53 
(s, 9 H) ppm. 
MS (ESI): m/z = 249.1 [M+H]+. (C14H19NO3). 
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General procedure for hydroamination reaction 
 
PtCl2 (5 mol %) and Xantophos (5 mol %) were added to a solution of the corresponding allyl derivative (1 
equiv.) in toluene (15 mL/mmol) and the mixture was stirred at 110 °C for 5 h. The reaction mixture was 
concentrated in vacuo, brine was added and the mixture extracted with AcOEt (3 ×). The combined organic 
phases were dried with Na2SO4, filtered and the solvent removed in vacuo. The product was purified by 
flash chromatography on silica gel. 
 
 
 
4-Benzyl-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (38a) 
 
Yield: 93%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.30 (m, 5 H), 6.79 (m, 2 H), 6.59 (m, 2 H), 4.46 (q, J = 16.5 Hz, 2 H), 4.20 
(m, 1 H), 4.06 (m, 1 H), 3.51 (m, 1 H), 1.23 (d, J = 6.6 Hz, 3 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 143.9 (s), 139.0 (s), 135.1 (s), 128.9 (d), 127.3 (d), 127.0 (d), 122.1 (d), 
117.5 (d), 116.4 (d), 113.1 (d), 69.5 (t), 53.3 (t), 51.5 (d), 15.8 (q) ppm. 
IR: ν˜ = 3400, 3063, 3031, 2973, 2924, 2873 cm-1. 
MS (ESI): m/z = 240.1 [M+H]+. (C16H17NO). 
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4-Benzyl-6-methoxy-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (38b) 
 
Yield: 57%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.28 (m, 5 H), 6.73 (m, 1 H), 6.15 (m, 2 H), 4.44 (q, J = 16.8 Hz, 2 H), 4.13 
(m, 1 H), 4.01 (m, 1 H), 3.64 (s, 3 H), 3.49 (m, 1 H), 1.23 (d, J = 6.6 Hz, 3 
H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 155.2 (s), 138.8 (s), 138.2 (s), 135.8 (s), 128.9 (d), 127.3 (d), 126.9 (d), 
116.2 (d), 101.1 (d), 99.9 (d), 69.4 (t), 55.7 (q), 53.2 (t), 51.6 (d), 15.9 (q) 
ppm. 
IR: ν˜ = 3400, 3063, 3031, 2973, 2924, 2873 cm-1. 
MS (ESI): m/z = 270.1 [M+H]+. (C17H19NO2). 
 
 
 
4-Benzyl-3-methyl-6-(trifluoromethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (38c) 
 
Yield: 88%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.31 (m, 5 H), 6.88 (s, 2 H), 6.87 (s, 1 H), 4.47 (q, J = 46.5 Hz; J = 16.5 Hz, 
2 H), 4.14 (m, 2 H), 3.51 (m, 1 H), 1,22 (d, J = 6,6 Hz, 3 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 146.5 (s), 137.3 (s), 134.2 (s), 129.2 (d), 127.8 (d), 127.4 (d), 127.37 (s), 
124.6 (q, J = 329.7 Hz), 124.2 (q, J = 32.0 Hz), 116.d (d), 115.3 (d), 110.2 
(d), 69.2 (t), 53.4 (t), 50.8 (d), 15.4 (q) ppm. 
IR: ν˜ = 3400, 3063, 3031, 2973, 2924, 2873 cm-1. 
MS (ESI): m/z = 308.1 [M+H]+. (C17H16F3NO). 
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4-Benzyl-3-methyl-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine (38d) 
 
Yield: 70%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.52 (m, 2 H), 7.32 (m, 5 H), 6.84 (m, 1 H), 4.45 (m, 2 H), 4.19 (m, 2 H), 
3.56 (m, 1 H), 1.23 (d, J = 6.2 Hz, 3 H) ppm. 
IR: ν˜ = 3400, 3063, 3031, 2973, 2924, 2873 cm-1. 
MS (ESI): m/z = 285.1 [M+H]+. (C16H16N2O3). 
 
 
4-Benzyl-3,6-dimethyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (38e) 
 
Yield: 87%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.31 (m, 5 H), 6.75 (d, J = 7.7 Hz, 1 H), 6.45 (m, 2 H), 4.47 (q, J = 16.5 Hz, 
2 H), 4.10 (m, 2 H), 3.48 (m, 1 H), 2.19 (s, 3 H), 1.22 (d, J = 6.6 Hz, 3 H) 
ppm. 
13C NMR (50 MHz; CDCl3): δ = 141.7 (s), 139.1 (s), 134.8 (s), 131.4 (s), 128.8 (d), 127.2 (d), 127.0 (d), 
118.0 (d), 116.1 (d), 113.6 (d), 69.4 (t), 53.2 (t), 51.3 (d), 21.4 (q), 15.7 (q) 
ppm. 
IR: ν˜ = 3400, 3063, 3031, 2973, 2924, 2873 cm-1. 
MS (ESI): m/z = 254.1 [M+H]+. (C17H19NO). 
  
108 
 
4-Benzyl-6-chloro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (38f) 
 
Yield: 97%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.31 (m, 5 H), 6.75 (d, J = 8.4 Hz, 1 H), 6.56 (m, 2 H), 4.44 (q, J = 16.5 Hz, 
2 H), 4.09 (m, 2 H), 3.50 (m, 1 H), 1.23 (d, J = 6.6 Hz, 3 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 42.4 (s), 138.0 (s), 135.9 (s), 129.0 (d), 127.5 (d), 127.0 (d), 126.9 (s), 117.1 
(d), 116.9 (d), 112.4 (d), 69.3 (t), 52.9 (t), 51.1 (d), 15.7 (q) ppm. 
IR: ν˜ = 3400, 3063, 3031, 2973, 2924, 2873 cm-1. 
MS (ESI): m/z = 274.5 [M+H]+. (C16H16ClNO). 
 
1-Benzyl-2-methyl-4-tosyl-1,2,3,4-tetrahydroquinoxaline (38g) 
 
Yield: 30%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.54 (d, J = 8.5 Hz, 2 H), 7.28 (m, 5 H), 7.06 (d, J = 2.6 Hz, 2 H), 6.93 (t, J 
= 6.6 Hz, 1 H). 6.66 (t, J = 6.9 Hz, 1 H), 6.47 (d, J = 1.2 Hz, 1 H), 4.23 (s, 2 
H), 4.05 (dd, J = 13.9, 4.0 Hz, 1 H), 3.59 (m, 1 H), 3.24 (m, 1 H), 2.42 (s, 3 
H), 1.06 (d, J = 6.2 Hz, 3 H) ppm. 
MS (ESI): m/z = 415.2 [M+H]+. (C23H24N2O2S).  
 
4-Butyl-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (38h) 
 
Yield: 10%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 6.77 (m, 2 H), 6.57 (m, 2 H), 4.01 (d, J = 1.8 Hz, 2 H), 3.44 (m, 1 H), 3.21 
(m, 2 H), 1.56 (m, 2 H), 1.28 (m, 5 H), 0.95 (t, J = 7.3 Hz, 3 H) ppm. 
 MS (ESI): m/z = 206.1 [M+H]+. (C13H19NO). 
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4-Butyl-6-methoxy-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (38i) 
 
Yield: 35%. 
1H NMR (200 MHz; CDCl3): δ = 6.70 (d, J = 8.4 Hz, 1H), 6.20 (m, 1 H), 6.11 (dd, J = 8.4, 2.6 Hz, 1 H), 3.94 
(m, 2 H), 3.75 (s, 3 H), 3.40 (m, 1 H), 3.17 (m, 2 H), 1.58 (m, 2 H), 1.35 (m, 
2 H), 1.20 (d, J = 6.6 Hz, 3 H), 0.95 (t, J = 7.3 Hz, 3 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 155.2 (s), 138.1 (s), 135.4 (s), 116.0 (d), 99.7 (d), 91.1 (d), 69.2 (t), 55.8 (q), 
51.3 (d), 48.9 (t), 29.6 (t), 20.6 (t), 16.2 (q), 14.2 (q) ppm. 
MS (ESI): m/z = 236.1 [M+H]+. (C14H21NO2). 
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General procedure for hydroarilation reaction 
 
To a solution of propargyl derivative 3 or 8 (1 equiv.) in toluene (5 ml/mmol) was added PtCl2 (5 mol %) and 
was stirred at 80 °C for 3 h. The reaction mixture was concentrated in vacuo, brine was added and the 
mixture extracted with AcOEt (3 ×). The combined organic phases were dried with Na2SO4, filtered and the 
solvent removed in vacuo. The product was purified by flash chromatography on silica gel. 
 
tert-Butyl 2H-chromen-8-ylcarbamate (39a) 
 
Yield: 40%.  
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.91 (d, J = 8.2 Hz, 1 H), 6.93 (br. s, 1 H, exchange with D2O), 6.84 (t, J = 
7.9 Hz, 1 H), 6.64 (dd, J = 7.5, 1.4 Hz, 1 H), 6.41 (dt, J = 9.9, 1.8 Hz, 1 H), 
5.76 (dt, J = 9.9, 3.5 Hz, 1 H), 4.83 (dd, J = 3.5, 1.9 Hz, 2 H), 1.54 (s, 9 H) 
ppm.  
IR: ν˜ = 3425, 2970, 1920, 1720 cm-1. 
MS (ESI): m/z = 270.0 [M+Na]+. (C14H17NO3). 
 
tert-Butyl (6-chloro-2H-chromen-8-yl)carbamate (39b) 
 
Yield: 20%. 
Colourless oil. 
1H NMR (200 MHz; CDCl3): δ = 7.99 (s, 1 H), 6.94 (br. s, 1 H, exchange with D2O), 6.63 (d, J = 2.5 Hz, 1 
H), 6.34 (dt, J = 9.9, 1.9 Hz, 1 H), 5.81 (dt, J = 9.9, 3.5 Hz, 1 H), 4.84 (dd, J 
= 3.5, 1.9 Hz, 2 H), 1.54 (s, 9 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 152.6 (s), 140.1 (s), 128.1 (s), 126.6 (s), 124.1 (d), 122.8 (d), 122.6 (s), 
119.7 (d), 118.2 (d), 81.0 (s), 66.1 (t), 28.5 (q) ppm. 
IR: ν˜ = 3432, 2979, 2930, 1728 cm-1. 
MS (ESI): m/z = 304.0 [M+Na]+. (C14H16ClNO3). 
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  tert-Butyl (6-methyl-2H-chromen-8-yl)carbamate (39c) 
 
Yield: 65%. 
Colourless oil. 
Massa: (m/z)  
1H NMR (200 MHz; CDCl3): δ = 7.72 (d, J = 16.2 Hz, 1 H), 6.88 (m, 1 H), 6.46 (br. s, 1 H, exchange with 
D2O), 6.37 (dt, J = 9.8, 1.7 Hz, 1 H), 5.75 (dt, J = 9.8, 3.5 Hz, 1 H), 4.79 
(dd, J = 3.5, 1.8 Hz, 2 H) 2.24 (s, 3 H), 1.53 (s, 9 H) ppm. 
IR: ν˜ = 3436, 2977, 2920, 1728 cm-1. 
MS (ESI): m/z = 284.0 [M+Na]+. (C15H19NO3). 
 
tert-Butyl (6-methoxy-2H-chromen-8-yl)carbamate (39d) 
 
Yield: 65%.  
1H NMR (200 MHz; CDCl3): δ = 7.61 (d, J = 2.6 Hz, 1 H), 6.94 (s, 1 H), 6.37 (m, 1 H), 6.23 (d, J = 2.6 Hz, 1 
H), 5.81 (m, 1 H), 4.75 (m, 2 H), 3.76 (s, 3 H), 1,52 (s, 9 H) ppm. 
IR: ν˜ = 3435, 2911, 2934, 2844, 1727 cm-1. 
MS (ESI): m/z = 300.1 [M+Na]+. (C15H19NO4). 
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General procedure for the carboamination reactions 
 
 
 
K2CO3 (1.4 equiv.), Pd(PPh3)4 (5 mol %) and the corresponding aryl iodide or bromide (1.4 equiv.) was 
added to a solution of the corresponding allene (1 equiv.) in MeCN (20 mL/mmol) and the mixture was 
heated at 80 °C for 8 h. The reaction mixture was concentrated in vacuo, then brine was added and the 
mixture extracted with AcOEt (3 ×). The organic phases were dried with Na2SO4, filtered and the solvent 
removed in vacuo. The product was purified by flash chromatography on silica gel. 
 
 
 
 
 
 
 
 
tert-Butyl 2-(1-Phenylvinyl)benzo[d]oxazole-3(2H)-carboxylate (43a) 
 
Yield: 76%. 
White solid; m.p.: 76 - 78 °C. 
1H NMR (400 MHz, CDCl3): δ =  7.56 (br. s, 1 H), 7.44–7.46 (m, 2 H), 7.29–7.36 (m, 3 H), 6.87–6.94 (m, 2 
H), 6.79 (d, J = 8.5 Hz, 2 H), 5.55 (s, 1 H), 5.52 (s, 1 H), 1.53 (s, 9 H) ppm. 
13C NMR (100 MHz, CDCl3): δ = 150.3 (s), 149.9 (s), 144.9 (s), 137.5 (s), 130.2 (s), 128.3 (d), 128.0 (d), 
127.2 (d), 123.3 (d), 121.2 (d), 117.0 (t), 113.8 (d), 108.8 (d), 94.5 (d), 82.3 
(s), 28.2 (q) ppm. 
IR: ν˜ = 3411, 2970, 2930, 1722, 1600 cm–1. 
MS (ESI): m/z = 346.0 [M+Na]+. (C20H21NO3). 
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tert-Butyl 5-nitro-2-(1-phenylvinyl)benzo[d]oxazole-3(2H)-carboxylate (43b) 
 
Yield: 62%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ =  8.28 (br. s, 1 H), 7.90 (dd, J = 8.7, 2.4 Hz, 1 H), 7.26–7.39 (m, 5 H), 6.87 
(br. s, 1 H), 6.77 (d, J = 8.7 Hz, 1 H), 5.57 (s, 1 H), 5.53 (s, 1 H), 1.53 (s, 9 
H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 155.5 (s), 149.8 (s), 144.2 (s), 142.9 (s), 136.9 (s), 132.4 (d), 131.4 (s), 
128.6 (d), 127.5 (d), 121.2 (d), 109.5 (d), 118.7 (t), 108.1 (d), 97.2 (d), 83.9 
(s), 28.3 (q), ppm. 
IR: ν˜ = 3423, 2978, 2933, 1721 cm–1. 
MS (ESI): m/z = 391.0 [M+Na]+. (C20H20N2O5). 
 
 
 
tert-Butyl 5-chloro-2-(1-phenylvinyl)benzo[d]oxazole-3(2H)-carboxylate (43c) 
 
Yield: 54%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 1.49 (s, 9 H), 5.48 (s, 1 H), 5.53 (s, 1 H), 6.65 (d, J = 8.4 Hz, 1 H), 6.75 (s, 
1 H), 6.85 (dd, J = 8.4, 2.2 Hz, 1 H), 7.26–7.65 (m, 6 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 28.4 (q), 83.1 (s), 95.8 (d), 109.3 (d), 114.4 (d), 117.7 (t), 123.0 (d), 126.4 
(s), 127.5 (d), 128.4 (d), 128.6 (d), 131.6 (s), 137.4 (s), 144.7 (s), 149.0 (s), 150.1 (s) ppm. 
IR: ν˜ = 3415, 2980, 2930, 1721 cm–1. 
MS (ESI): m/z = 380.0 [M+Na]+. (C20H20ClNO3). 
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tert-Butyl 5-methyl-2-(1-phenylvinyl)benzo[d]oxazole-3(2H)-carboxylate (43d) 
 
Yield: 48%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 7.37–7.46 (m, 3 H), 7.27–7.36 (m, 3 H), 6.63–6.73 (m, 3 H), 5.52 (s, 1 H), 
5.48 (s, 1 H), 2.30 (s, 3 H), 1.50 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 150.5 (s), 148.1 (s), 145.0 (s), 137.8 (s), 131.1 (s), 130.3 (s), 128.6 (d), 
128.2 (d), 127.4 (d), 123.6 (d), 117.1 (t), 114.9 (d), 108.4 (d), 94.9 (d), 82.4 
(s), 28.4 (q), 21.4 (q) ppm.  
IR: ν˜ = 3436, 2976, 2920, 1708 cm–1. 
MS (ESI): m/z = 360.0 [M+Na]+. (C21H23NO3). 
 
 
 
 
tert-Butyl 2-(1-(3-(trifluoromethyl)phenyl)vinyl)benzo[d]oxazole-3(2H)-carboxylate (43e) 
 
Yield: 57%. 
White solid; m.p.: 58 - 60 °C. 
1H NMR (400 MHz, CDCl3): δ = 7.68 (br. s, 1 H), 7.55– 7.60 (m, 2 H), 7.22–7.44 (m, 2 H), 6.86–6.94 (m, 2 
H), 6.79 (d, J = 7.5 Hz, 1 H), 6.76 (br. s, 1 H), 5.62 (s, 1 H), 5.58 (s, 1 H), 
1.54 (s, 9 H), ppm. 
13C NMR (100 MHz, CDCl3): δ = 149.9 (s), 149.8 (s), 138.2 (s), 130.9 (s), 130.6 (d), 130.2 (s), 128.7 (d), 
124.7 (d), 124.3 (d), 124.0 (s), 123.4 (d), 123.1 (s), 121.4 (d), 118.7 (t), 
113.8 (d), 108.8 (d), 94.4 (d), 82.5 (s), 28.2 (q), ppm. 
IR: ν˜ = 3420, 2985, 2973, 1717 cm–1. 
MS (ESI): m/ z = 414.0 [M+Na]+. (C21H20F3NO3). 
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tert-Butyl 2-(1-(4-(ethoxycarbonyl)phenyl)vinyl)benzo[d]oxazole-3(2H)-carboxylate (43f) 
 
 
Yield: 78%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 7.94–8.00 (m, 2 H), 7.44–7.50 (m, 3 H), 6.85–6.91 (m, 2 H), 6.73–6.78 (m, 
2 H), 5.59 (s, 1 H), 5.58 (s, 1 H), 4.36 (q, J = 7.1 Hz, 2 H), 1.50 (s, 9 H), 
1.38 (t, J = 7.1 Hz, 3 H), ppm. 
13C NMR (50 MHz, CDCl3): δ = 166.5 (s), 150.5 (s), 150.1 (s), 144.3 (s), 142.2 (s), 130.2 (s), 130.1 (s), 
129.8 (d), 127.5 (d), 123.6 (d), 121.6 (d), 118.9 (t), 114.1 (d), 109.0 (d), 
94.7 (d), 82.7 (s), 61.2 (t), 28.4 (q), 14.5 (q) ppm. 
IR: ν˜ = 3415, 3059, 2979, 1712, 1609 cm–1. 
MS (ESI): m/z = 418.0 [M+Na]+. (C23H25NO5). 
 
 
tert-Butyl 2-(1-(4-nitrophenyl)vinyl)benzo[d]oxazole-3(2H)-carboxylate (43g) 
 
Yield: 71%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 8.15 (dd, J = 6.6, 1.8 Hz, 2 H), 7.56 (dd, J = 6.6, 1.8 Hz, 2 H), 7.29–7.49 
(br. s, 1 H), 6.86–6.95 (m, 2 H), 6.74–6.79 (m, 2 H), 5.67 (s, 1 H), 5.63 (s, 1 
H), 1.51 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 150.5 (s), 149.9 (s), 147.8 (s), 144.3 (s), 143.5 (s), 129.9 (s), 128.5 (d), 
123.8 (d), 123.7 (d), 121.8 (d), 120.4 (t), 114.2 (d), 109.1 (d), 94.5 (d), 83.0 
(s), 28.4 (q) ppm. 
IR: ν˜ = 3412, 3073, 2978, 2933, 1712 cm–1. 
MS (ESI): m/z = 391.0 [M+Na]+. (C20H20N2O5). 
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tert-Butyl 2-(1-(4-methoxyphenyl)vinyl)benzo[d]oxazole-3(2H)-carboxylate (43h) 
 
Yield: 65%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ =  7.55 (br. s, 1 H), 7.38 (d, J = 8.4 Hz, 2 H), 6.75–6.95 (m, 6 H), 5.48 (s, 1 H), 
5.42 (s, 1 H), 3.79 (s, 3 H), 1.52 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 159.8 (s), 150.6 (s), 150.3 (s), 144.3 (s), 130.4 (s), 130.2 (s), 128.6 (d), 
123.5 (d), 121.5 (d), 116.0 (t), 114.1 (d), 114.0 (d), 109.0 (d), 95.0 (d), 82.4 
(s), 55.4 (q), 28.5 (q) ppm. 
IR: ν˜ = 3414, 2978, 2934, 1713, 1609 cm–1. 
MS (ESI): m/z = 376.0 [M+Na]+. (C21H23NO4). 
 
 
 
tert-Butyl 2-(1-(thiophen-2-yl)vinyl)benzo[d]oxazole-3(2H)-carboxylate (43i) 
 
Yield: 64%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ = 7.37–7.66 (br. s, 1 H), 7.20 (dd, J = 5.1, 1.1 Hz, 1 H), 7.10 (d, J = 3.2 Hz, 1 
H), 6.85–6.98 (m, 3 H), 6.76–6.80 (m, 1 H), 6.72 (br. s, 1 H), 5.65 (s, 1 H), 
5.41 (s, 1 H), 1.50 (s, 9 H) ppm.  
13C NMR (50 MHz, CDCl3): δ =  150.5 (s), 150.3 (s), 139.5 (s), 138.3 (s), 130.3 (s), 127.6 (d), 125.5 (d), 
125.4 (d), 123.6 (d), 121.6 (d), 116.3 (t), 114.1 (d), 109.1 (d), 94.8 (d), 82.7 
(s), 28.4 (q) ppm. 
IR: ν˜ = 3410, 3072, 2977, 2931, 1713 cm–1. 
MS (ESI): m/z = 352.0 [M+Na]+. (C18H19NO3S). 
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tert-Butyl 2-(1-(1-(phenylsulfonyl)-1H-indol-3-yl)vinyl)-benzo[d]oxazole-3(2H)-carboxylate (43j) 
 
Yield: 67%. 
Colourless oil. 
1H NMR (200 MHz, CDCl3): δ =  7.91 (dd, J = 6.6, 1.5 Hz, 1 H), 7.66 (dd, J = 7.0, 2.5 Hz, 1 H), 7.44–7.62 
(m, 4 H), 7.19–7.42 (m, 5 H), 6.80–7.00 (m, 3 H), 6.67 (br. s, 1 H), 5.78 (s, 
1 H), 5.70 (s, 1 H), 1.47 (s, 9 H) ppm.  
13C NMR (50 MHz, CDCl3): δ = 150.5 (s), 138.1 (s), 136.3 (s), 136.2 (s), 134.9 (d), 133.9 (d), 130.3 (s), 
129.5 (d), 127.4 (s), 127.0 (d), 125.0 (d), 124.3 (d), 123.7 (d), 123.6 (d), 121.6 (d), 120.6 (s), 120.3 (t), 
117.9 (s), 113.9 (d), 113.7 (d), 108.7 (d), 96.3 (d), 82.7 (s), 28.4 (q) ppm. 
IR: ν˜ = 3415, 2977, 2931, 1711 cm–1. 
MS (ESI): m/ z = 525.0 [M+Na]+. (C28H26N2O5S). 
 
 
 
tert-Butyl 2-(1-(pyridin-2-yl)vinyl)benzo[d]oxazole-3(2H)-carboxylate (43k) 
 
Yield: 86%. 
White solid; m.p.: 86 - 88 °C. 
1H NMR (400 MHz, CDCl3): δ = 8.66 (d, J = 4.1 Hz, 1 H), 7.69 (t, J = 7.4 Hz, 1 H), 7.58 (d, J = 7.8 Hz, 1 H), 
7.48 (br. s, 1 H), 7.31 (br. s, 1 H), 7.21–7.24 (m, 1 H), 6.87–6.97 (m, 2 H), 
6.77–6.79 (m, 1 H), 6.04 (s, 1 H), 5.65 (s, 1 H), 1.50 (s, 9 H) ppm.  
13C NMR (100 MHz, CDCl3): δ = 155.1 (s), 150.4 (s), 150.0 (s), 149.0 (d), 136.6 (d), 130.1 (s), 130.0 (s), 
123.4 (d), 122.7 (d), 121.2 (d), 120.8 (d), 117.6 (t), 113.9 (d), 109.1 (d), 
91.9 (d), 82.2 (s), 28.2 (q) ppm.  
IR: ν˜ = 3434, 3058, 2978, 2292, 1871, 1716 cm–1. 
MS (ESI): m/z = 347.1 [M+Na]+. (C19H20N2O3). 
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tert-Butyl 2-(1-phenylvinyl)-3-tosyl-2,3-dihydro-1H-benzo[d]-imidazole-1-carboxylate (43l) 
 
Yield: 86%. 
Pale yellow solid; m.p.: 99 - 101 °C. 
1H NMR (200 MHz, CDCl3): δ = 7.53 (dd, J = 7.3, 1.8 Hz, 1 H), 7.38 (d, J = 8.1 Hz, 2 H), 7.23–7.32 (m, 5 
H), 7.10 (d, J = 8.1 Hz, 2 H), 6.95–7.03 (m, 3 H), 6.52 (br. s, 1 H), 5.38 (s, 1 
H), 5.24 (s, 1 H), 2.31 (s, 3 H), 1.36 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 150.1 (s), 145.4 (s), 144.8 (s), 138.0 (s), 135.3 (s), 133.3 (s), 131.9 (s), 
129.7 (d), 128.4 (d), 128.2 (d), 128.1 (d), 127.6 (d), 127.0 (d), 123.5 (d), 
119.6 (d), 117.3 (t), 115.2 (d), 82.3 (s), 78.6 (d), 28.2 (q), 21.7 (q) ppm. 
IR: ν˜ = 3402, 2973, 2928, 1709 cm–1. 
MS (ESI): m/z = 499.0 [M+Na]+. (C27H28N2O4S). 
 
 
tert-Butyl 
3-Tosyl-2-(1-(3-(trifluoromethyl)phenyl)vinyl)-2,3-dihydro-1H-benzo[d]imidazole-1carboxylate (43m) 
 
 
Yield: 70%. 
White solid; m.p.: 114 - 116 °C. 
1H NMR (400 MHz, CDCl3): δ =  7.33–7.62 (m, 8 H), 7.14 (d, J = 8.0 Hz, 2 H), 7.06–7.12 (m, 1 H), 7.03 (d, J 
= 7.6 Hz, 1 H), 6.58 (br. s, 1 H), 5.51 (br. s, 1 H), 5.32 (s, 1 H), 2.34 (s, 3 
H), 1.38 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ =  149.9 (s), 144.8 (s), 144.4 (s), 138.7 (s), 134.9 (s), 133.1 (s), 131.8 (d), 
130.8 (s), 129.7 (d), 128.6 (d), 127.5 (d), 126.9 (d), 125.3 (d), 125.2 (d),
 124.7 (d), 123.9 (s), 123.6 (d), 121.4 (s), 118.6 (t), 115.2 (d), 82.5 
(s), 78.6 (d), 28.2 (q), 21.6 (q) ppm.  
IR: ν˜ = 3435, 2980, 2932, 1716 cm–1. 
MS (ESI): m/z = 567.0 [M+Na]+. (C28H27F3N2O4S). 
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tert-Butyl 2-(1-(4-nitrophenyl)vinyl)-3-tosyl-2,3-dihydro-1Hbenzo[d]imidazole-1-carboxylate (43n) 
 
Yield: 65%. 
Pale-yellow solid; m.p.: 145 - 147 °C. 
1H NMR (400 MHz, CDCl3): δ =  8.15 (d, J = 8.5 Hz, 2 H), 7.45–7.53 (m, 3 H), 7.39 (d, J = 7.9 Hz, 2 H), 
7.02–7.20 (m, 5 H), 6.61 (br. s, 1 H), 5.51 (s, 1 H), 5.36 (s, 1 H), 2.34 (s, 3 
H), 1.41 (s, 9 H) ppm. 
13C NMR (50 MHz, CDCl3): δ =  147.7 (s), 145.0 (s), 144.7 (s), 143.8 (s), 134.9 (s), 132.9 (s), 131.8 (s), 
129.8 (d), 129.4 (d), 127.5 (d), 127.2 (d), 125.3 (s), 123.8 (d), 123.4 (d), 
119.3 (t), 115.3 (d), 82.8 (s), 28.3 (q), 21.7 (q), ppm. 
IR: ν˜ = 3413, 3071, 2980, 2932, 2258, 1925, 1713 cm–1. 
MS (ESI): m/z = 544.2 [M+Na]+. (C27H27N3O6S). 
 
 
 
tert-Butyl 2-(1-(thiophen-2-yl)vinyl)-3-tosyl-2,3-dihydro-1Hbenzo[d]imidazole-1-carboxylate (43o) 
 
Yield: 46%. 
Yellow solid; m.p.: 141 - 142 °C 
1H NMR (200 MHz, CDCl3): δ = 1.39 (s, 9 H), 2.33 (s, 3 H), 5.23 (s, 1 H), 5.47 (s, 1 H), 6.52 (br. s, 1 H), 
6.94 (dd, J = 5.13, 3.6 Hz, 2 H), 7.01– 7.33 (m, 6 H), 7.41 (d, J = 8.4 Hz, 2 H), 7.55 (d, J = 8.1 Hz, 1 H) 
ppm. 
13C NMR (50 MHz, CDCl3): δ = 21.8 (q), 28.3 (q), 78.5 (d), 82.6 (s), 114.9 (d), 116.8 (t), 119.6 (d), 123.5 (d), 
125.4 (d), 126.3 (d), 127.0 (d), 127.6 (d), 127.7 (d), 129.7 (d), 132.0 (s), 133.2 (s), 135.5 (s), 138.6 (s), 
139.4 (s), 144.9 (s), 150.0 (s) ppm. 
IR: ν˜ = 3429, 2971, 2921, 1709 cm–1. 
MS (ESI): m/z = 505.1 [M+Na]+. (C25H26N2O4S2). 
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tert-Butyl 2-(penta-1,4-dien-2-yl)benzo[d]oxazole-3(2H)-carboxylate 
 
Yield: 65%. 
Colourless oil. 
1H NMR (400 MHz, CDCl3): δ =  7.54 (br. s, 1 H), 6.86–6.94 (m, 2 H), 6.78 (d, J = 7.1 Hz, 1 H), 6.41 (br. s, 1 
H), 5.81 (m, 1 H), 5.32 (s, 1 H), 5.13 (s, 1 H), 5.00–5.06 (m, 2 H), 2.82 (s, 2 
H), 1.56 (s, 9 H), ppm. 
13C NMR (100 MHz, CDCl3): δ = 150.6 (s), 150.3 (s), 143.1 (s), 134.9 (d), 130.1 (s), 123.2 (d), 121.1 (d),  
116.9 (t), 116.2 (t), 113.8 (d), 108.3 (d), 95.8 (d), 82.2 (s), 33.7 (t), 28.3 (q), 
ppm. 
IR: ν˜ = 3401, 3079, 2978, 2931, 1713 cm–1. 
MS (ESI): m/z = 309.9 [M+Na]+. (C17H21NO3). 
 
 
 
 
4-Methoxy-7-(4-nitrophenyl)-9-tosyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepine (44a) 
 
Yield: 35%. 
Orange solid; m.p.: 235 - 238 °C 
1H NMR (200 MHz, CDCl3): δ = 8.22 (s, 1 H), 8.16 (d, J = 9.1 Hz, 2 H), 7.98 (d, J = 8.1 Hz, 2 H), 7.41 (d, J 
= 9.1 Hz, 2 H), 7.30 (d, J = 8.1 Hz, 2 H), 6.67 (d, J = 7.0 Hz, 1 H), 6.51 (br. 
d, J = 7.0 Hz, 1 H, exchange with D2O), 4.55 (s, 2 H), 4.07 (s, 3 H), 2.43 (s, 
3 H) ppm. 
13C NMR (50 MHz, DMSO): δ = 160.5 (s), 147.6 (s), 147.4 (d), 146.2 (s), 144.8 (s), 144.2 (s), 138.3 (s), 
132.6 (d), 130.1 (d), 128.4 (d), 124.8 (d), 124.6 (d), 119.5 (s), 112.2 (s), 
55.4 (q), 50.0 (t), 21.7 (q) ppm. 
IR: ν˜ = 3368, 2921, 1712, 1645 cm-1. 
MS (ESI): m/z = 452.2 [M]-. (C21H19N5O5S). 
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3-(4-Nitrophenyl)-1-tosyl-2,5-dihydro-1H-pyrido[3,4-b][1,4]diazepine (44b) 
 
Yield: 42%. 
Orange oil.  
1H MNR (200 MHz, CDCl3): δ = 8.14 (d, J = 8.0 Hz, 2 H); 8.16 (d, J = 9.1 Hz, 2 H); 8.00 (d, J = 5.1 Hz, 1 H); 
7.86 (s, 1 H); 7.53 (d, J = 5.1 Hz, 1 H); 7.52 (d, J = 8.0 Hz, 2 H); 7.41 (d, J 
= 9.1 Hz, 2 H); 6.36 (s, 1 H); 5.51 (s, 2 H); 4.39 (br. s, 1 H, exchange with 
D2O) ppm. 
MS (ESI): m/z = 421.2 [M]-. (C21H18N4O4S). 
 
Synthesis of 
2,2,2-trifluoro-N-(2-(4-methyl-N-(prop-2-yn-1-yl)phenylsulfonamido)phenyl)acetamide (45) 
 
 
The compound 7 (1 equiv.) was dissolved in THF (3.5 mL/mmol) and the solution cooled to 0 °C, then 
(CF3CO)2O (3.5 equiv.) was added dropwise. The resulting mixture was stirred for 1 h. After completion of 
the reaction the mixture was concentrated under reduced pressure and extracted with AcOEt (3 ×). The 
organic phases were washed with a saturated solution of NaHCO3 (2 x) and water, dried with Na2SO4, 
filtered and the solvent removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel. 
 
Yield: 75%. 
Pale-yellow solid; m.p.: 133 -135 °C. 
1H NMR (300 MHz, CDCl3): δ = 9.15 (br. s, 1 H, exchange with D2O), 8.24 (dd, J = 8.3, 1.4 Hz, 1 H), 7.54 
(d, J = 8.4 Hz, 2 H), 7.41 (td, J = 8.4, 1.4 Hz, 1 H), 7.27 (d, J = 8.4 Hz, 2 H), 
7.09 (td, J = 8.0, 1.4 Hz, 1 H), 6.80 (dd, J = 8.3, 1.4 Hz, 1 H), 4.48 (br. s, 1 
H), 4.30 (br. s, 1 H), 2.45 (s, 3 H), 2.21 (t, J = 2.6 Hz, 1 H) ppm.  
13C NMR (75 MHz, CDCl3): δ = 155.3 (q, J = 38.0 Hz), 145.2 (s), 135.4 (s), 133.9 (s), 130.4 (d), 130.0 (s), 
129.9 (d), 128.9 (d), 128.5 (d), 126.5 (d), 123.0 (d), 115.9 (q, J = 288.6 Hz), 
77.2 (s), 74.6 (d), 42.2 (t), 21.9 (q) ppm. 
IR: ν˜ = 3393, 3206, 3069, 2923, 2126, 1738, 1597, 1548 cm–1. 
MS (ESI): m/z = 419.0 [M+Na]+. (C18H15F3N2O3S). 
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Synthesis of 
2,2,2-trifluoro-N-(2-(4-methyl-N-(propa-1,2-dien-1-yl)phenylsulfonxamido)phenyl)acetamide (46) 
 
 
The compound 45 (1 equiv.) was dissolved in THF (15 mL/mmol). The solution was cooled to 0 °C and 
tBuOK (2 equiv) was added in one portion. The reaction was stirred for 5 min, then water was added and 
the mixture was extracted with AcOEt (3 × 50 mL). The solvent was removed in vacuo and the crude was 
purified by flash chromatography on silica gel to afford the product. 
 
Yield: 35%. 
Pale-yellow solid; m.p.: 111 - 114 °C. 
1H NMR (300 MHz, CDCl3): δ =  8.80 (br. s, 1 H, exchange with D2O), 8.23 (dd, J = 8.0, 1.4 Hz, 1 H), 7.56 
(d, J = 8.3 Hz, 2 H), 7.39 (td, J = 8.0, 1.4 Hz, 1 H), 7.30 (d, J = 8.3 Hz, 2 H), 
7.10 (t, J = 6.2 Hz, 1 H), 7.03 (td, J = 8.0, 1.4 Hz, 1 H), 6.55 (dd, J = 8.0, 
1.4 Hz, 1 H), 5.05 (d, J = 6.2 Hz, 2 H), 2.46 (s, 3 H), ppm. 
13C NMR (75 MHz, CDCl3): δ = 200.7 (s), 155.1 (q, J = 37.5 Hz), 145.4 (s), 134.6 (s), 133.8 (s), 130.4 (d), 
130.3 (d), 130.1 (d), 128.2 (d), 127.8 (s), 125.9 (d), 122.8 (d), 115.8 (q, J = 
289.6 Hz), 101.9 (d), 88.7 (t), 21.8 (q), ppm. 
IR: ν˜ = 3403, 3057, 2922, 1966, 1931, 1744, 1733, 1598, 1543 cm–1. 
MS (ESI): m/z = 419.0 [M+Na]+. (C18H15F3N2O3S). 
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Synthesis of 
3-(4-nitrophenyl)-5-tosyl-2,5-dihydro-1H-benzo[b][1,4]diazepine (47) 
 
 
K2CO3 (1.4 equiv.), Pd(PPh3)4 (5 mol %) and 1-iodo-4-nitrobenzene (1.4 equiv.) was added to a solution of 
the compound 46 (1 equiv.) in MeCN (20 mL/mmol) and the mixture was heated at 80 °C for 8 h. The 
reaction mixture was concentrated in vacuo, then brine was added and the mixture extracted with AcOEt (3 
×). The organic phases were dried with Na2SO4, filtered and the solvent removed in vacuo. The product 
was purified by flash chromatography on silica gel. 
 
Yield: 78%. 
Red solid; m.p.: 215 - 217 °C. 
1H NMR (500 MHz, DMSO): δ = 8.78 (d, J = 7.1 Hz, 1 H, exchange with D2O), 8.15 (d, J = 9.0 Hz, 2 H), 
7.33 (d, J = 9.0 Hz, 2 H), 7.13– 7.28 (m, 6 H), 6.90–6.96 (m, 2 H), 6.28 (d, J 
= 7.2 Hz, 1 H), 4.70 (br. s, 2 H), 2.38 (s, 3 H), ppm. 
13C NMR (125 MHz, DMSO): δ = 148.8 (s), 144.4 (s), 144.1 (s), 141.4 (s), 137.6 (s), 132.5 (d), 132.3 (d), 
129.9 (d), 128.9 (s), 128.8 (d), 128.0 (d), 124.7 (d), 124.6 (d), 121.9 (d), 
120.4 (s), 107.9 (s), 52.1 (t), 21.9 (q) ppm. 
IR: ν˜ = 3372, 3064, 2921, 2431, 1736, 1644, 1584 cm–1. 
MS (ESI): m/z = 444.2 [M+Na]+. (C22H19N3O4S). 
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Synthesis of tert-butyl N-(2-Nitrophenyl)-N-(prop-2-yn-1-yl)carbamate (49) 
 
A solution of compound 48 (1 equiv.) in THF/DMF (5 mL/1 mL) was cooled to 0 °C and NaH (1.5 equiv.) 
was added. The mixture was stirred for 15 min at 0 °C and propargyl bromide (1.5 equiv.) was added. The 
resulting mixture was stirred at room temperature overnight. The solvent was removed under reduced 
pressure, the residue was extracted with AcOEt (3 ×) and then washed with brine. The organic phases 
were dried with Na2SO4, filtered and the solvent removed under reduced pressure. The crude product was 
purified by flash chromatography on silica gel. 
Yield: 85%. 
Pale-yellow solid; m.p.: 52 - 55 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.94 (d, J = 8.0 Hz, 1 H), 7.57–7.66 (m, 2 H), 7.41–7.46 (m, 1 H), 4.81 (dd, 
J = 17.8, 2.0 Hz, 1 H), 4.12 (dd, J = 17.8, 2.0 Hz, 1 H), 2.27 (t, J = 2.4 Hz, 1 
H), 1.51 (s, 3 H), 1.30 (s, 6 H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 152.9 (s), 146.8 (s), 135.4 (s), 133.8 (d), 130.3 (d), 128.2 (d), 125.1 (d), 
82.4 (s), 79.5 (s), 73.1 (d), 39.3 (t), 28.0 (q) ppm.  
R: ν˜ = 3393, 3254, 2980, 2118, 1703, 1606, 1580, 1525 cm–1. 
MS (ESI): m/z = 298.9 [M+Na]+. (C14H16N2O4). 
 
Synthesis of tert-butyl N-(2-aminophenyl)-N-(prop-2-yn-1-yl)carbamate (50) 
 
Fe powder (6 equiv.) was added to a suspension of compound 49 (1 equiv.) in a mixture of AcOH (20 % in 
H2O, 2.5 ml/mmol), EtOH (5 ml/mmol). The resulting suspension was heated at reflux for 3 h. The reaction 
mixture was filtered through a pad of Celite using AcOEt as eluent to remove the excess iron. The filtrate 
was washed with water (3 ×), dried with Na2SO4, filtered and the solvent removed under reduced pressure. 
The crude product was purified by flash chromatography on silica gel to afford the product. 
Yield: 98%. 
Colourless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.06–7.12 (m, 2 H), 6.77 (d, J = 8.0 Hz, 2 H), 4.32 (br. s, 1 H), 4.23 (br. s, 1 
H), 3.72 (br. s, 2 H, exchange with D2O), 2.24 (s, 1 H), 1.42 (s, 9 H), ppm. 
13C NMR (75 MHz, CDCl3): δ = 154.9 (s), 143.2 (s), 128.7 (d), 128.6 (d), 128.3 (s), 118.9 (d), 116.4 (d), 
80.3 (s), 77.5 (s), 72.0 (d), 38.8 (t), 28.5 (q), ppm. 
IR: ν˜ = 3467, 3367, 3290, 2979, 2932, 2119, 1694, 1621, 1503 cm–1. 
MS (ESI): m/z = 268.9 [M+Na]+. (C14H18N2O2). 
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Synthesis of tert-butyl N-Prop-2-yn-1-yl-N-(2-(2,2,2-trifluoroacetamido)-phenyl)carbamate (51) 
 
The compound 50 (1 equiv.) was dissolved in THF (5 mL) and the solution cooled to 0 °C, then (CF3CO)2O 
(1.5 equiv.) was added dropwise. The resulting mixture was stirred for 1h. After completion of the reaction 
the mixture was concentrated under reduced pressure and extracted with AcOEt (3 ×). The organic phases 
were washed with a saturated solution of NaHCO3 (2 x) and water, dried with Na2SO4, filtered and the 
solvent removed under reduced pressure. The crude product was purified by flash chromatography on 
silica gel. 
Yield: 75%. 
White solid; m.p.: 55 - 58 °C. 
1H NMR (300 MHz, CD3CN): δ = 8.84 (br. s, 1 H, exchange with D2O), 7.80 (d, J = 7.6 Hz, 1 H), 7.52 (dd, J 
= 7.6, 1.6 Hz, 1 H), 7.35–7.47 (m, 2 H), 4.33 (s, 2 H), 2.60 (t, J = 2.5 Hz, 1 
H), 1.43 (s, 9 H), ppm. 
13C NMR (75 MHz, CD3CN): δ = 155.3 (q, J = 37.0 Hz), 153.8 (s), 135.5 (s), 132.3 (s), 128.4 (d), 128.0 (d), 
127.8 (d), 124.9 (d), 114.7 (q, J = 288.0 Hz), 81.8 (s), 80.0 (s), 72.9 (d), 
39.9 (t), 27.5 (q), ppm. 
IR: ν˜ = 3314, 3262, 2985, 2936, 1732, 1686, 1674, 1601, 1589 cm–1. 
MS (ESI): m/ z = 364.9 [M+Na]+. (C16H17F3N2O3). 
Syntesis of tert-butyl N-(propa-1,2-dien-1-yl)-N-(2-(2,2,2-trifluoroacetamido) phenyl)carbamate (52) 
 
The compound 51 (1 equiv.) was dissolved in THF (15 ml/mmol). The solution was cooled to 0 °C and 
tBuOK (2 equiv) was added in one portion. The reaction was stirred for 5 min, then water was added and 
the mixture was extracted with AcOEt (3 × 50 mL). The solvent was removed in vacuo and the crude was 
purified by flash chromatography on silica gel to afford the product. 
Yield: 85%. 
Colourless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.15 (br. s, 1 H, exchange with D2O), 8.05 (d, J = 8.2 Hz, 1 H), 7.32–7.39 
(m, 2 H), 7.20–7.28 (m, 2 H), 5.05 (d, J = 6.3 Hz, 2 H), 1.45 (s, 9 H), ppm. 
13C NMR (75 MHz, CDCl3): δ = 200.7 (s), 155.0 (q, J = 37.5 Hz), 152.2 (s), 132.1 (s), 130.7 (s), 129.3 (d), 
129.2 (d), 129.1 (d), 126.3 (d), 116.0 (q, J = 288.6 Hz), 101.1 (d), 87.7 (t), 
83.3 (s), 28.2 (q), ppm. 
IR: ν˜ = 3414, 3292, 2982, 1715, 1600, 1540 cm–1. 
MS (ESI): m/z = 364.9 [M+Na]+. (C16H17F3N2O3). 
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Synthesis of 
tert-Butyl 3-(4-nitrophenyl)- 2-(1-(4-nitrophenyl)vinyl)-2,3-dihydro-1H-benzo[d]imidazole-1-
carboxylate (53) 
and 
tert-Butyl 2-(1-(4-nitrophenyl)vinyl]-2,3-dihydro-1H-benzo[d]- imidazole-1-carboxylate (54) 
 
 
K2CO3 (3 equiv.), Pd(PPh3)4 (5 mol %) and 1-iodo-4-nitrobenzene (2.5 equiv.) were added to a solution of 
compound 52  (1 equiv.) in MeCN (20 ml/mmol) and the mixture was heated at 80 °C for 48 h. It was then 
concentrated in vacuo, brine was added and the mixture extracted with AcOEt (3 ×). The combined organic 
phases were dried with Na2SO4, filtered and the solvent removed in vacuo. The mixture was purified by 
flash chromatography on silica gel to obtain pure compound 53 and a mixture of compounds 53 and 54 
(20%). 
 
tert-Butyl 3-(4-nitrophenyl)-2-[1-(4-nitrophenyl)vinyl]-2,3-dihydro-1H-benzo[d]imidazole-1-
carboxylate (53) 
 
Yield: 50%. 
Orange solid; m.p.: 180 - 182 °C. 
1H NMR (300 MHz, CDCl3): δ =  8.21 (d, J = 9.2 Hz, 2 H), 7.99 (d, J = 8.6 Hz, 2 H), 7.32 (d, J = 9.2 Hz, 2 H), 
7.27 (m, 3 H), 7.02 (m, 1 H), 6.82–6.90 (m, 2 H), 6.66 (br. s, 1 H), 5.78 (s, 1 
H), 5.48 (s, 1 H), 1.57 (s, 9 H), ppm. 
13C NMR (75 MHz, CDCl3): δ =  150.5 (s), 147.7 (s), 147.4 (s), 144.4 (s), 143.8 (s), 141.9 (s), 129.4 (d), 
125.9 (d), 123.5 (d), 123.4 (d), 123.0 (d), 122.2 (t), 116.9 (d), 115.5 (d), 
111.4 (d), 83.4 (s), 82.5 (d), 28.5 (q), ppm. 
IR: ν˜ = 3435, 2969, 2919, 2850, 1705, 1586 cm–1. 
MS (ESI): m/z = 511.0 [M+Na]+. (C26H24N4O6). 
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tert-Butyl 2-(1-(4-nitrophenyl)vinyl)-2,3-dihydro-1H-benzo[d]-imidazole-1-carboxylate (54) 
 
1H NMR (300 MHz, CDCl3): δ = 8.12 (d, J = 9.1 Hz, 2 H), 7.55 (d, J = 9.1 Hz, 2 H), 7.28 (m, 1 H), 6.72–6.85 
(m, 2 H), 6.60 (dd, J = 1.4, 7.7 Hz, 1 H), 6.32 (br. s, 1 H), 5.51 (s, 1 H), 5.48 
(s, 1 H), ppm.a 
a only  distinguishing signals found in the mixture are reported. 
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General procedure for carboamination reaction 
 
The compound 33a (1 equiv.) in toluene (10 ml/mmol) were added to a solution of Pd2(dba)3 (2 mol %) and 
Xantphos (8 mol %) in toluene (2 ml). Then were added the corresponding aryl bromide (1.4 equiv.) and 
tBuONa (1.4 equiv.) and the mixture was heated at 110 °C for 4 h. The reaction mixture was concentrated 
in vacuo, then brine was added and the mixture extracted with AcOEt (3 ×). The organic phases were dried 
with Na2SO4, filtered and the solvent removed in vacuo. The product was purified by flash chromatography 
on silica gel. 
  4-Benzyl-3-(4-methylbenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (55a) 
 
Yield: 70%. 
White solid; m.p.: 76 – 78 °C.  
1H NMR (300 MHz, CDCl3): δ = 7.32 (m, 5 H), 7.13 (m, 3 H), 6.80 (m, 3 H), 6.69 (m, 2 H), 4.43 (d, J = 13.8 
Hz, 1 H), 4.38 (d, J = 13.8 Hz, 1 H), 4.31 (m, 1 H), 3.26 (m, 3 H), 2.86 (m, 1 
H), 2.36 (s, 3 H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 143.8 (s), 238.3 (s), 136.4 (s), 135.3 (s), 134.4 (s), 129.5 (d), 129.5 (d), 
128.9 (d), 127.3 (d), 127.2 (d), 121.7 (d), 118.2 (d), 116.8 (d), 112.7 (d), 74.5 
(d), 55.3 (t), 51.3 (t), 39.2 (t), 21.3 (q) ppm. 
IR: ν˜ = 3435, 3023, 2913, 1601, 1577, 1502 cm–1. 
MS (ESI): m/z = 330.3 [M+H]+. (C23H23NO). 
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4-Benzyl-3-(4-chlorobenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (55b) 
 
Yield: 80%. 
White solid; m.p.: 101 – 103 °C.  
1H NMR (300 MHz, CDCl3): δ = 7.30 (m, 7 H), 7.14 (m, 2 H), 6.74 (m, 2 H), 6.34 (m, 2 H), 4.45 (d, J = 15.4 
Hz, 1 H), 4.40 (d, J = 15.4 Hz, 1 H), 4.35 (m, 1 H), 3.25 (m, 1 H), 3.03-3.17 
(m, 2 H), 2.84 (m, 1 H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 143.5 (s), 138.2 (s), 136.0 (s), 135.2 (s), 132.7 (s), 131.0 (d), 128.9 (d), 
128.8 (d), 127.4 (d), 127.3 (d), 121.8 (d), 118.3 (d), 116.8 (d), 112.7 (d), 
74.0 (d), 55.2 (t), 51.1 (t), 38.8 (t) ppm. 
IR: ν˜ = 3440, 2900, 1601, 1575, 1516 cm–1.  
MS (ESI): m/z = 350.6 [M+H]+. (C22H20ClNO). 
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Synthesis of methyl (2-(indol-3-yl)ethyl)carbamates (57a-b) 
 
 
 
The products were synthesized following the procedure reported in literature.[110] 
 
Methyl (2-(1H-indol-3-yl)ethyl)carbamate (57a) 
 
 
 
Data are consistent with literature.[111] 
Methyl (2-(5-methoxy-1H-indol-3-yl)ethyl)carbamate 
 
 
Data are consistent with literature.[112] 
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Synthesis of tetrahydropyrrolindoles (58a-b) 
 
To a solution of Pd(PPh3)4 (0.5 mol %) in THF (5 ml/mmol), cooled at 0 °C, was added the appropriate 
methyl (2-(indolin-3-yl)ethyl) carbamate 2 (1 equiv.), allyl alcohol (1.2 equiv), and Et3B (1 M in THF, 1.2 
equiv). The reaction mixturewas stirred at rt for 24 h. Then the reaction mixture was poured into sat. 
NaHCO3, concentrated under vacuum and extracted with AcOEt (3 x). The organic layer was dried over 
Na2SO4 and concentrated under vacuum. The product was purified trough silica gel chromatography. 
 
Methyl 3a-allyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole- 1(2H)-carboxylate (58a) 
 
Yield: 77%. 
White solid; m.p.: 94 - 96 °C. 
1H NMR (300 MHz; C6D6): δ =  6.99 (m, 1 H), 6.83 (m, 1 H), 6.73 (m, 1 H), 6.33 (m, 1 H), 5.59 (m, 1 H), 
5.22 (s, 0.6 H, exchange with D2O), 5.14 (s, 1 H), 4.89 (m, 2 H), 4.41 (s, 0.4 
H, exchange with D2O), 3.70 (t, J = 9.2 Hz, 0.3 H), 3.49 (s, 1 H), 3.45 (s, 2 
H), 3.32 (t, J = 9.2 Hz, 0.7 H), 2.92 (m, 1 H), 2.16 (d, J = 6.9 Hz, 2 H), 1.68 
(m, 1 H), 1.55 (m, 1 H) ppm. 
13C NMR (75 MHz; C6D6): δ = 154.3 (s), 154.2 (s), 149.8 (s), 149.5 (s), 134.1 (s), 131.6 (s), 128.6 (d), 132.3 
(d), 118.9 (d), 118.6 (d), 117.9 (t), 117.8 (t), 109.5 (d), 109.2 (d), 80.6 (d), 
79.7 (d), 57.5 (s), 56.2 (t), 51.9 (q), 51.8 (q), 45.9 (t), 45.5 (t), 42.6 (t), 42.2 
(t), 34.9 (t) ppm. 
IR: ν˜ = 3352, 2949, 2890, 1686, 1608 cm-1. 
MS (ESI): m/z = 259.2 [M+H]+, 258.1 [M+Na]+. (C15H18N2O2). 
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Methyl 3a-allyl-5-methoxy-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate (58b) 
 
 
Yield: 91%.  
White solid; m.p.: 65 - 67 °C. 
1H NMR (200 MHz; CDCl3): δ = 6.58 (m, 3 H), 5.73 (m, 1 H), 5.09 (m, 3 H), 4.87 (br. s, 1 H, exchange with 
D2O), 3.74 (s, 3 H), 3.67 (s, 3 H), 3.58 (m, 1 H), 3.05 (m, 1 H), 2.43 (d, J = 
7.5 Hz, 2 H), 2.13 (m, 2 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 155.7 (s), 154.9 (s), 153.9 (s), 153.7 (s), 143.4 (s), 143.1 (s), 133.8 (d), 
133.5 (s), 133.4 (s), 118.7 (t), 113.3 (d), 113.2 (d), 110.6 (d), 110.5 (d), 
110.2 (d), 110.1 (d), 81.8 (d), 80.5 (d), 58.1 (s), 57.0 (s), 56.2 (q), 52.7 (q), 
52.4 (q), 46.0 (t), 45.7 (t), 42.5 (t), 42.2 (t), 35.1 (t) ppm. 
IR: ν˜ = 3350, 2949, 1693 cm-1. 
MS (ESI): m/z = 289.1 [M+H]+. (C16H20N2O3). 
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Synthesis of preparation of 2-chloroquinoline-3-dioxolanes (60a-b) 
 
The products were synthesized following the procedure reported in literature. [113] 
 
 
2-Chloro-3-(1,3-dioxolan-2-yl)quinolone (60a) 
 
Data are consistent with literature. [114] 
 
2-Chloro-3-(1,3-dioxolan-2-yl)-6-methoxyquinoline (60b) 
 
Data are consistent with literature. [113] 
 
 
General procedure for N-arylation of tetrahydropyrrolindoles (31a-d) 
 
To a solution of Pd2(dba)3 (2 mol %) and triisobutylphosphatrane (8 mol %) in toluene (25 ml/mmol) were 
added the compound 58 (1 equiv.), the appropriate 2-chloroquinoline 60 (1 equiv.) and tBuONa (1.4 equiv.). 
The reaction mixture was warmed at 110 °C for 5 h. After completion the reaction mixture was filtered 
through a Celite pad, washed with brine (3 x) and extracted with AcOEt. The organic layer was dried over 
Na2SO4 and concentrated under vacuum. The crude was purified trough silica gel chromatography. 
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Methyl 8-(3-(1,3-dioxolan-2-yl)quinolin-2-yl)-3a-allyl- 3,3a,8,8a-tetrahydropyrrolo 
[2,3-b]indole-1(2H)-carboxylate (61a) 
 
 
Yield: 87%.  
White solid. m.p.: 127 - 130 °C. 
1H NMR (200 MHz; CDCl3): δ = 8.52 (s, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 8.1 Hz, 1H), 7.68 (m, 1H), 
7.51 (m, 1H), 7.11 (m, 2H), 6.84 (m, 1H), 6.66 (m, 1H), 6.14 (s, 1H), 6.11 
(s, 1H), 5.94 (m, 1H), 5.15 (m, 2H), 4.22 (m, 2H), 3.97 (m, 2H), 3.33 (m, 
2H), 2.85 (s, 3H), 2.70 (m, 2H), 2.22 (m, 2H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 55.1 (s), 154.5 (s), 149.2 (s), 148.3 (s), 136.8 (d), 134.2 (d), 133.5 (s), 130.2 
(d), 129.7 (s), 128.9 (d), 128.6 (d), 128.0 (d), 127.2 (s), 126.5 (d), 123.4 (d), 
120.2 (d), 118.9 (t), 110.0 (d), 100.4 (d), 84.8 (d), 65.8 (t), 65.6 (t), 57.6 (s), 
51.9 (q), 45.8 (t), 43.4 (t), 36.1 (t) ppm. 
IR: ν˜ = 3423 (br.), 2950, 2855, 1706 cm-1. 
MS (ESI): m/z = 480.3 [M+Na]+. (C27H27N3O4). 
  
135 
 
 
Methyl 8-(3-(1,3-dioxolan-2-yl)-6-methoxyquinolin-2-yl)- 
3a-allyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate (61b) 
 
 
Yield: 92%.  
White solid: m.p.: 152-155 °C. 
1H NMR (200 MHz; CDCl3): δ = 8.41 (s, 1 H), 7.89 (d, J = 9.5 Hz, 1 H), 7.33 (m, 1 H), 7.14 (m, 1 H), 7.05 
(m, 2 H), 6.81 (m, 1 H), 6.55 (m, 1 H), 6.16 (s, 1 H), 6.07 (s, 1 H), 5.93 (m, 
1 H), 5.17 (m, 2 H), 4.17 (m, 2 H), 4.03 (m, 2 H), 3.92 (s, 3 H), 3.31 (m, 2 
H), 2.90 (s, 3 H), 2.69 (m, 2 H), 2.18 (m, 2 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 158.0 (s), 155.2 (s), 152.6 (s), 149.6 (s), 144.4 (s), 135.4 (d), 135.3 (d), 
133.4 (s), 130.4 (d), 130.0 (s), 128.6 (d), 128.2 (s), 123.3 (d), 122.9 (d), 
120.0 (d), 118.8 (t), 109.7 (d), 105.5 (d), 100.5 (d), 85.0 (d), 65.8 (t), 65.6 
(t), 57.6 (s), 55.8 (q), 51.9 (q), 45.8 (t), 43.5 (t), 36.3 (t) ppm.  
IR: ν˜ = 3402 (br.), 2951 (br.), 1705 cm-1. 
MS (ESI): m/z = 488.5 [M+H]+, 510.3 [M+Na]+. (C28H29N3O5). 
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Methyl 8-(3-(1,3-dioxolan-2-yl)quinolin-2-yl)-3a-allyl-5-methoxy-3,3a,8,8a-tetrahydropyrrolo 
[2,3-b]indole-1(2H)-carboxylate (61c) 
 
 
Yield: 92%.  
White solid; m.p.: 154 - 159 °C  
1H NMR (200 MHz; CDCl3): δ = 8.49 (s, 1 H), 7.97 (d, J = 8.0 Hz, 1 H), 7.84 (d, J = 8.0 Hz, 1H), 7.66 (m, 1 
H), 7.48 (m, 1 H), 6.69 (m, 3 H), 6.20 (s, 1 H), 6.13 (s, 1 H), 5.95 (m, 1 H), 
5.16 (m, 2 H), 4.24 (m, 2 H), 4.07 (m, 2 H), 3.75 (s, 3 H), 3.31 (m, 2 H), 
2.93 (s, 3 H), 2.70 (m, 2 H), 2.18 (m, 2 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 155.2 (s), 154.5 (s), 148.2 (s), 143.3 (s), 136.8 (d), 135.2 (s), 134.9 (s), 
134.2 (d), 130.2 (d), 129.5 (s), 128.8 (t), 128.0 (d), 127.0 (s), 126.3 (d), 
118.9 (s), 113.2 (d), 110.9 (d), 110.4 (d), 100.5 (d), 85.3 (d), 65.8 (t), 65.6 
(t), 57.8 (s), 56.2 (q), 51.9 (q), 45.9 (t), 43.1 (t), 35.8 (t) ppm. 
IR: ν˜ = 3416 (br.), 2950 (br.), 1705 cm-1. 
MS (ESI): m/z = 488.4 [M+H]+, 510.3 [M+Na]+. (C28H29N3O5). 
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Methyl 8-(3-(1,3-dioxolan-2-yl)-6-methoxyquinolin-2-yl)-3a-allyl-5-methoxy-3,3a,8,8a-
tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate (61d) 
 
 
Yield: 88%. 
White solid; m.p.: 142 - 145 °C. 
1H NMR (300 MHz; CDCl3): δ = 8.36 (s, 1 H), 7.87 (d, J = 9.3 Hz, 1 H), 7.32 (d, J = 9.3 Hz, 1 H), 7.12 (d, J 
= 2.6 Hz, 1 H), 6.74 (d, J = 1.8 Hz, 1 H), 6.60 (m, 2 H), 6.10 (s, 1 H), 6.01 
(s, 1 H), 5.95 (m, 1 H), 5.18 (m, 2 H), 4.20 (m, 2 H), 4.04 (m, 2 H), 3.91 (s, 
3 H), 3.74 (s, 3 H), 3.30 (m, 2 H), 2.95 (s, 3 H), 2.70 (m, 2 H), 2.12 (m, 2 H) 
ppm.  
13C NMR (75 MHz; CDCl3): δ = 158.0 (s), 155.4 (s), 154.6 (s), 144.5 (s), 144.0 (s), 135.6 (d), 135.3 (s), 
134.4 (d), 130.5 (d), 130.0 (s), 128.2 (s), 123.0 (d), 119.0 (t), 118.8 (s), 
113.4 (d), 110.8 (d), 110.5 (d), 105.7 (d), 100.7 (d), 85.6 (d), 66.0 (t), 65.8 
(t), 57.9 (s), 56.4 (q), 56.0 (q), 52.1 (q), 46.0 (t), 43.4 (t), 36.1 (t) ppm. 
IR: ν˜ = 3393 (br.), 2951 (br.), 1705 cm-1. 
MS (ESI): m/z = 518.2 [M+H]+, 540.2 [M+Na]+. (C29H31N3O6). 
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General procedure for the intramolecular Friedel-Crafts and oxidation reactions  
 
 
a) To a solution of compound 61 (1 equiv.) in CH2Cl2 (10 ml/mmol), cooled at 0 °C, was added BF3-Et2O (3 
- 5 equiv.). The reaction mixture was stirred at rt for 48 h. After completion the mixture was poured into a 
NaHCO3 sat. at 0 °C, and stirred for 30 min. Then was extracted with CH2Cl2 (3 x) and the organic layer 
was dried under vacuum. 
b) The crude was dissolved in THF (20 ml/mmol) and water (5 ml/mmol), and MnO2 (3 equiv.) and m-CPBA 
(5 mmol %) were added. The reaction mixture was warmed at 60 °C for 12 h. After the complete oxidation 
of the intermediate, the reaction mixture was filtered through a Celite pad and concentrated under vacuum. 
Then was extracted with AcOEt  and washed with water (3 x). The organic layer was dried over Na2SO4 
and concentrated under vacuum. The crude was purified trough silica gel chromatography. 
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Methyl 3a-allyl-7-oxo-3,3a,7,14a-tetrahydrobenzo[g]pyrrolo 
[20,3':2,3]indolo[1,7-ab][1,8]naphthyridine-1(2H)-carboxylate (63a) 
 
 
Yield: 50%.  
Yellow solid; m.p.: 133 - 135 °C. 
1H NMR (200 MHz; CDCl3): δ = 9.28 (d, 1 H), 8.12 (d, J = 8.1 Hz, 1 H), 7.96 (m, 2 H), 7.72 (td, J = 6.8, 1.4 
Hz, 1 H), 7.55 (dd, J = 7.1, 0.9 Hz, 1 H), 7.44 (td, J = 7.1, 0.9 Hz, 1 H), 7.25 
(m, 1 H), 7.02 (s, 1 H), 5.68 (m, 1 H), 5.27 (m, 2 H), 4.12 (m, 1 H), 3.97 (s, 
3 H), 2.84 (m, 3 H), 2.12 (m, 2 H) ppm. 
13C NMR (50 MHz; CDCl3): δ =179.7 (s), 155.4 (s), 150.0 (s), 147.9 (s), 145.8 (s), 139.5 (d), 135.5 (s), 
132.8 (d), 132.7 (d), 129.9 (d), 128.6 (d), 128.0 (d), 125.0 (d), 124.9 (d), 
124.7 (s), 122.7 (d), 120.2 (t), 119.2 (s), 117.7 (s), 81.9 (d), 58.2 (s), 53.2 
(q), 46.1 (t), 43.1 (t), 39.7 (t) ppm. 
IR: ν˜ = 3436 (br.), 1698, 1655 cm-1. 
MS (ESI): m/z = 434.2 [M+Na]+. (C25H21N3O3) 
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Methyl 3a-allyl-10-methoxy-7-oxo-3,3a,7,14a-tetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo 
[1,7-ab][1,8]naphthyridine-1(2H)-carboxylate (63b) 
 
 
Yield: 62%.  
Yellow solid; m.p.: 157 - 160 °C. 
1H NMR (200 MHz; CDCl3): δ = 9.22 (s, 1 H), 8.15 (dd, J = 8.1; 1.1 Hz, 1 H), 7.90 (d, J = 9.5 Hz, 1H), 7.54 
(m, 2 H), 7.24 (m, 2 H), 7.01 (s, 1 H), 5.70 (m, 1 H), 5.09 (m, 2 H), 4.14 (m, 
1 H), 3.97 (s, 3 H), 3.96 (s, 3 H), 2.94 (m, 3 H), 2.18 (m, 2 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 179.7 (s), 156.7 (s), 155.4 (s), 146.5 (s), 146.4 (s), 145.8 (s), 137.6 (d), 
135.2 (s), 132.8 (d), 129.5 (d), 128.3 (d), 126.4 (d), 125.4 (s), 125.0 (d), 
122.4 (d), 120.1 (t), 119.2 (s), 117.6 (s), 106.1 (d), 81.9 (d), 58.2 (s), 55.8 
(q), 53.1 (q), 46.1 (t), 43.1 (t), 39.7 (t) ppm. 
IR: ν˜ = 3467 (br.), 1702, 1647 cm-1. 
MS (ESI): m/z = 440.3 [M]-. (C26H23N3O4). 
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Methyl 3a-allyl-5-methoxy-7-oxo-3,3a,7,14a-tetrahydrobenzo[g]pyrrolo 
[20,3':2,3]indolo[1,7-ab][1,8]naphthyridine-1(2H)-carboxylate (63c) 
 
Yield: 70%.  
Orange solid; m.p.: 165 - 167 °C. 
1H NMR (200 MHz; CDCl3): δ = 9.31 (s, 1 H), 7.97 (m, 2 H), 7.77 (m, 1 H), 7.50 (d, J = 2.5 Hz, 1 H), 7.44 
(m, 1 H), 7.23 (d, J = 2.5 Hz, 1 H), 7.02 (s, 1 H), 5.71 (m, 1 H), 5.18 (m, 2 
H), 4.12 (m, 1 H), 3.97 (s, 3 H), 3.91 (s, 3 H), 2.84 (m, 3 H), 2.16 (m, 2 H) 
ppm. 
13C NMR (50 MHz; CDCl3): δ = 179.3 (s), 156.5 (s), 155.3 (s), 150.0 (s), 147.4 (s), 140.9 (s), 139.5 (d), 
137.1 (s), 132.6 (d), 132.6 (d), 129.9 (d), 128.0 (d), 124.7 (d), 124.6 (s), 
120.3 (t), 120.2 (d), 118.7 (s), 117.5 (s), 103.8 (d), 82.1 (d), 58.1 (s), 56.3 
(q), 53.2 (q), 46.0 (t), 43.0 (t), 39.6 (t) ppm. 
IR: ν˜ = 3467 (br.), 1701, 1647 cm-1. 
MS (ESI): m/z = 464.3 [M+Na]+. (C26H23N3O4). 
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Methyl 3a-allyl-5,10-dimethoxy-7-oxo-3,3a,7,14a-tetrahydrobenzo[g]pyrrolo 
[20,3':2,3]indolo[1,7-ab][1,8]naphthyridine-1(2H)-carboxylate (63d) 
 
Yield: 80%. 
Orange solid; m.p.: 157 - 160 °C. 
1H NMR (200 MHz; CDCl3): δ = 9.22 (s, 1 H), 7.87 (d, J = 9.2 Hz, 1 H), 7.48 (m, 2 H), 7.24 (m, 2 H), 7.00 
(m, 1 H), 5.71 (m, 1 H), 5.16 (m, 2 H), 4.14 (m, 1 H), 3.97 (s, 3 H), 3.95 (s, 
3 H), 3.92 (s, 3 H), 2.83 (m, 3 H), 2.36 (m, 2 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 179.3 (s), 156.6 (s), 156.3 (s), 155.4 (s), 146.5 (s), 146.1 (s), 140.9 (s), 
137.5 (d), 137.2 (s), 132.7 (d), 129.5 (d), 126.5 (d), 125.3 (s), 120.3 (t), 
120.1 (d), 118.7 (s), 117.3 (s), 106.0 (d), 103.6 (d), 82.1 (d), 58.1 (s), 56.3 
(q), 56.8 (q), 53.2 (q), 46.0 (t), 43.0 (t), 39.6 (t) ppm. 
IR: ν˜ = 3437 (br.), 2959 (br.), 1713, 1645 cm-1. 
MS (ESI): m/z = 472.3 [M+H]+, 494.3 [M+Na]+. (C27H25N3O5). 
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Synthesis of 3a-allyl-5,10-dimethoxy-1-methyl-
1,3,3a,14atetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo[1,7-ab][1,8]naphthyridin-7(2H)-one (64) 
 
 
To a solution of compound 63d (1 equiv.) in toluene (10 ml/mmol), cooled at 0 °C, Red-Al® (65% in 
toluene, 10 mmol) was added dropwise. After 10 min at rt, the reaction mixture was warmed at 110 °C for 5 
h. After completion the reaction mixture was poured into water at 0 °C, stirred at rt for 30 min. Then the 
mixture was filtered through a Celite pad with AcOEt and washed with water (3 x). The organic layer was 
dried over Na2SO4 and concentrated under vacuum. The product was purified trough silica gel 
chromatography. 
 
Yield: 50%. 
Orange solid; m.p.: 173 - 175 °C.  
1H NMR (200 MHz; CDCl3): δ = 9.23 (s, 1 H), 7.91 (d, J = 9.1 Hz, 1 H), 7.50 (m, 2 H), 7.24 (m, 1 H), 7.18 (d, 
J = 2.4 Hz, 1 H), 5.99 (s, 1 H), 5.68 (m, 1 H), 5.11 (m, 2 H), 3.95 (s, 3 H), 
3.91 (s, 3 H), 2.91 (s, 3 H), 2.82 (m, 2 H), 2.66 (m, 2 H), 2.34 (m, 1 H), 2.18 
(m, 1H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 179.4 (s), 156.4 (s), 156.2 (s), 147.2 (s), 146.3 (s), 141.2 (s), 139.1 (s), 
137.5 (d), 133.3 (d), 129.1 (d), 126.4 (d), 125.2 (s), 119.9 (d), 119.6 (t), 
118.7 (s), 117.5 (s), 106.0 (d), 103.1 (d), 89.5 (d), 58.6 (s), 56.3 (q), 55.8 
(q), 54.7 (t), 43.5 (t), 40.9 (q), 37.7 (t) ppm. 
IR: ν˜ = 3401 (br.), 2785 (br.), 1640 cm-1. 
MS (ESI): m/z = 429.3 [M+Na]+. (C26H25N3O3). 
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General procedure for hydrolysis of methylcarbamate derivatives 
 
To a solution of compound 63a-d (1 equiv.) in EtOH (30 ml/mmol) was added NaOH (15 equiv.) in H2O (5 
ml/mmol). The reaction mixture was warmed at 80 °C until the consumption of the starting material 
(monitored by TLC). After completion the reaction mixture was concentrated under vacuum, extracted with 
AcOEt and washed with water (3 x). The organic layer was dried over Na2SO4 and concentrated under 
vacuum. The product was purified trough silica gel chromatography. 
 
 
3a-Allyl-1,3,3a,14a-tetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo[1,7-ab][1,8]naphthyridin-7(2H)-one 
(65a) 
 
Yield: 66%. 
Yellow solid; m.p.: 125 - 128 °C. 
1H NMR (200 MHz; CDCl3): δ = 9.36 (s, 1 H), 8.08 (dd, J = 8.1; 0.8 Hz, 1 H), 7.98 (d, J = 9.1 Hz, 2 H), 7.77 
(td, J = 7.0; 1.4 Hz, 1 H), 7.57 (dd, J = 7.0; 0.8 Hz, 1 H), 7.44 (td, J = 8.1; 
0.8 Hz, 1 H), 7.21 (m, 1 H), 6.20 (s, 1 H), 5.80 (m, 1 H), 5.17 (m, 2 H), 3.42 
(br. s, 1H, exchange with D2O), 3.16 (m, 1 H), 2.80 (m, 3 H), 2.20 (m, 2 H) 
ppm. 
13C NMR (50 MHz; CDCl3): δ = 179.7 (s), 150.0 (s), 148.1 (s), 146.1 (s), 139.9 (d), 137.0 (s), 133.8 (d), 
138.8 (d), 130.8 (d), 128.6 (d), 127.6 (d), 124.6 (d), 124.5 (s), 124.4 (d), 
122.6 (d), 119.4 (t), 119.3 (s), 117.2 (s), 84.7 (d), 56.9 (s), 44.9 (t), 43.5 (t), 
40.6 (t) ppm. 
IR: ν˜ = 3351 (br.), 2930 (br.), 1651 cm-1. 
MS (ESI): m/z = 354.2 [M+H]+, 376.1 [M+Na]+. (C23H19N3O). 
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3a-Allyl-10-methoxy-1,3,3a,14a-tetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo[1,7-ab][1,8]naphthyridin-
7(2H)-one (65b) 
 
Yield: 85%. 
Yellow solid; m.p.: 94 - 96 °C. 
1H NMR (200 MHz; CDCl3): δ = 9.16 (s, 1 H), 8.07 (dd, J = 8.1; 1.1 Hz, 1 H), 7.88 (d, J = 9.2 Hz, 1 H), 7.53 
(dd, J = 7.0; 1.1 Hz, 1 H), 7.43 (dd, J = 9.2; 2.6 Hz, 1 H), 7.20 (m, 2 H), 
6.18 (s, 1 H), 5.76 (m, 1 H), 5.13 (m, 2 H), 3.92 (s, 3 H), 3.27 (br. s, 1H, 
exchange with D2O), 3.14 (m, 1 H), 2.75 (m, 3 H), 2.17 (m, 2 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 179.6 (s), 156.4 (s), 146.8 (s), 146.4 (s), 146.1 (s), 137.9 (d), 137.0 (s), 
133.9 (d), 129.0 (d), 128.4 (d), 126.4 (d), 125.2 (s), 124.3 (d), 122.3 (d), 
119.3 (t), 119.0 (s), 117.0 (s), 106.2 (d), 84.7 (d), 56.9 (s), 55.8 (q), 44.9 (t), 
43.5 (t), 40.6 (t) ppm. 
IR: ν˜ = 3435 (br.), 2932 (br.), 1647 cm-1. 
MS (ESI): m/z = 384.3 [M+H]+. (C24H21N3O2). 
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3a-Allyl-5-methoxy-1,3,3a,14a-tetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo[1,7-ab][1,8]naphthyridin-
7(2H)-one (63c) 
 
Yield: 68%. 
Orange solid; m.p.: 165 - 168 °C. 
1H NMR (200 MHz; CDCl3): δ = 9.30 (s, 1 H), 7.97 (d, J = 8.8 Hz, 2 H), 7.76 (td, J = 7.7; 0.7 Hz, 1 H), 7.42 
(m, 2 H), 7.23 (d, J = 2.3 Hz, 1 H), 6.21 (s, 1 H), 5.77 (m, 1 H), 5.15 (m, 2 
H), 3.90 (s, 3 H), 3.43 (br. s, 1 H, exchange with D2O), 3.15 (m, 1 H), 2.78 
(m, 3 H), 2.25 (m, 1 H), 2.10 (m, 1 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 179.2 (s), 156.5 (s), 150.0 (s), 147.6 (s), 141.3 (s), 139.8 (d), 139.0 (s), 
133.7 (d), 132.7 (d), 130.1 (d), 127.6 (d), 124.4 (d), 124.3 (s), 120.4 (d), 
119.5 (t), 118.7 (s), 116.8 (s), 103.1 (d), 84.9 (d), 56.9 (s), 56.3 (q), 44.9 (t), 
43.3 (t), 40.5 (t) ppm. 
IR: ν˜ = 3435 (br.), 1932 (br.), 1645 cm-1. 
MS (ESI): m/z = 384.3 [M+H]+. (C24H21N3O2). 
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3a-Allyl-5,10-dimethoxy-1,3,3a,14a-tetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo 
[1,7-ab][1,8]naphthyridin-7(2H)-one (63d) 
 
 
Yield: 65%. 
Orange solid; m.p.: 165 - 168 °C. 
1H NMR (200 MHz; CDCl3): δ = 9.24 (s, 1 H), 7.92 (d, J = 9.1 Hz, 1 H), 7.43 (m, 2 H), 7.22 (m, 2 H), 6.21 (s, 
1 H), 5.75 (m, 1 H), 5.16 (m, 2 H), 3.96 (s, 3 H), 3.92 (s, 3 H), 3.43 (br. s, 1 
H, exchange with D2O), 3.16 (m, 1H), 2.78 (m, 3 H), 2.24 (m, 1 H), 2.10 (m, 
1 H) ppm. 
13C NMR (50 MHz; CDCl3): δ = 179.0 (s), 156.3 (s), 146.5 (s), 146.3 (s), 141.3 (s), 139.0 (s), 137.8 (d), 
133.7 (d), 129.0 (d), 126.4 (d), 125.1 (s), 120.2 (d), 119.4 (t), 118.7 (s), 
116.6 (s), 106.1 (d), 102.9 (d), 84.9 (d), 56.9 (s), 56.2 (q), 55.8 (q), 44.9 (t), 
43.3 (t), 40.5 (t) ppm. 
IR: ν˜ = 3435 (br.), 2933 (br.), 1640 cm-1. 
MS (ESI): m/z = 414.3 [M+H]+. (C25H23N3O3). 
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General procedure for hydrolysis of methylether derivatives 
 
To a solution of compound 65b-d (1 equiv.) in CH2Cl2 (10 ml/mmol), cooled at -78 °C, was added dropwise 
BBr3 (1 M in Hexane, 2.5-5 wquiv.). After 1 h at rt the mixture was warmed at 40 °C until the consumption of 
the starting material (monitored by TLC). Then, the mixture, cooled at 0 °C, was poured into a NaHCO3 sat.  
and was extracted with CH2Cl2 (3 x). The organic layer was dried over Na2SO4 and concentrated under 
vacuum. The product was purified by crystallization (AcOEt/Hexane). 
 
 
3a-Allyl-10-hydroxy-1,3,3a,14a-tetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo 
[1,7-ab][1,8]naphthyridin-7(2H)-one (66a) 
 
 
Yield: 70%. 
Red solid; m.p.: 296 - 299 °C. 
1H NMR (200 MHz; DMSO): δ = 10.04 (s, 1 H, exchange with D2O), 9.12 (s, 1 H), 7.88 (m, 2 H), 7.70 (d, J = 
6.2 Hz, 1 H), 7.45 (m, 2 H), 7.22 (m, 1 H), 6.08 (s, 1 H), 5.70 (m, 1 H), 5.12 
(d, J = 17.1 Hz, 1 H), 5.00 (dd, J = 10.1; 2.2 Hz, 1 H), 4.20 (br. s, 1 H, 
exchange with D2O), 2.95 (m, 1 H), 2.65 (m, 3 H), 2.10 (m, 2 H) ppm. 
13C NMR (50 MHz; DMSO): δ = 179.0 (s), 154.6 (s), 146.4 (s), 146.1 (s), 145.3 (s), 137.7 (s), 137.4 (d), 
135.0 (d), 129.4 (d), 129.0 (d), 126.9 (d), 125.8 (s), 123.8 (d), 122.7 (d), 
119.4 (s), 119.2 (t), 116.5 (s), 110.2 (d), 84.5 (d), 57.4 (s), 57.4 (t), 45.3 (t), 
43.1 (t) ppm. 
IR: ν˜ = 3419 (br.), 2961 (br.), 1643 cm-1. 
MS (ESI): m/z = 370.3 [M+H]+. (C23H19N3O2). 
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3a-Allyl-5,10-dihydroxy-1,3,3a,14a-tetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo 
[1,7-ab][1,8]naphthyridin-7(2H)-one (66b) 
 
 
Yield: 80%. 
Red solid; m.p.: 342 - 345 °C. 
1H NMR (200 MHz; DMSO): δ = 10.02 (br. s, 1 H, exchange with D2O), 9.70 (br. s, 1 H, exchange with 
D2O), 9.10 (s, 1 H), 7.85 (d, J = 9.2 Hz, 1 H), 7,51-7.23 (m, 4 H), 6.16 (s, 1 
H), 6.57 (br. s, 1 H, exchange with D2O), 5.66 (m, 1 H), 5.08 (m, 2 H), 3.14 
(m, 1 H), 2.73 (m, 3 H), 2.17 (m, 2 H) ppm. 
13C NMR (50 MHz; DMSO): δ = 178.4 (s), 154.4 (s), 154.3 (s), 145.7 (s), 145.2 (s), 139.7 (s), 138.4 (s), 
137.3 (d), 134.6 (d), 128.9 (d), 127.0 (d), 125.7 (s), 120.4 (d), 119.7 (s), 
118.5 (t), 117.0 (s), 110.2 (d), 106.4 (d), 83.3 (d), 57.7 (s), 57.7 (t), 45.5 (t), 
42.7 (t) ppm. 
IR: ν˜ = 3323 (br.), 1623 cm-1. 
MS (ESI): m/z = 386.3 [M+H]+. (C23H19N3O3). 
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Synthesis of 
10-methoxy-7-oxo-3a-(2-oxoethyl)-3,3a,7,14a-tetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo 
[1,7-ab][1,8] naphthyridine-1(2H)-carboxylate (67) 
 
 
To a solution of compound 65b (1 equiv.) in THF (15 ml/mmol) and H2O (3 ml/mmol) was added NaIO4 (3 
equiv.), lutidine (2 equiv.) and OsO4 (4% in H2O, 5 mol %). The reaction mixture was stirred at rt. After 24 h 
the reaction mixture was concentrated under vacuum and was extracted with AcOEt. The organic layer was 
washed with water (3 x), dried Na2SO4 and concentrated under vacuum. The product was purified trough 
silica gel chromatography. 
 
 
Yield: 75%.  
Orange solid; m.p.: 241 - 243 °C. 
1H NMR (300 MHz; CDCl3): δ = 9.77 (s, 1 H), 9.16 (s, 1 H), 8.12 (dd, J = 8.0, 1.1 Hz, 1 H), 7.86 (d, J = 9.3 
Hz, 1 H), 7.60 (dd, J = 7.1, 1.1 Hz, 1 H), 7.46 (dd, J = 9.3, 2.8 Hz, 1 H), 
7.22 (m, 2 H), 7.12 (s, 1 H), 4.16 (m, 1 H), 3.96 (s, 3 H), 3.94 (s, 3 H), 3.27 
(ddd, J = 22.5,18.1, 0.8 Hz, 2 H), 2.95 (dt, J = 12.1, 5.5 Hz, 1 H), 2.38 (m, 1 
H), 2.22 (m, 1 H) ppm. 
13C NMR (75 MHz; CDCl3): δ = 198.8 (d), 179.5 (s), 156.7 (s), 155.4 (s), 146.3 (s), 145.6 (s), 137.7 (d), 
134.2 (s), 129.4 (d), 128.7 (d), 126.5 (d), 125.5 (s), 125.4 (d), 122.6 (d), 119.1 (s), 117.6 (s), 106.1 (d), 82.5 
(d), 55.9 (q), 54.9 (s), 53.3 (q), 52.2 (t), 45.7 (t), 40.2 (t) ppm. 
IR: ν˜ = 3437 (br.), 2945, 1718, 1701 cm-1. 
MS (ESI): m/z = 444.1 [M+H]+. (C25H21N3O5). 
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Synthesis of  
methyl 3a-(2-hydroxyethyl)-10-methoxy-7-oxo-3,3a,7,14atetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo 
[1,7-ab][1,8]naphthyridine-1(2H)-carboxylate (68) 
 
 
 
To a solution of compound 67 (1 equiv.) in MeOH (10 ml/mmol), cooled at 0 °C, was added NaBH4 (1.2 
equiv.) and the reaction mixture was stirred at rt. After 3 h the reaction mixture was poured into water and 
concentrated under vacuum. Then the mixture was extracted with AcOEt and washed with brine (3 x). The 
organic layer was dried Na2SO4 and concentrated under vacuum. The product was purified trough silica gel 
chromatography. 
 
 
Yield: 65%. 
Yellow solid; M.p.: 121 - 123 °C.  
1H NMR (300 MHz; CDCl3): δ = 8.95 (s, 1 H), 7.91 (d, J = 8.1 Hz, 1 H), 7.73 (d, J = 9.3 Hz, 1 H), 7.48 (d, J 
= 7.1 Hz, 1 H), 7.35 (dd, J = 9.3; 2.6 Hz, 1 H), 7.21 (s, 1 H), 7.17 (m, 1 H), 
7.10 (d, J = 2.6 Hz, 1 H), 4.05 (m, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.72 (m, 
2 H), 2.83 (m, 1 H), 2.58 (br. s, 1 H, exchange with D2O), 2.34 (m, 2 H). 
2.17 (m, 2 H) ppm. 
13C NMR (75 MHz; CDCl3): δ = 179.4 (s), 156.5 (s), 155.5 (s), 146.2 (s), 145.8 (s), 137.4 (d), 134.6 (s), 
129.1 (d), 128.3 (d), 126.4 (d), 125.2 (s), 124.9 (d), 122.2 (d), 118.8 (s), 
117.3 (s), 106.1 (d), 82.2 (d), 59.7 (t), 57.0 (s), 55.8 (q), 53.1 (q), 45.5 (t), 
41.0 (t), 40.7 (t) ppm. 
IR: ν˜ = 3451, 2956, 1673, 1650, 1626, 1606, 1598 cm-1. 
MS (ESI): m/z = 446.1 [M+H]+. (C25H23N3O5). 
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Synthesis of 
3a-(2-hydroxyethyl)-10-methoxy-1,3,3a,14atetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo[1,7-ab][1,8] 
naphthyridin-7(2H)-one (69) 
 
 
 
To a solution of compound 68 (1 equiv.) in EtOH (30 ml/ mmol) was added NaOH (15 equiv.) in H2O (5 
ml/mmol). The reaction mixture was warmed at 80 °C. After 6 h the reaction mixture was concentrated 
under vacuum, extracted with AcOEt and washed with water (3 x). The organic layer was dried over 
Na2SO4 and concentrated under vacuum. The product was purified trough silica gel chromatography. 
 
Yield: 61%. 
Yellow solid; m.p.: 211 – 213 °C 
1H NMR (300 MHz; DMSO): δ = 9.21 (s, 1 H), 7.90 (m, 2 H), 7.69 (d, J = 7.1 Hz, 1 H), 7.64 (d, J = 2.8 Hz, 1 
H), 7.54 (dd, J = 9.2; 2.8 Hz, 1 H), 7.23 (m, 1 H), 6.30 (s, 1 H), 4.15 (t, J = 
4.8 Hz, 1 H, exchange with D2O), 3.90 (s, 3 H), 3.69 8 (br. s, 1 H, exchange 
with D2O), 3.38 (m, 2 H), 2.95 (m, 1 H), 2.44 (m, 1 H), 2.27-1.97 (m, 4 H) 
ppm. 
13C NMR (75 MHz; DMSO): δ = 178.9 (s), 156.3 (s), 146.9 (s), 146.3 (s), 146.2 (s), 137.9 (d), 137.8 (s), 
129.4 (d), 129.1 (d), 126.8 (d), 125.4 (s), 123.5 (d), 122.8 (d), 119.3 (s), 
116.6 (s), 107.6 (d), 85.3 (d), 58.6 (s), 56.4 (t), 56.3 (q), 44.8 (t), 41.7 (t), 
41.4 (t) ppm. 
IR: ν˜ = 3434 (br.), 2915, 2876, 1651 cm-1. 
MS (ESI): m/z = 388.1 [M+H]+, 410.0 [M+Na]+. (C23H21N3O3). 
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Synthesis of 
tert-butyl 3a-allyl-10-hydroxy-7-oxo-3,3a,7,14a-tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo 
[1,7-ab][1,8]naphthyridine-1(2H)-carboxylate (70) 
 
 
 
To a solution of compound 66a (1 equiv.) in EtOH (10 ml/mmol) was added TEA (3 equiv.) and (Boc)2O (3 
equiv.). The reaction mixture was stirred at rt for 48 h. After consumption of starting material (monitored by 
TLC) the mixture was concentrated under vacuum and extracted with AcOEt. The organic layer was 
washed with water (3 x), dried over Na2SO4 and concentrated under vacuum. The crude, consisting of a 
mixture of mono- and di-protected product, was diluted in EtOH (10 ml) and piperidine (3 mmol) was added, 
in order to remove the Boc on the OH in position 10. The reaction mixture was stirred at 80 °C until the 
consumption of the di-protected intermediate (monitored by TLC). Then the mixture was poured in water 
and was extracted with CH2Cl2 (3 x). The organic layer was dried over Na2SO4 and concentrated under 
vacuum. The product was purified trough silica gel chromatography. 
 
 
Yield: 60%. 
Orange solid; m.p.: 147 - 149 °C. 
1H NMR (300 MHz; DMSO): δ =10.15 (s, 1 H, exchange with D2O), 9.06 (s, 1 H), 7.91 (d. J = 8.1 Hz, 1 H), 
7.76 (m, 2 H), 7.50 (dd, J = 9.1; 2.6 Hz, 1 H), 7.39 (d, J = 2.6 Hz, 1 H), 7.25 
(m, 1 H), 6.88 (s, 1 H), 5.67 (m, 1 H), 5.18 (d, J = 17.1 Hz, 1 H), 5.07 (d, J = 
9.9 Hz, 1 H), 3.89 (m, 1 H), 2.72 (m, 3 H), 2.09 (m, 2 H), 1.53 (s, 9 H) ppm. 
13C NMR (75 MHz; DMSO): δ = 179.1 (s), 157.7 (s), 153.7 (s), 146.1 (s), 145.9 (s), 145.2 (s), 137.1 (d), 
135.5 (s), 134.3 (d), 129.3 (d), 128.9 (d), 126.9 (d), 125.9 (t), 124.2 (d), 
122.9 (d), 120.1 (s), 119.2 (s), 117.0 (s), 110.2 (d), 82.0 (d), 80.2 (s), 57.8 
(s), 46.1 (t), 42.4 (t), 40.0 (t), 28.9 (q) ppm.  
IR: ν˜ = 3403, 2976, 2930, 1700, 1623, 1606, 1587 cm-1. 
MS (ESI): m/z = 470.0 [M+H]+, 492.0 [M+Na]+. (C28H27N3O4). 
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Synthesis of  
tert-Butyl 3a-allyl-9-((dimethylamino)methyl)-10-hydroxy- 7-oxo-
3,3a,7,14atetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo[1,7-ab][1,8]naphthyridine-1(2H)-carboxylate 
(71) 
 
To a solution of compound 70 (1 equiv.) in EtOH (25 ml/mmol) was added CH2O (37% in H2O, 4 equiv.) 
and Me2NH (40% in H2O, 3 equiv.). The reaction mixture was stirred at rt for 24-48 h. After consumption of 
starting material (monitored by TLC) the mixture was concentrated under vacuum and water was added. 
The mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over Na2SO4 and concentrated 
under vacuum. The product was purified trough silica gel chromatography. 
 
 
Yield: 56%. 
Orange solid; m.p.: 125 - 127 °C dec. 
1H NMR (300 MHz; CDCl3): δ = 9.34 (s, 1 H), 8.16 (dd, J = 8.1; 1.0 Hz, 1 H), 7.97 (d, J = 9.1 Hz, 1 H), 7.57 
(dd, J = 7.1; 1.0 Hz, 1 H), 7.47 (d, J = 9.1 Hz, 1 H), 7.26 (dd, J = 8.1; 7.1 
Hz, 1 H), 7.08 (s, 1 H), 5.78 (m, 1H), 5.23 (dd, J = 8.5; 1.4 Hz, 1 H), 5.15 
(d, J = 10.5 Hz, 1 H), 4.28 (s, 2 H), 4.10 (m, 1 H), 2.88 (m, 2 H), 2.73 (m, 2 
H), 2.50 (s, 6 H), 2.18 (m, 2 H), 1.64 (s, 9 H) ppm. 
13C NMR (75 MHz; CDCl3): δ = 179.8 (s), 155.5 (s), 153.6 (s), 146.0 (s), 145.7 (s), 145.4 (s), 135.4 (s), 
132.8 (d), 131.7 (d), 129.1 (d), 128.1 (d), 126.7 (d), 124.6 (d), 123.8 (s), 
122.0 (d), 119.9 (t), 118.3 (s), 117.1 (s), 111.9 (s), 81.9 (d), 80.5 (s), 57.5 
(t), 57.5 (s), 45.8 (t), 45.6 (q), 42.9 (t), 39.9 (t), 28.5 (q) ppm. 
IR: ν˜ = 3436, 3061, 2976, 2784, 1704, 1644, 1618, 1606, 1586 cm-1. 
MS (ESI): m/z = 527.0 [M+H]+, 550.0 [M+Na]þ. (C31H34N4O4). 
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Synthesis of 
3a-allyl-9-((dimethylamino)methyl)-10- hydroxy-1,3,3a,14a 
tetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo[1,7-ab][1,8]naphthyridin-7(2H)-one (72) 
 
 
To a solution of compund 71 (1 equiv.) in MeOH (20 ml/mmol) was added TMSCl (5 equiv.). The reaction 
mixture was stirred at rt for 6 h. After completion the mixture was poured into NaHCO3 sat. and was 
extracted with CH2Cl2 (3 x). The organic layer was dried over Na2SO4 and was concentrated under vacuum. 
The product was purified trough silica gel chromatography. 
 
Yield: 78%. 
Orange solid; m.p.: 285 - 287 °C dec. 
1H NMR (300 MHz; DMSO): δ = 9.30 (s, 1 H), 7.88 (d, J = 7.1 Hz, 1 H), 7.79 (d, J = 9.1 Hz, 1 H), 7.70 (d, J 
= 7.1 Hz, 1 H), 7.47 (d, J = 9.1 Hz, 1 H), 7.20 (m, 1 H), 6.07 (s, 1 H), 5.70 
(ddd, J = 17.0, 10.1, 2.0 Hz, 1 H), 5.12 (d, J = 17.0, 1 H), 5.00 (dd, J = 10.1, 
2.0 Hz. 1 H), 4.04 (s, 2 H), 2.97 (m, 1 H), 2.80 (m, 1 H), 2.65 (m, 1 H), 2.50 
(m, 1 H), 2.29 (s, 6 H), 2.05 (m, 2 H) ppm. 
13C NMR (75 MHz; DMSO): δ = 178.9 (s), 154.1 (s), 146.1 (s), 145.9 (s), 145.6 (s), 173.8 (s), 135.0 (d), 
134.0 (d), 129.3 (d), 128.4 (d), 126.6 (d), 124.6 (s), 123.8 (d), 122.7 (d), 
119.3 (t), 118.5 (s), 116.5 (s), 115.4 (s), 84.6 (d), 58.5 (s), 57.3 (t), 55.4 (t), 
45.3 (t), 45.1 (q), 43.1 (t) ppm. 
IR: ν˜ = 3435, 3067, 2919, 2850, 1648, 1618, 1605, 1586 cm-1. 
MS (ESI): m/z = 427.0 [M+H]+. (C26H26N4O2). 
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Synthesis of 10-hydroxy-3a-(2-hydroxyethyl)-7-oxo-1,2,3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo[1,7-ab][1,8]naphthyridin-1-ium bromide (73) 
 
 
To a solution of compound 69 (1 equiv.) in CH2Cl2 (10 ml/mmol), cooled at 78 °C, was added dropwise BBr3 
(1 M in Hexane, 2.5 equiv.). After 1 h at rt the mixture was warmed at 40 °C for 12 h. Then the reaction 
mixture was poured over ice and the organic layer was separated, dried over Na2SO4 and concentrated 
under vacuum. The crude product was used directly for the subsequent reaction without purification. 
 
Yield: 50%. 
Red solid; m.p.: 255 - 256 °C.  
1H NMR (300 MHz; DMSO): δ = 10.47 (br. s, 1 H, exchange with D2O), 9.57 (br. s, 1 H, exchange with 
D2O), 9.16 (s, 1 H), 8.00-7.83 (m, 3 H), 7.60 (m, 1 H), 7.48 (d, J = 2.7 Hz, 1 
H), 7.36 (m, 1 H), 6.68 (s, 1 H), 4.70 (br. s, 2 H, exchange with D2O), 3.46 
(m, 2 H), 3.11 (m, 1 H), 2.88 (m, 1 H), 2.47 (m, 2 H), 2.24 (m, 2H) ppm. 
13C NMR (75 MHz; DMSO): δ = 170.1 (s), 155.1 (s), 145.7 (s), 144.7 (s), 137.8 (d), 134.6 (s), 130.0 (d), 
129.0 (d), 127.3 (d), 126.5 (s), 126.2 (s), 124.8 (d), 123.8 (d), 119.2 (s), 
117.7 (s), 110.6 (d), 80.2 (d), 57.9 (t), 57.7 (s), 57.6 (t), 45.0 (t), 37.9 (t) 
ppm. 
IR: ν˜ = 3435, 2929, 2709, 1670, 1641, 1640 cm-1. 
MS (ESI): m/z = 374.3 [M]+, 372.3 [M]-. (C22H20N3O3). 
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Synthesis of 
tert-butyl 10-hydroxy-3a-(2-hydroxyethyl)-7-oxo-3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[20,3':2,3]indolo[1,7-ab][1,8]naphthyridine-1(2H)-carboxylate (74) 
 
To a solution of compound 73 (1 equiv.) in EtOH (10 ml/mmol) was added TEA (3 equiv.) and (Boc)2O (3 
equiv.). The reaction mixture was stirred at rt for 48 h. After consumption of starting material (monitored by 
TLC) the mixture was concentrated under vacuum and extracted with AcOEt. The organic layer was 
washed with water (3 x), dried over Na2SO4 and concentrated under vacuum. The crude, consisting of a 
mixture of mono- and di-protected product, was diluted in EtOH (10 ml) and piperidine (3 mmol) was added, 
in order to remove the Boc on the OH in position 10. The reaction mixture was stirred at 80 °C until the 
consumption of the di protected intermediate (monitored by TLC). Then the mixture was poured in water 
and was extracted with CH2Cl2 (3 x). The organic layer was dried over Na2SO4 and concentrated under 
vacuum. The product was purified trough silica gel chromatography. 
 
Yield: 80%. 
Orange solid; m.p.: 207 - 209 °C dec. 
1H NMR (300 MHz; C3D6O): δ = 9.06 (s, 1 H), 8.96 (s, 1 H, exchange with D2O), 8.00 (dd, J = 8.1, 1.1 Hz, 
1H), 7.98 (d, J = 9.2 Hz, 1 H), 7.72 (dd, J = 7.1, 1.1 Hz, 1 H), 7.56 (dd, J = 
9.2, 2.7 Hz, 1 H), 7.44 (d, J = 2.7 Hz, 1 H), 7.32 (s, 1 H), 7.27 (dd, J = 8.1, 
7.1 Hz, 1 H), 4.06 (m, 1 H), 3.71-3.53 (m, 3 H, 2 H after exchange with 
D2O), 2.80 (m, 1 H), 2.42-2.14 (m, 4 H), 1.62 (s, 9 H) ppm. 
13C NMR (75 MHz; C3D6O): δ = 178.8 (s), 154.3 (s), 154.2 (s), 146.4 (s), 146.3 (s), 145.6 (s), 136.4 (d), 
135.8 (s), 129.3 (d), 128.7 (d), 125.8 (d), 125.7 (s), 123.9 (d), 122.1 (d), 
119.3 (s), 117.2 (s), 109.6 (d), 82.7 (d), 79.6 (s), 58.7 (t), 58.6 (s), 45.2 (t), 
41.4 (t), 40.1 (t), 28.1 (q) ppm. 
IR: ν˜ = 3414, 2959, 2927, 1702, 1638, 1622, 1608, 1586 cm-1. 
MS (ESI): m/z = 474.2 [M+H]+. (C27H27N3O5). 
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Synthesis of tert-butyl 9-((dimethylamino)methyl)-10-hydroxy-3a-(2- hydroxyethyl)-7-oxo 3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[20,3':2,3] indolo[1,7-ab][1,8]naphthyridine-1(2H)-carboxylate (75) 
 
To a solution of compound 74 (1 equiv.) in EtOH (25 ml/mmol) was added CH2O (37% in H2O, 4 equiv.) 
and Me2NH (40% in H2O, 3 equiv.). The reaction mixture was stirred at rt for 24-48 h. After consumption of 
starting material (monitored by TLC) the mixture was concentrated under vacuum and H2O was added. The 
mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over Na2SO4 and concentrated under 
vacuum. The product was purified trough silica gel chromatography. 
 
Yield: 60%.  
Orange solid; m.p.: 157 - 159 °C dec. 
1H NMR (300 MHz; CDCl3): δ = 9.11 (s, 1 H), 7.86 (d, J = 7.7 Hz, 1 H), 7.63 (d, J = 9.1 Hz, 1 H), 7.41 (d, J 
= 6.9 Hz, 1 H), 7.22 (d, J = 9.1 Hz, 1 H), 7.16 (s, 1 H), 7.10 (m, 1 H), 6.50 
(br. s, 1 H, exchange with D2O), 4.40 (d, J = 14.7 Hz, 1 H), 4.22 (d, J = 14.7 
Hz, 1 H), 3.90 (m, 1 H), 3.75 (br. s, 2 H), 2.68 (m, 1 H), 2.48 (s, 6 H), 2.38 
(m, 3 H, 2 H after exchange with D2O), 2.09 (m, 2 H), 1.51 (s, 9 H) ppm. 
13C NMR (75 MHz; CDCl3): δ = 179.5 (s), 155.5 (s), 153.9 (s), 145.8 (s), 145.6 (s), 144.9 (s), 134.9 (s), 
131.8 (d), 128.6 (d), 128.0 (d), 126.7 (d), 124.5 (d), 123.7 (s), 121.9 (d), 
118.0 (s), 116.8 (s), 112.3 (s), 82.0 (d), 80.8 (s), 59.7 (t), 57.9 (s), 56.4 (t), 
45.6 (t), 44.9 (q), 41.4 (t), 40.6 (t), 28.7 (q) ppm. 
IR: ν˜ = 3435, 2974, 2954, 2928, 2882, 1698, 1645, 1619, 1606, 1584 cm-1. 
MS (ESI): m/z = 531.8 [M+H]+. (C30H34N4O5). 
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Synthesis of 5',7'-dibromo-1'-(2-hydroxyethyl)spiro([1,3]dioxolane-2,3'-indolin)-2'-one (77) 
 
To a solution on NaH (2 equiv.) in DMF (5 ml/mmol) at 0 °C, was added dropwise a solution of 76 in DMF 
(1 ml/mmol). After 10 minutes was added 2-bromoethanol (2 equiv.). The reaction mixture was stirred at 70 
°C for 24 h. Then, the reaction mixture was concentrated in vacuo, extracted with AcOEt and washed with 
brine (5 x). The organic phases were dried with Na2SO4, filtered and the solvent removed in vacuo. The 
product was purified by flash chromatography on silica gel. 
Yield: 75%. 
White solid; m.p.: 107 – 110 °C. 
1H NMR (300 MHz; CDCl3): δ = 7.64 (d, J = 1.8 Hz, 1 H), 7.42 (d, J = 1.8 Hz, 1 H), 4.54 (m, 2 H), 4.28 (m, 4 
H), 3.91 (t, J = 5.8 Hz, 2 H), 1.68 (br. s, 1 H, exchange with D2O) ppm. 
MS (ESI): m/z = 394.0 [M+H]+. (C12H11Br2NO4). 
 
 
Synthesis of 5,7-dibromo-3,3-diethoxyindolin-2-one (78) 
 
5,7-dibromoisatin (76) was added to a solution of triethyl ortoformate (15 equiv.) in EtOH (5 ml/mmol). The 
reaction mixture was stirred at 70 °C for 48 h. Then, the reaction mixture was concentrated in vacuo, 
extracted with AcOEt and washed with water (3 x). The organic phases were dried with Na2SO4, filtered 
and the solvent removed in vacuo. The product was purified by flash chromatography on silica gel. 
Yield:  
White solid; m.p.: 167 – 170 °C. 
1H NMR (300 MHz; CDCl3): δ = 7.98 (br. s, 1 H, exchange with D2O), 7.59 (d, J = 1.8 Hz, 1 H), 7.45 (d, J = 
1.8 Hz, 1 H), 3.86 (m, 4 H); 1.24 (t, J = 7.0 Hz, 6 H) ppm. 
13C NMR (75 MHz; CDCl3): δ = 171.42 (s), 139.01 (s), 135.40 (d), 129.18 (s), 127.33 (d), 115.87 (s), 104.55 
(s), 97.85 (s), 59.39 (t), 15.41 (q) ppm. 
IR: ν˜ = 3430, 3204, 2974, 1728 cm-1. 
MS (ESI): m/z = 401.9 [M+Na]+. (C12H13Br2NO3). 
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Synthesis of 5,7-dibromo-3,3-diethoxy-1-(2-hydroxyethyl)indolin-2-one (79) 
 
The compound 78 (1 equiv.) in DMF (10 ml/mmol) was added dropwise to a solution of NaH (1.5 equiv.) in 
DMF (2 ml/mmol) at 0 °C. After 10 minutes was added 2-bromoethanol. The reaction mixture was stirred at 
70 °C for 48 h. Then, the reaction mixture was concentrated in vacuo, extracted with AcOEt and washed 
with water (3 x). The organic phases were dried with Na2SO4, filtered and the solvent removed in vacuo. 
The product was purified by flash chromatography on silica gel. 
Yield: 85%. 
White solid; m.p.: 90 – 92 °C. 
1H NMR (300 MHz; CDCl3): δ = 7.63 (d, J = 1.8 Hz, 1 H), 7.46 (d, J = 1.8 Hz, 1 H), 4.31 (t, J = 5.9 Hz, 2 H), 
3.91 (t, J = 5.9 Hz, 2 H), 3.78 (m, 4 H), 1.84 (s, 1 H, exchange with D2O), 
1.22 (t, J = 7.3 Hz, 6 H) ppm. 
13C NMR (75 MHz; CDCl3): δ = 172.7 (s), 139.4 (s), 138.3 (d), 131.1 (s), 127.3 (d), 116.2 (s), 103.5 (s), 95.9 
(s), 61.6 (t), 59.5 (t), 43.5 (t), 15.4 (q). 
IR: ν˜ = 3571; 3517; 3077; 2973; 2933; 2885; 1737 cm-1. 
MS (ESI): m/z = 446.0 [M+Na]+. (C14H17Br2NO4). 
 
Synthesis of 5',7'-dibromospiro([1,3]dioxane-2,3'-indolin)-2'-one (80) 
 
To a solution of 76 (1 equiv.) in toluene (10 ml/mmol) was added propylene glycol (10 equiv.) and p-TSA (5 
mol %). The reaction mixture was refluxed with Marcusson apparatus for 24 h. Then, the reaction mixture 
was concentrated in vacuo, extracted with AcOEt and washed with NaHCO3 sat. (1 x) and water (2 x). The 
organic phases were dried with Na2SO4, filtered and the solvent removed in vacuo. The product was 
purified by flash chromatography on silica gel. 
 
Yield: 60%. 
White solid; m.p.: 193 -195 °C. 
1H NMR (300 MHz; CDCl3): δ = 7.57 (d, J = 1.9 Hz, 1 H), 7.49 (d, J = 1.9 Hz, 1 H), 7.44 (br. s, 1 H, 
exchange with D2O), 4.93 (m, 2 H), 3.97 (m, 2 H), 2.38 (m, 1 H), 1.65 (m, 1 H) ppm. 
MS (ESI): m/z = 385.8 [M+Na]+. (C11H9Br2NO3). 
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  Synthesis of 5',7'-dibromo-1'-(2-hydroxyethyl)spiro([1,3]dioxane-2,3'-indolin)-2'-one (81) 
 
The compound 80 (1 equiv.) in DMF (10 ml/mmol) was added dropwise to a solution of NaH (1.5 equiv.) in 
DMF (2 ml/mmol) at 0 °C. After 10 minutes was added 2-bromoethanol. The reaction mixture was stirred at 
70 °C for 48 h. Then, the reaction mixture was concentrated in vacuo, extracted with AcOEt and washed 
with water (3 x). The organic phases were dried with Na2SO4, filtered and the solvent removed in vacuo. 
The product was purified by flash chromatography on silica gel. 
Yield: 70%. 
White solid; m.p.: 116 – 118 °C. 
1H NMR (300 MHz; CDCl3): δ = 7.60 (d, J = 1.9 Hz, 1 H), 7.50 (d, J = 1.9 Hz, 1 H), 4.93 (m, 2 H), 4.26 (t, J 
= 5.8 Hz, 2 H), 3.94 (m, 4 H), 2.39 (m, 1 H), 1.80 (br. s, 1 H, exchange with 
D2O), 1.63 (M, 1 H) ppm. 
13C NMR (75 MHz; CDCl3): δ = 172.9 (s), 139.1 (s), 138.6 (d), 132.2 (s), 127.2 (d), 116.6 (s), 102.9 (s), 92.5 
(s), 61.8 (t), 61.7 (t), 43.1 (t), 25.4 (t) ppm. 
IR: ν˜ = 3457, 2960, 1708, 1608, 1574 cm-1. 
MS (ESI): m/z = 429.5 [M+Na]+. (C13H13Br2NO4). 
Synthesis of 8-bromo-6,6-diethoxy-2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-5(6H)-one (82) 
 
The compound 79 (1 equiv.) in toluene (10 ml/mmol) was added dropwise to a solution of NaH (2 equiv.) in 
toluene (5 ml/mmol) at 0 °C. After 10 minutes was added Cu(OAc)2 (10 mol %). The reaction mixture was 
stirred at 110 °C for 2 h. Then, the reaction mixture was fitered through a celite pad and was concentrated 
in vacuo, extracted with AcOEt and washed with brine (3 x). The organic phases were dried with Na2SO4, 
filtered and the solvent removed in vacuo. The product was purified by flash chromatography on silica gel. 
Yield: 80%. 
White solid; m.p.: 108 - 110 °C. 
1H NMR (300 MHz; CDCl3): δ = 7.13 (s, 1 H), 7.05 (s, 1 H), 4.25 (t, J = 4.4 Hz, 2 H), 3.96 (m, 2 H), 3.80 (m, 
5 H), 1.24 (t, J = 6.6 Hz, 6 H) ppm.  
13C NMR (75 MHz; CDCl3): δ = 168.5 (s), 142.3 (s), 127.3 (s), 126.6 (s), 121.3 (d), 120.7 (d), 115.4 (s), 98.8 
(s), 65.1 (t), 59.3 (t), 38.65 (t), 15.4 (q) ppm. 
IR: ν˜ = 3457, 2974, 2925, 1738 cm-1. 
MS (ESI): m/z = 365.9 [M+Na]+. (C14H17BrNO4). 
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Synthesis of 8-bromo-2H-spiroC[1,4]oxazino[2,3,4-hi]indole-6,2'-[1,3]dioxin)-5(3H)-one (83) 
 
The compound 81 (1 equiv.) in toluene (10 ml/mmol) was added dropwise to a solution of NaH (2 equiv.) in 
toluene (5 ml/mmol) at 0 °C. After 10 minutes was added CuI (10 mol %) and 8-hydroxyquinoline (10 mol 
%). The reaction mixture was stirred at 110 °C for 2 h. Then, the reaction mixture was fitered through a 
celite pad and was concentrated in vacuo, extracted with AcOEt and washed with brine (3 x). The organic 
phases were dried with Na2SO4, filtered and the solvent removed in vacuo. The product was purified by 
flash chromatography on silica gel. 
Yield: 60%. 
White solid; m.p.: 126 – 129 °C. 
1H NMR (300 MHz; CDCl3): δ = 7.20 (d, J = 1.3 Hz, 1 H), 7.06 (d, J = 1.3 Hz, 1 H), 4.91 (m, 2 H), 4.26 (m, 2 
H), 4.07 (m, 1 H), 4.03 (m, 1 H), 3.78 (m, 2 H), 2.25-2.41 (m, 1 H), 1.72 (m, 
1 H) ppm. 
13C NMR (75 MHz; CDCl3): δ = 169.2 (s), 142.0 (s), 127.6 (s), 127.1 (s), 121.1 (d), 120.7 (d), 115.8 (s), 95.9 
(s), 65.1 (t), 61.5 (t), 38.5 (t), 25.4 (t) ppm. 
IR: ν˜ = 3425, 2965, 1714, 1638, 1497 cm-1. 
MS (ESI): m/z = 349.9 [M+Na]+. (C13H12BrNO4). 
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Synthesis of 6,6-diethoxy-8-(p-tolyl)-2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-5(6H)-one (84) 
 
The compound 79 (1 equiv.) in toluene (10 ml/mmol) was added dropwise to a solution of NaH (2 equiv.) in 
toluene (5 ml/mmol) at 0 °C. After 10 minutes was added Cu(OAc)2 (10 mol %). The reaction mixture was 
stirred at 110 °C for 2 h. Then, was added Pd(OAc)2 (5 mol %), PPh3 (5 mol %) and p-tolylboronic acid (1 
equiv.) and the reaction mixture was stirred at 110 °C for additional 4 h. Then, the reaction mixture was 
fitered through a celite pad and was concentrated in vacuo, extracted with AcOEt and washed with brine (3 
x). The organic phases were dried with Na2SO4, filtered and the solvent removed in vacuo. The product 
was purified by flash chromatography on silica gel. 
Yield: 50%. 
1H NMR (300 MHz; CDCl3): δ = 7.42 (d, J = 8.0 Hz, 2 H), 7.23 (m, 3 H), 7.10 (d, J = 1.5 Hz, 1 H), 4.29 (dd, 
J = 7.7 Hz, J = 4.4 Hz, 2 H), 4.02 (m, 2 H), 3.82 (m, 4 H), 2.38 (m, 3 H), 
1.26 (m, 6 H) ppm. 
13C NMR (75 MHz; CDCl3): δ = 169.1 (s), 141.9 (s), 138.3 (s), 137.4 (s), 137.3 (s), 129.7 (d), 127.2 (s), 
127.1 (d), 127.1 (s), 125.6 (s), 171.2 (d), 116.2 (d), 99.4 (s), 65.0 (t), 59.2 
(t), 38.9 (t), 21.3 (q), 15.5 (q). 
IR: ν˜ = 3429, 2978, 2933, 2898, 1727 cm-1. 
MS (ESI): m/z =376.1 [M+Na]+.(C21H23NO4). 
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General procedure for the copper catalyzed amination or alkoxylation reaction 
 
To a solution of 82 or 83 (1 equiv.) in the appropriate solvent (1-2 ml/mmol) was added Cs2CO3 (1.5 equiv.), 
the appropriate aniline or pyrazole or phenol (1.5 equiv.) and the catalyst (10-15 mol %). The reaction 
mixture was stirred at 110 °C for 8-24 h. Then, the reaction mixture was fitered through a celite pad and 
was concentrated in vacuo, extracted with AcOEt and washed with brine (3 x). The organic phases were 
dried with Na2SO4, filtered and the solvent removed in vacuo. The product was purified by flash 
chromatography on silica gel. 
8-(p-Tolylamino)-2H-spiro([1,4]oxazino[2,3,4-hi]indole-6,2'-[1,3]dioxan)-5(3H)-one (85a) 
 
Yield: 40%. 
Colourless oil.  
1H NMR (300 MHz; CD3CN): δ = 7.08 (d, J = 8.0 Hz, 2 H), 6.92 (d, J = 8.0, 1.9 Hz, 2 H), 6.75 (d, J = 1.9 Hz, 
1 H), 6.63 (d, J = 1.9 Hz, 1 H), 6.40 (br. s, 1 H, exchange with D2O), 4.75 
(m, 2 H), 4.26 (m, 2 H), 3.99 (m, 2 H), 3.73 (m, 2 H), 1.78 (m, 2 H) ppm.   
13C NMR (75 MHz; CD3CN): δ = 190.6 (s), 168.9 (s), 142.1 (s), 142.0 (s), 140.9 (s), 130.0 (d), 129.9 (d), 
127.2 (s), 121.7 (s), 108.1 (d), 107.1 (d), 96.5 (s),  65.4 (t), 61.1 (t), 38.4 (t), 
25.3 (t), 19.9 (q) ppm. 
MS (ESI): m/z = 375.1 [M+H]+. (C20H20N2O4). 
8-(1H-pyrazol-1-yl)-2H-spiro[[1,4]oxazino[2,3,4-hi]indole-6,2'-[1,3]dioxan]-5(3H)-one (85b) 
 
Yield: 20%. 
Colourless oil. 
1H NMR (300 MHz; CDCl3): δ = 7.57 (d, J = 2.2 Hz, 1 H), 7.48 (dd, J = 8.0, 1.6 Hz, 1 H), 7.05 (d, J = 2.2, 1 
H), 6.91 (dd, J = 8.0, 1.6 Hz, 1 H), 6.53 (td, J = 8.0, 1.6 Hz, 1 H), 4.43 (m, 2 
H), 4.22 (m, 2 H), 3.76 (m, 2 H), 3.54 (m, 2 H), 2.17 (s, 3 H), 1.98 (m, 2 H) 
ppm.  
MS (ESI): m/z = 336.1 [M+Na]+. (C16H15N3O4). 
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6,6-Diethoxy-8-(p-tolylamino)-2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-5(6H)-one (85c) 
 
Yield: 50%. 
Colourless oil. 
1H NMR (300 MHz; CDCl3): δ = 7.06 (d, J = 8.3 Hz, 2 H), 6.89 (d, J = 8.3 Hz, 2 H), 6.75 (d, J = 1.9 Hz, 1 H), 
6.64 (d, J = 1.9 Hz, 1 H), 5.48 (br. s, 1 H, exchange with D2O), 4.26 (m, 2 
H), 3.96 (m, 2 H), 3.81 (m, 4 H), 2.29 (s, 3 H), 1.25 (t, J = 7.1 Hz, 6 H) ppm. 
MS (ESI): m/z = 391.3 [M+H]+. (C21H24N2O4). 
8-((4-Chlorophenyl)amino)-6,6-diethoxy-2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-5(6H)-one (85d) 
 
Yield: 40%. 
Colourless oil. 
1H NMR (300 MHz; CDCl3): δ = 7.18 (d, J = 8.9 Hz, 2 H), 6.87 (d, J = 8.9 Hz, 2 H), 6.77 (d, J = 1.6 Hz, 1 H), 
6.67 (d, J = 1.6 Hz, 1 H), 4.29 (br. s, 1 H, exchange with D2O), 4.27 (m, 2 
H), 3.89 (m, 2 H), 3.75 (m, 4 H), 1.25 (t, J = 7.1 Hz, 6 H) ppm. 
MS (ESI): m/z = 413.6 [M+H]+. (C20H21ClN2O4). 
 
 
6,6-Diethoxy-8-(p-tolyloxy)-2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-5(6H)-one (86) 
 
Yield: 10%. 
Colourless oil. 
1H NMR (300 MHz; CDCl3): δ = 7.12 (d, J = 8.5 Hz, 2 H), 6.86 (d, J = 8.5 Hz, 2 H), 6.75 (d, J = 2.0 Hz, 1 H), 
6.57 (d, J = 2.0, 1 H), 4.27 (m, 2 H), 3.94 (m, 2 H), 3.80 (m, 4 H), 2.32 (s, 3 
H), 1.24 (t, J = 7.1 Hz, 6 H) ppm. 
MS (ESI): m/z = 392.1 [M+H]+. (C21H23NO5). 
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2. Biological evaluation 
 
Inhibition growth assay 
HeLa (human cervix adenocarcinoma cells) were grown in Nutrient Mixture F-12 [HAM] (Sigma Chemical 
Co.); H-460 (large cell lung carcinoma) and MSTO-211H (human biphasic mesothelioma cells) were grown 
in RPMI 1640 (Sigma Chemical Co.) supplemented with 2.38 g/l Hepes, 0.11 g/l pyruvate sodium and 2.5 
g/l glucose. 1.5 g/L NaHCO3, 10% heat-inactivated fetal calf serum (Invitrogen), 100 U/mL penicillin, 100 
mg/mL streptomycin, and 0.25 mg/ml amphotericin B (Sigma Chemical Co.) were added to the media. The 
cells were cultured at 37 °C in a moist atmosphere of 5% carbon dioxide in air. Cells (3e4 x 104) were 
seeded into each well of a 24-well cell culture plate. After incubation for 24 h, various concentrations of the 
test agents were added to the complete medium and incubated for a further 72 h. A Trypan blue assay was 
performed to determine cell viability. Cytotoxicity data were expressed as GI50 values, i.e., the 
concentration of the test agent inducing 50% reduction in cell number compared with control cultures. 
 
Linear flow dichroism 
Linear dichroism (LD) measurements were performed on a Jasco J500A circular dichroism 
spectropolarimeter, converted for LD and equipped with an IBM PC and a Jasco J interface. Linear 
dichroism was defined as:  
LD() = A// - A() 
where A// and A⊥ correspond to the absorbances of the sample when polarized light was oriented parallel or 
perpendicular to the flow direction, respectively. The orientation was produced by a device designed by 
Wada and Kozawa[86] at a shear gradient of 500e700 rpm, and each spectrum was accumulated twice. 
Aqueous solutions of DNA (1.9 x 10-3 M) in 10 mM TRIS, 1 mM EDTA (pH 7.0) and 0.01 M NaCl were used 
(ETN buffer). Spectra were recorded at 25 °C at [drug]/[DNA] = 0 and 0.08. 
 
Topoisomerase I-mediated DNA relaxation 
Supercoiled pBR322 plasmid DNA (0.25 mg, Fermentas Life Sciences) was incubated with 2U 
topoisomerase I (human recombinant topoisomerase I, TopoGen) and the test compounds as indicated, for 
60 min at 37 °C in 20 ml reaction buffer. Reactions were stopped by adding 4 ml stop buffer (5% sodium 
dodecyl sulfate (SDS), 0.125% bromophenol blue, and 25% glycerol), 50 mg/ml proteinase K (Sigma) and 
incubating for a further 30 min at 37 °C. The samples were separated by electrophoresis on a 1% agarose 
gel at room temperature. The gels were stained with ethidium bromide 1 mg/ml in TAE buffer (0.04 M Tris-
acetate and 0.001 M EDTA), transilluminated by UV light, and fluorescence emission was visualized by a 
CCD camera coupled to a Bio-Rad Gel Doc XR apparatus. 
 
Topoisomerase I-mediated DNA cleavage 
Reaction mixtures (20 ml) containing 35mMTris-HCl (pH = 8.0), 72 mM KCl, 5 mM MgCl2, 5 mM DTT, 5 mM 
spermidine, 0.01% bovine serum albumin, 20 ng pBR322 plasmid DNA (Fer- mentas Life Sciences), 5 U 
topoisomerase I (human recombinant topoisomerase I, TopoGen) and test compounds at indicated 
concentrations were incubated for 60 min at 37 °C. Reactions were stopped by adding 4 ml of stop buffer 
(5% SDS, 0.125% bromophenol blue and 25% glycerol), 50 mg/ml proteinase K (Sigma) and incubating for 
a further 30 min at 37 °C. The samples were separated by electrophoresis on a 1% agarose gel containing 
ethidium bromide 0.5 mg/ml (Sigma) at room temperature in TBE buffer (0.09 M Tris-borate and 0.002 M 
EDTA), transilluminated by UV light, and fluorescence emission was visualized by a CCD camera coupled 
to a Bio-Rad GelDoc XR apparatus. 
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3. Computational 
The structure of the receptor was obtained from the crystal structure of the topoisomeraseI-DNA-topotecan 
ternary complex (PDB code: 1K4T) and prepared as previously described.[115] Docking calculations were 
performed with the software PLANTS.[116] The search space was defined by using the crystallographic 
ligand center of mass coordinates as the binding site center (x = 49.3764, y = 46.9081 and z = 48.2818) 
and the binding site radius was set to 14 Å, corresponding to the ligand radius of gyration augmented by 6 
Å. Maximum accuracy was requested by setting the search_speed parameters to “speed1”. All the other 
parameterswere used as default. Ligands were prepared using MOE 2015,[117] and processed by SPORES 
in order to assign the correct atom types required for docking calculations with PLANTS.[118] By using this 
setup, the overlay between the lowest energy docked conformation of topotecan (binding energy = -129.4 
kcal/mol, computed with the CHEMPLP scoring function)[119] and its crystallographic structure was 
excellent, with a RMSD of 1.52 Å, computed with VMD 1.9.1.[120] 
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